Pe142 Tell All: Big Money in Cannabis_Part 2

Hucksters exist in every industry, and many get away with it, even getting bonuses and pay outs while the business fails. Big money has been moving into cannabis for a while now, but is it all bad? Certainly some of it is, but many big companies do good, how can you tell the difference? Our guest is Jesse Peters, Founder & CEO of Mantis Growth Investments. Jesse has plenty of experience in cannabis and the ways of big money. Listen in to see behind the curtain!

Link to Join Email List Community for insights we don’t share anywhere else.

Pe141 Tell All: Big Money in Cannabis_Part 1

Hucksters exist in every industry, and many get away with it, even getting bonuses and pay outs while the business fails. Big money has been moving into cannabis for a while now, but is it all bad? Certainly some of it is, but many big companies do good, how can you tell the difference? Our guest is Jesse Peters, Founder & CEO of Mantis Growth Investments. Jesse has plenty of experience in cannabis and the ways of big money. Listen in to see behind the curtain!

Link to Join Email List Community for insights we don’t share anywhere else.

Pe140 The Race to Patent Cannabis_Part 2

As Big Ag works to patent, own and control cannabis, what will be the outcome? In this podcast series we discuss “This company filed the first cannabis patent—and nobody knows who they are” from Leafly by David Bienenstock.

Link to watch Mark Lewis’s Cannabis Pharmacology video.

Link to Join Email List Community for insights we don’t share anywhere else.

Listen to our podcast episode with the series author discussing cannabis history & the evolution of cannabis media Pe071 - Author & Producer David Bienenstock.

Pe139 The Race to Patent Cannabis_Part 1

As Big Ag works to patent, own and control cannabis, what will be the outcome? In this podcast series we discuss “Inside the billion-dollar race to patent cannabis” from Leafly by David Bienenstock.

Listen to our podcast episode with the series author discussing cannabis history & the evolution of cannabis media Pe071 - Author & Producer David Bienenstock.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe138 Why is there no “Craft” Cannabis License?

There’s a clear Craft Business framework for beer, wine and spirits, but why not cannabis? Can we create an industry where the local/ small business can also win in the David vs Goliath battle? Our guest is Micah Sherman, co-owner of Raven Grass. We discuss the small business landscape in cannabis and how the regulations currently lean towards big money.

Resources from episodes Washington Craft Cannabis & The Cannabis Observer.

Link to Join Email List Community for insights we don’t share anywhere else.

Episode Transcription:

Wayne Schwind, Host: Joining us today is Micah Sherman, Co-owner and Director of Ops for Raven Grass in Washington. Excited to have you on today, Micah, talk a little bit about Raven Grass, your background and some of the bigger initiatives, projects and bills you're working on - some exciting stuff I haven't really seen yet in the cannabis industry. So something unique, I think will be really good for the listeners to learn about. So thank you for taking the time to come on today.

Micah Sherman, Guest: Yeah, thanks. Thanks for the opportunity to have a conversation with you, looking forward to it.

Wayne: Let's start with just context for listeners kind of a simple introduction to yourself, Raven Grass, you know what year you started, and maybe how and why you started the business and got involved with it.

Micah: Yeah, so Raven is a - what's called a tier two farm here in Washington. So we're on the smaller end and we produce our own organic cannabis in an indoor facility here in Olympia. And then we also make a variety of products with that in our processing facility. We started here in Washington's i502 system in 2014, kind of right at the beginning of, of that legal recreational system, we did a little bit of medical production out of the same facility while we were getting all of that set up and going through the very long permitting process with state and our local county. So there's three of us that own Raven Grass, myself, Nichole Graf, who's our creative director, and then David Stein, who is our farmer/grower. Nichole and I moved out here in 2013 from New York. We both came out of design professions, she worked in fashion and I worked in the architecture and building industry. So we moved out here specifically with the intention of starting this business with David who was located here in Olympia. You know, it was right around the time when Washington and Colorado passed their legalization initiatives. Nichole and I were living in New York and were ready for a change in our lives. We had both gotten to places in our careers that, you know, caused us to have - to come up against some broader considerations of kind of what we wanted to do with our lives and how we wanted to spend what limited time we had on this world, and decided it wasn't going to be progressing the profit interests of the already extremely wealthy and saw the cannabis industry as a space to, to come into something that was, you know, in this moment of dramatic transition from an illicit market to a regulated market. We knew that there was going to be a lot of opportunity in there to, you know, have a role in shaping something that was going to be important and new and were there was going to be a lot of conversations that we thought probably hadn't happened in a really long time in, you know, such a economically significant industry.

Wayne: Yeah, and socially impactful. I mean, it's like, I don't think we've ever really seen an industry like this come to light. You know, Tech, those things were new, but this thing - I mean cannabis has been around forever. Now to rebuild it in a legal landscape is very interesting.

Micah: Yeah, it was, you know, it's kind of just a fascinating once in a lifetime moment, and we decided that it was something that we wanted to be a part of. I don't necessarily think we knew exactly how that was going to go and where it was going to lead us. And, you know, like, I certainly didn't have this exact plan of what we're working on now as far as our legislation, but it was certainly - you know, we knew it was going to be there and we were willing to kind of dive in and try to make sure that the conversation and the direction of things stayed on some of the stuff that we thought was, was really important, which is reminding folks that, you know, a lot of times, especially in the, in the sort of investment and business world of the cannabis industry, where you hear terms like, you know, "new industry", and it's an emerging market, and it's, you know, massive growth for this new market. And really what it is, is it's transition from the illicit market to the legal market. And so anything that comes into the legal market, probably comes out of what was once the illicit market and has a profound, you know, economic and social impact on on those people who maybe didn't, didn't have the capacity to make the transition or didn't want to or, you know, had - had had a lifetime of bad experiences with the state and didn't trust that the process was going to go in a way that was going to be considerate to their needs. And you know, most of those people were, were right, it turns out.

Wayne: Right. How - I'm always interested in this stories, and you have three people as co-owners and partnerships, how to make those work long term. Was David a friend that - you said he was already in Washington, was he, you know, familiar with cultivation, wanted to do the business side, and you and Nichole were those other puzzle pieces that kind of rounded that out? Did you know him previously, like, how did you decide to move to Washington and not have a different state?

Micah: Yeah, well, so. David is of my father's generation and has been growing since he was in high school. So he's, he's in his late 60s now, and has you know, been grown for close to 50 years in a variety of different ways and forms and places and - so yeah, we got connected with him through a friend of my father. He was interested in getting into the legal system he had been growing, you know, in the illicit market and in the medical market and wanted to get into the recreational market but didn't want to deal with any of the business side of things, didn't want to deal with, you know, the permitting and all that.

Wayne: And Admin and logistics and - yeah, that's a whole other landscape.

Micah: Oh, yeah, that's where - that's where our setup came from. So we all have different and complimentary roles in the business. You know, which I think just fundamentally, I think that's an important part of a partnership is understanding what everybody's supposed to be doing and what the expectations are and making sure that you know, you're coming together with a group of people that can also work well together. So there's, you know, there's also just - especially in the, in the early days of this industry, so much of its based on on trust. You know, we didn't have a ton of money when we started all this. And, you know, we at first we took all of the very traditional business advice of, you know, get a lawyer and write up really detailed partnership agreements and, and get everything down on paper. And, you know, then about $10,000 of lawyers later, we, you know, just didn't have - like, that process wasn't really becoming satisfying for us. And it wasn't like allowing us to really get that sort of stuff dealt with. I think so we, you know, we decided at some point in that process to pause that and to just kind of sit down with the three of us and make sure that we all knew what was expected of the others and that we, you know, agreed in principle on kind of where we were going and how we were going to get there and just wrote out some really simple agreements ourselves. And definitely that, for us was, was a better process. But again, you know, the scale of our operations was very small, we didn't have a lot of, you know, complicated investment stuff to deal with. You know, we got a couple of like loans from friends and family and we don't have any equity investors. So it was really just the three of us making sure that, that the expectations and, and roles were clear. And that we had a good way to continue to communicate and, you know, that has been easier at different points than others. But we're all still doing it together. And that part of it is moving along well.

Wayne: That's good.

Micah: Yeah. So we've been doing this for about five years and in that process, and you know, part of why, why you're interested in talking to me was about our, our kind of next steps for, for the industry, and how, you know, our experience thus far has informed that.

Wayne: Yeah. And before we jump into that, I kind of want to lay out the landscape of - I'm not as familiar with the Washington market, even though we're right next door. Sometimes you're so focused in your own market, you hear things here and there. But there's so much to focus on in your own state. For listeners, and leading up to why this legislation, why this approach? It's very fascinating to me, and seems almost something like - almost impossible to do from a small business perspective. What led up to this approach to like trying to get this legislation, this bill passed? You know, what's the landscape of the Washington market, the pricing landscape, you know, small business versus corporate businesses? What was the motivation? And then we'll get into the details of what this legislation is. But what's the landscape of Washington over the past couple few years?

Micah: Yeah, so Washington State started with what their - what they call the three tiered system similar to distribution for alcohol. Where they had a production license, which was the farm, a processing license, which was the ability to make any sort of products from those, and then the retail license. They prohibited anyone from having a wholesale license, which is the producer or the processor license, and a retail license. You have farmers. And then you have farmers that are also processors. And then you have people that are just processors, and then you have all the retailers.

Wayne: And did they cap those licenses as well?

Micah: Everything's capped here. Yeah. And everything's pretty much closed at this point, there was an initial round of licensing. Occasionally a license will, will go for sale or get forfeited or something like that and get reissued. But -

Wayne: And it was a small window, right? It was like a couple months? (Very small) Yeah, you had to be like, on the dot the timing of that, to come in later's almost really hard in Washington. It sounds like.

Micah: Yeah, I mean, you can - at this point, you can, you can buy a license from somebody that already has one. And there is a secondary market for licenses. But it's, you know, it's pretty expensive. So that's the basic structure of the industry where you have wholesalers and retailers, and there's no ability for any sort of vertical integration in those relationships. So what we've seen, you know, we started out with about 2,500 production licenses. And these days, we're, we're right at about 600 active licenses. (Wow, wow) And so what what's happened in that time is there's been a lot of consolidation. So a lot of people have now acquired multiple licenses for on the production side. And then there's a lot of licenses that are inactive or dormant. Maybe they're licenses that are that are moving around, but the real story is a story of consolidation. A story of more and more of the sales in the market going to bigger and bigger companies. One of the things that Washington did, as well is they limited ownership in a license entity to Washington residents, so that meant no money could come from out of state directly into a licensed cannabis business. And the way that folks that wanted to get bigger than than they could get and wanted to bring in some money is they was set up, you know, like a secondary company that might own a facility and then lease that out to a licensed entity. So there's, you know, there's lots of ways for bigger companies to bring in, to bring in money. So, you know, licensing agreements, and -

Wayne: So that rule didn't have its intended - it was, they worked around it, essentially.

Micah: Yeah. And if anything, it made it more difficult for small businesses because we didn't have the complicated legal capacities to set up those sort of arrangements. So it almost limited the out of state money to being used only by the big guy.

Wayne: Yeah, that's crazy.

Micah: Yeah. And now, you know, a big part of what I talk about as as we're moving forward with this legislative process is to remind people to like, turn around and look at some of the unintended consequences of choices we made along the way. Because I think sometimes that gets that gets overlooked. So that's really been the story of the Washington cannabis industry over the last five years has been small farmers just struggling to make ends meet, going out of business, selling their license for you know, pennies on the dollar. And a lot of you know, so many people that I know, that have just given up. (Yeah) But now we're at this place where there's a lot less farmers in the market and We're, we're trying to have a conversation about how do we keep those farmers that are left (right) still here and able to make profit. And actually, you know, have this be a business that we could continue to run into the future. (Yeah.) You know, it's still a very tight situation for small farmers.

Wayne: Yeah. On the regulations and the licensing. You know, I thinking of Oregon, we didn't cap any licenses. They did last year decided to stop taking applications for new grow licenses. But I think we're at like, at almost 1,000 - somewhere between 1,000 grow licenses or 1,200. There's another 12,000 applications in the hopper. Washington's at 600 and your population is almost double of Oregon. So when you look at the saturation in Oregon, we should have done something. Why were the growers - Why was it such a struggle? Was their price cutting extremes, was the cap not set low enough, and there was still too much capacity for the state?

Micah: Yeah, it was kind of multifaceted. So one fact is that when 502, the initiative first passed, there was a study, and they determined that we needed about 2 million square feet of production overall for the state. And there's about 20 million square feet licensed. So we do have an excess production capacity here. And I think that 2 million number was probably a bit low. But even if you double it, it's still five times more canopy that we might need.

Wayne: And did they not listen to the report? They decided to go with 20 or?

Micah: Um, it was - more of a, they just basically gave licenses to everybody that applied in the first window. Yeah. And they were originally - So originally everybody was going to be able to have up to three licenses. So there was a lot of people that planned their businesses around that. Then when they realized they had so many more licenses that got applied for than they needed, they said, okay, you can only have one license. And then at some point, once enough people had, you know, the writing was on the wall, people were closing down, they wanted to be able to sell their licenses, then they changed the rules again, that allowed everybody to have three licenses, but you can only only get them by acquiring a license from somebody else. So that was a moment where there was the ability for some of these bigger companies to triple their production capacity by adding two more licenses and - and you know, just keep getting bigger.

Wayne: Yeah, were they driving price down? Because if they're going to triple but it was already over capacity and saturated. Did that allow them just to drive lower prices? Was that where the farmers were really struggling, the local, craft and small?

Micah: Absolutely, and yeah, absolutely. That was exactly what happened. It was just a you know, there was a real race to the bottom for years. I mean, there was, there was seasons where you could buy pretty decent like useable flower for 40 cents a gram, 30 cents a gram in that range. And you know…

Wayne: Yeah, we saw that in Oregon.

Micah: Yeah, yeah, it was - it was similar. I think we hit some similar prices to you guys. But yeah, definitely there was this moment where it was pretty much impossible to make a living growing weed in Washington and so there was a very large overproduction. You know, there was a lot of it that probably ended up getting in diverted into the black market.

Wayne: Yeah, how'd you guys survive that?

Micah: So we're - we're a pretty small farm, we have a couple of different differentiations to what we're doing here from most folks. We were, very early on in our business we, we made a decision to start working on breeding, type two and type three genetics. So mixed ratios, CBD and THC strains, and high CBD low THC strains. And while in the first couple of years, that was something that you know, the market really struggled to find a place for. One of the - one of the situations that really defines our marketplace here is that there's a set number of stores and they're assigned by geographic area. And so that relationship of a limited number of outlets to be able to sell your product combined with this very large over productive capacity, you know, created a situation where the people that did the best were the people that made the jobs and the profit margins of the retailers, the easiest. And so we're - we've been able to do that with, just because of the fact that we're so small we can seek out stores across the state that have similar values. And so one of the things that allowed us to do that was our work with these with these CBD genetics allows us to provide something different to the market. We've always gone above and beyond on following organic standards since since early on in the market. So there was, there was a moment early on where we were, you know, one of three or four companies that were putting out products that could have been certified organic if there was a program for that. So those differentiations helped us to, you know, keep our price a little higher, as well as just the fact that we were such a small scale, we really could, you know, pick our battles as far as which stores to work with and we didn't have to go this route of trying to be for everybody. So we were a bit of a niche.

Wayne: Be more adaptable, didn't have to drop the price, not competing on that. How many stores do you normally work with?

Micah: We work with about 35 stores right now.

Wayne: Okay, that's kind of what I've heard from most, I mean, craft growers - 30-40 stores seems like the norm.

Micah: You know, it's that number where you can still have meaningful relationships with the people that run the stores. It's not, it's not so big that you can't have those conversations on a regular basis. And, you know, and that's, that's really the idea of, of defining craft production. It's about the scale of a business relative to the overall market. And that's, that's the the type of relationship and the type of business model that we're trying to preserve with this legislation by defining what a craft producer is, we can start to have a conversation, you know, really cogently about what is the proper scale to be able to maintain that type of production? And yeah, so that that number seems to be, you know, sort of a natural size for a lot of people, that seems to work really well.

Wayne: Build that brand stronger inside of those. Yeah.

Micah: Yeah. So that was how we were able to basically stay afloat during this time of, you know, really depressed prices and then people closing, and you know, we were we were definitely on on the edge a lot of times. You know, there was a lot of weeks where payroll was late, you know.

Wayne: I've heard that story a lot, yeah. In Oregon, our partners - we look, we try to work with the same type of growers. It was the same thing. Like we've had partners that were close to that edge when we had that same drop, and now that 2019 was one of their better years, and it's great to see that it turned around but a lot of people didn't make it through. Was processors and retailers in a similar situation, or was it really the growers that had bad market crunch and price pinch?

Micah: The growers definitely had the hardest time. You know, a lot of processors, depending on their business model, struggled as well. But there was definitely a lot of processers that did really well in that time because, you know, their input prices were so low that they can you know, if time - especially, you know, folks that were looking for good inputs for edibles and stuff like that, that those prices came down so that I feel like they really got to compete on you know, who had the product that people like to consume the most and it was less about just the price, although, of course, there's still huge price component and all that but yeah. So and then - so retailers are, are essentially the most important people in our industry right now in Washington, because of their very you know, special place in the supply chain.

Wayne: Yeah, there's one gateway to the consumer.

Micah: Exactly. So they're, you know, they're the ones that have really over the years, gotten to have the most impact on how value is defined in the industry. You know, they really got to have all of these conversations with, with the customers, they got to decide what to emphasized in their stores, as far as you know, are we going to talk, you know, how are we going to physically set up our store? How are we going to label the sections, you know, all these you know, what may seem kind of incidental decisions, you know, they really frame how people think about cannabis, right? It's a brand new thing for them. They're coming into a store for the first time. They see you know, the whole store divided up between indicas hybrids and sativas, and that reinforces those conceptions for them. And they see, you know, the THC percentage prominently displayed on every single product -

Wayne: The most important thing! (Laughter)

Micah: Yeah, because it was legally required, so it becomes this really important thing. It's the only thing that's the same on every single product. And so of course, it's important, right? Like that, you know, that's just common sense if you're, if you're somebody who doesn't know that much about cannabis, and so they -you know whether intentionally or not, they got to set the stage for what people thought mattered. And I think a lot of stores, you know, did a really good job in that role. And a lot of stores took that role and decided to use it in a way that allowed them to make the most money the most easily. And those tended to be the stores that found the most success in the market, because they were willing and able to play the game of price. And so, you know, more and more our industry as its consolidated and as different retailers have, you know, figured out there, they're place in the thing, in the situation relative to each other, we've seen these stores that have tended towards high volume, low price. You know, a lot of a lot of foot traffic, you know, quick transactions. These have been the people that have that have found the most profit and the most success. And then I think we've seen more and more of our production capacity, sort of pivot towards supplying that part of the market. Because that's what we tend to do when there's a you know, opportunity to make a profit. Somebody's gonna kind of fill in that space. I think we've seen as a whole, our productive capacity has really shifted towards meeting the needs of a particular kind of retailer. And I think that we're seeing, you know, a pretty substantial shift in the way that the industry is, is oriented towards that.

Wayne: Right. Right.

Micah: And, and that's a big problem in my mind, for a couple of different reasons. One, it, it puts folks, the, you know, the retailers who are, you know, a really important component of any industry, but it puts them in this position to have conversations about what's valuable without understanding the production process. And they, you know, just as a result of that, are not always going to make the decision that makes the most sense for the things that we're making because they don't know about the things that we're making. And so part of, part of our bill is, is really about thinking about the ramifications of those sorts of moments. And how can we, you know, without completely disrupting our whole supply chain, like how can we start to make important, targeted changes to re-evaluate how those power structures are distributed? Yeah, who gets to make the choices about what matters and what's valuable, and have those conversations with consumers and the public to start to come up with a collective idea about, you know, what matters the most for the cannabis industry? Because that's the conversation I think that we're not really having in a transparent way right now.

Wayne: Yeah, well, especially in the Northwest, I mean craft industries. I mean, the Northwest cares about that so much, and we're seeing other areas keeping the money in the state. And to have a craft industry, you know, small businesses, if you look at how much just in general that makes up employment and revenue, I mean, it's a huge number. But it's not one unify - it's hard to unify that. But to have that craft industry, small scale aren't going to - they're producing on quality and differentiation. It's not going to be volume in price. And if you have retailers that come in early, you know, the first few years, that's the model, that's how you're attracting customers, because if the flower isn't getting differentiated, other than the THC percentage, consumers aren't educated, you know, they're not going to start figuring that stuff out. So this is leading you up to this legislation approach, the bill. I want to first talk about what it is, then I think we can circle back to the process of it how you did it. Cuz that seems very elusive to me. Okay, so let's set up the bill. What is the bill? When did you start working on it? And I guess we just kind of give listeners a definition and then where we're at in the progress of it.

Micah: Yeah, so our bill is a bill to do three things. It establishes a new license on the production side. That is called a craft cannabis production license. And that is limited in, in size in a similar way to our existing licenses. Except for it does something slightly different where it looks to talk about productive capacity rather than just square footage. So right now, all of the licenses whether it's indoor or outdoor, are the same square footage. So the craft production license would limit people to 10,000 feet of indoor canopy or 30,000 square feet of outdoor canopy. And then you can also have a blend. So if you had 5000 feet indoor, you could have 15,000 square foot outdoor. So it adds up to the, you know, kind of the total number. So that's new, in and of itself. And we're saying that, you know, it's just acknowledging the difference between the productive capacity of an indoor operation and an outdoor operation to get to a business size that is approximately the same size as a craft brewery or craft distillery here in Washington. We looked at, you know, how big those businesses are and worked our way back from there. The second thing it does is it allows for those craft producers to set up on-site direct sales for the products that are grown exclusively within their operation. And so we're talking about something similar to a you know, craft brewery where you can go in and, and, you know, fill a growler, all those. And then the third thing it does is it, it creates an advisory board of craft producers, craft farmers to work with the liquor and cannabis board on future rulemaking projects. All future rule making projects, but specifically rulemaking projects around the implementation of this new craft license, and then the expansion of the craft economy into the rest of the license types in our industry. So it's, you know, creates this ongoing working relationship between regulators and craft farmers. And - because that's really the idea of this build, it's to establish - what is craft? It's to create a differentiation in the rules for that business model that allows them to succeed in the face of you know, all of the issues that we just talked about. And then it sets up a framework to continue that differentiation in really meaningful ways and move our industry forward.

Wayne: Yeah. Is home delivery allowed at all in Washington?

Micah: Not right now.

Wayne: Okay. Okay. Yeah we see - I actually see a similar approached by some edible companies and other companies in Oregon. They're actually starting hemp CBD lines and then setting up a little retail store - you know, they can't sell their THC products but at least they're making that consumer connection, which we struggle with, you know, we don't see that end consumer because we don't have that direct relationship. And you get so much value and feedback and market research from actually talking to the consumer and the budtenders are great, the dispensaries are great, but there's still that telephone game you know of information being passed down. What, what -

Micah: I don't know about in Oregon but in - one of the things we run up against in Washington is there's an incredibly high turnover for budtenders and for buyers. Apparently it's not a job that people enjoy very much.

Wayne: Yeah, absolutely. But those top ones are succeeding. The ones that are differentiating, it seems like they have really low turnover. But that volume-price player, I see more turnover in those dispensaries.

Micah: Yeah, it's - it's a mix here, I think, you know, small stores in Washington, I think sometimes still struggle to, you know, financially some of the small stores and more rural areas. And, and I think some of that might just be, you know, people get people get burnout on working a low wage job in a stressful situation where there's not money getting made. So.

Wayne: Yeah. What did you learn from - I think in our pre-call, we talked a little bit about the craft beer industry, micro distilleries. What approach to those is there in Washington to help them succeed where Budweiser is don't just run the entire industry? Is there parts of those that should, we should see in cannabis and craft cannabis?

Micah: Yeah, absolutely. So our legislation is really modeled off of those, those two things is craft brewing and craft spirits. So I think a lot of people know the story of craft brewing on the west coast, you know, in the 80s and 90s. The reason why that industry came into existence was because the rules were changed that allowed small brewers to sell their beer directly. And they didn't have to go through the distribution system, which wasn't going to work with small brewers because it just didn't make any financial sense.

Wayne: Yeah. Too much of a leap.

Micah: Yeah, yeah. So and then in 2005, Washington State passed a similar law for micro distillery. And so they define this micro distillery license. And they said, If you make less than a certain number of gallons of alcohol per year, that you could sell a portion of that directly to the consumer and that created a really thriving craft spirits industry here in Washington. And they've had their, you know, their their ups and downs and it's not a perfect industry and you know, model by any means, but it, it created a business type that didn't exist previously in the state of Washington. There were no small distilleries in Washington State. Prior to this, it just wasn't. It wasn't a viable business. So yeah, we're definitely looking at those two industries and seeing - and you know, the real big difference for both of those craft brewers and craft and micro distilleries is the direct sales component. That's the fundamental difference between them and the bigger producers. And, you know, it both allows them to sell a certain amount of their products at a retail margin, you know, which gives them comfortable profit for that. And it allows them to have a greater role in helping to educate the consumer and create, you know, good reality-focused expectations of value. And that is, you know, those that's like kind of the twofold component is going to allow us to sell a small amount of what we produce. Maybe the average brewery from my understanding sells about 25% of what they produce directly. And they make about 45% of their profits from that. So anybody can do the math on that and and realize that that's a good thing for small producers. And one of the things that does for us at that point is it really gives us the stable base of, of income to do more interesting things for our retail partners, and that is something that I've been working on and over the years with, with my retailers that I work with, is helping them understand what are some of the things that we're going to be able to do with this new privilege of selling direct, that's going to make us more valuable as a partner for them. Yeah, and there's a lot of opportunities for us to do things with this direct sales that we wouldn't really be able to do with retail partners effectively, that is going to help us A, make more money so we can continue to exist and other things. But and then Two, like start to broaden some of the stuff that's available for consumers, so they can really start to understand what are some of the different things that could be available that aren't now? Because, you know, we all know that the, the, you know, capitalist mode of production is inherently limiting to the only things that are produced are the things that are profitable, right? We don't see things made that aren't profitable to be made.

Wayne: Or scalable, or a commodity more like, you know.

Micah: Yeah. And there, you know, there tends to be an effect in that and that the things that are less profitable also don't get made, because why would you, you know, if you just own a business and you're kind of disconnected from it from what it's doing on a daily basis, why would you choose to do something that only made you half as much money as doing something else that made you more? You know, there may not be a reason to do that, in that in that system, especially in a system where the ability to get information from the people that are making it to the people that are using it isn't, isn't clear.

Wayne: Where - this seems inevitable. People love small businesses, they know their money staying local, they can actually meet or know who the owner is behind it. It seems inevitable, question is I think, when is this going to happen? Where - I think you said you've been working on this for about three years. Where are you at as far as progress, and is this something you think could happen, maybe 2021? As soon as 2020 as a timeline?

Micah: Yeah, that's - that's a good question because it you know, gives us a chance to talk a little bit about the legislative process. So I'm sure a lot of folks don't know about that. So the average time for a bill to make its way through a state house is like a three to five year process. So we're, you know, technically this is the third year that I've been working on it, but really, it's the second year that it's been on the radar of the legislature. The first year was me just trying to get the attention of my legislators that represent me, getting them up to speed on, on what's going on, help them to understand the cannabis industry, which, you know, hardly any of our state representatives really know, in any sort of detail what's going on. It's, you know, three years ago, I feel like the most common reaction to walking into legislators office was like a little bit of a giggle and a joke about something about cannabis because oftentimes that kind of made them uncomfortable. So they would try to, you know, laugh a little and that was, that was a frustrating dynamic because oftentimes you only get about 10 or 15 minutes to meet with a legislator during the legislative session and to spend, you know, a couple minutes trying to work through their uncomfortableness of talking to a "drug dealer." (Laughter)

So, year one was that, it was - it was education. It was, you know, establishing a relationship with these folks. So they knew that when they were talking to you, they were getting, you know, good information, that they could trust what was being told to them. You know, all those things are important in that process. So last year, we had a we had a bill that was, you know, officially proposed and, you know, we had a lot of meetings about it, but we didn't get a legislative hearing in the committee, so I wasn't able to move through that process. This year, we - we revised the bill. We clarified the language around that a little bit because that was something that, some of the feedback we got last year was that it wasn't clear exactly what we were trying to do, again, especially to people that don't understand the real details of the cannabis industry. And to be frank don't have the time to dive deep into any particular issue. In Washington and Oregon, we both have part time legislators and it creates this environment where, there's just not a lot of time for them to, to do their jobs, and to really understand a lot of nuance. So, learning how to how to interact with that without you know, it can be it can come across as dismissive sometimes. And I think a lot of people get upset about that. But I think if you really think about it, you know, these people have thousands of bills that are getting introduced every year and they have to figure out a way to know enough about all of them to represent their constituents. It's you know, it's a challenge for sure. So, you know, this some relationship building and making sure that people understood what we were trying to do, and that we were clear about its intent. And so this year, we got, we had a hearing for our bill. And it went really well. We had a lot of farmers show up and, and speak really eloquently about their experience and what this opportunity would mean for their businesses. It was, you know, there's some pretty powerful testimonies in that hearing about the idea. And I think that we made a lot of progress and we have a really good chance of the bill passing next year.

Wayne: Next year. It seems like you might be able to get support of the craft brewers or micro distillers because they're small. I mean, they're successful because of their system and what was set up for it. Are they engaged at all or interested on the cannabis craft side trying to create that same part of the industry? Or are they kind of separated from that?

Micah: That's definitely something that I'm working on now. I started reaching out to those that community, you know, over the last couple of months as well as it looked more and more likely that we were going to be able to get a hearing. And yeah, we're making some inroads and I think next year, we're really going to be able to have, you know, a coalition of craft producers from different industries come out and speak to, you know, both their, their struggles, things that have worked, and things that haven't worked. You know, there's a, there's decades of lived experience in those industries about the sorts of things that were helpful and the sorts of things that weren't and I and I definitely, you know, we're working really hard to try to get some of those folks engaged in this. You know, it's hard they're, you know, often busy business owners themselves and, and are, you know. But yeah, there's definitely opportunities to work together there. The other group that we've been talking to and I hope to have as a part of the conversation next year, are organic vegetable farmers that are that are working in CSA's or at the farmers market, because that's really the same sort of idea where it's about, how do we create different market access for different types of production that work, you know, better or worse for that type of production? And you know, CSA's and farmers markets are a big part of a lot of small, organic farmers business models and being able to explain how just the different form of access to the consumer is a really important component in and of itself.

Wayne: Is there any correlation on the hemp CBD side that might also you know get involved in this or because that's so unregulated, they're selling online maybe already directly to consumers or opening up stores, are they not as engaged in this on the CBD side?

Micah: Yeah I'm not, I don't have any hemp farmers that are federally interested in - you know that I find that the hemp farms tend to be, you know it's a larger scale of farming just because of the, you know, the nature of it.

Wayne: We're seeing craft hemp become a category here in Oregon and these craft growers around hemp and products. Yeah, it's really interesting

Micah: Yeah, you guys are definitely a few years ahead of us on on the hemp farming we, we only really last year was the first year that it was easy to get a hemp farming license and I think we're still seeing folks figure out what to do, kind of how to how to do that and the different ways to do it. There was this year was pretty, pretty ugly for Washington hemp farmers, a ton of stuff got planted and you know, we had an early frost and bad weather. And then, I think there was also not the processing facilities in place. So a lot of, a lot of usable material rotted in the field this year.

Wayne: Yeah. And I see a lot of that being industrial hemp right now, which is a whole you know, high volume extraction and processing these, this craft hemp we're seeing in Oregon now is - I mean, it's indistinguishable from craft flower that you would see. It's really interesting. It's as a category.

Micah: Yeah, we grow strains in our facility that would legally meet the definition of hemp. So yeah, we're, that's something we're looking at as you know, maybe doing a small crop locally here and just doing it for to get those type three flowers. So yeah, I wasn't. That's nice to hear about craft hemp flower in Oregon.

Wayne: Yeah people are smoking, I mean buying just the flower and actually smoking it like normal flower or it's you know going into edibles, vapes, different things like that. But the industrial hemp one is scary because I think that's more aligned for fiber, you know, different - paper, textiles. When you take that industrial hemp you've gotta process it so far down. It just doesn't seem like the right fit for an actual consumable product market. But it seems like a filler that's in place right now because it's just brand new. And that's what how hemp was grown before, those strains and cultivars. I mean, that's just been done now. It's so new.

Micah: Yeah, I know we're definitely going to see a whole lot of different stuff happening in that space. And yeah, just not - not something that I've spent a ton of time delving into. I think it's a much smaller activity here in Washington thus far because the state was, you know, pretty far behind Oregon on doing the licensing.

Wayne: Right? Back to the bill, two questions and they might kind of tie together. One, how do you write a bill? Do you have to hire a lawyer? Like what's that process? And then two, I saw your bill is sponsored by Rep. Lori Dolan. How do you get - does a bill have to be sponsored by someone to have to get a hearing to even be seen? How did you get her to sponsor, and is she involved in writing the actual bill on the language?

Micah: Okay. It can go a couple of different ways. I would say probably the most common way that a bill gets written is - Yeah, lawyer that the, the interest that is pushing the bill forward, you know, would hire a lawyer to write the bill in exactly the way that they want it done. Washington has an interesting option available to citizens and to legislators. So if a legislator has a constituent that has a bill that they support, that that legislators supports, what, and this is what happened for us, is so Lori Dolan represents me. She's, you know, I'm her constituent here in Olympia. She represents the 22nd Legislative District, which I live in and have the business in. So once we got to a point where she understood the bill that I was asking for, what, what we have here is each committee in the House or the Senate, has nonpartisan staff members that, their job is to is to write and understand bills. So sometimes they'll get a bill that's already written. But other times they'll just get a proposal for a bill and they actually draft it. So I was actually able to kind of be the contact with the person who wrote the bill that works for the house commerce and gaming committee, who's you know, he's a lawyer and a legal writer. And so over the course of a couple meetings and conversations, he was able to take the proposal that I had put together and put it into legal language that could be, you know, enacted into law. Yeah. So - not every state has that nonpartisan staff available. But it's -

Wayne: It's probably costly, to have a lawyer, if you had to have a lawyer and pay for that writing that up.

Micah: Yeah, I mean, that eliminates a lot of people from participating and in the process right there. So it's definitely a great system and something that I was really, I didn't know about and I was really happy to find out existed because the first year that we had the bill we actually did, we found some some, you know, kind of activist pot lawyers that were willing to help us draft the bill for free. And one of the downsides of doing that is oftentimes, you know, if something gets written in a way that the staff of the committee doesn't think is really executable, a bill can get kind of inherently slowed down just because, you know, the legislators, like I said, they're really busy. They have thousands of bills, only about 10% of the bills, that that get introduced progress, and only a small percentage of those actually get passed. So they have to, they have to really spend their time focusing on bills that they think have a chance of moving forward. So there's - if there's a technical or a structural problem in the bill, that can derail it, regardless of how good of an idea it is. So having something that the kind of bureaucracy that that assists the legislators in their jobs, making sure that they are supportive of it and it's implementable is a really important component. And so that involved for me, over the last couple of years, a lot of conversations with our regulatory authorities about, you know, if this idea were to go into place, what are some of the concerns and considerations that you would have as the people that would be writing these rules and enforcing it? You know, what are the things that you would want to see in it? What are the things you wouldn't want to see in it? And, well, they're not gonna, you know, come out and say, Oh, you know, we love this bill so much, and we, you know, we want it to pass. But having them on board and understanding what we're proposing and being willing to work with us on it is also, I think, a really important component of this process. Because if you don't have the support of the people that are going to put your ideas in and implement them, you know, it's going to be a struggle for the rest of the time. So I do, I would encourage anybody that's that's considering, you know, trying to interact with, with the legislature with a bill, to really spend some time talking to the folks that work for the state that that bill is going to affect and make sure that that you're not doing something that you don't understand the unintended consequences of also.

Wayne: Yeah, it's your own - managing your own time, energy and effort to go so far down a road just to hit up a definite roadblock that you could have caught a year or two earlier, by just asking questions is really important.

Micah: Yeah, and one of the ways that that uh, that a agency like that can derail a bill is by assigning a - So one of the things that has to happen for most bills is they have to get evaluated for their fiscal impacts. So one way that an agency can kill a bill without really very much work is to just put a real high fiscal impact on it, and to say, Oh, this is going to cost, you know, $20 million to implement because we're gonna have to hire 30 people and buy all this technology. And a lot of times, you know, that's a deal breaker.

Wayne: You almost have to address that. I imagine most of the infrastructure's in place for this type of craft license bill, shouldn't be too much of a cost. Yeah.

Micah: Yeah, yep. They but they can, you know, they can get creative and how they interpret things if they feel like it.

Wayne: There's one other part to this. So this is House Bill 2279. And I think you said there may - there's sometimes a way to do this where this license could be added to a, an amendment of a different bill or like an add-on and then if that bill got passed, it could go through? Is that, is there another strategy piece that this could happen?

Micah: Yeah, so that's definitely one of the things that we're now working on. It's it's - in all likelihood the bill, while it did get a hearing, it didn't progress past that point. So it's, it's pretty much impossible for the bill to go through as-is this year, because it's not, it hasn't progress out of committee by the time that it, what they call the cut off. So one of the things that we can do is we can look at some other bills that are in the cannabis space. And we can approach the people that are, that are advocating for those bills. So the, you know, the legislators or the people that those legislators are, you know, advancing that bill on behalf of, and we can try to see if there's areas of compromise where a component or all potentially of our bill could get added to theirs as an amendment. So one of the things that we're looking at are opportunities to introduce the definition of the craft producer, without the other components necessarily. Because you know our strategy there might be to, to establish this license type, give everybody the opportunities to switch over to it. And then that gives us a better place to organize all those small farmers for a push for direct sales, and for our advisory board and, you know, whatever other differentiations might be, might be amenable to folks. You know, there's definitely there's a longer term strategy for for some of the sorts of things that we want to see come out of the craft economy that this would produce, you know, or some of the ideas that people are really excited about are farmers markets. You know, we used to have farmers markets here in the medical days of Washington cannabis and those are really great places to acquire really fantastic cannabis, but also to, you know, just be in community and meet people that are, that are also doing the same thing you are in learn about plants and learn about different, you know, varietals that are available and smell and experience all of the, all the different things in one place. So bringing back that opportunity, I think is really appealing for a lot of folks. Another component of it is the ability to do like a special event license similar to what is allowed for alcohol. So if you're having a special event, you can get a permit from the Liquor Authority that allows you to serve alcohol at your event. I don't think there's any reason why we can't do something similar in the cannabis space and have had these sorts of events that are, that are about normalizing cannabis and allowing for community to build up out of it. Because you know, that's another big component of why we're working on this bill is to take a look at - what are the, what are the social relationships that come out of, you know, these economic interactions in the cannabis industry? And how can we change the structure of things to produce, you know, social and economic relationships that are, that are scaled more to community than they are now. And since certainly having a small farm that people work at and people can come into and tour and really see what's going on and understand the people that are growing for them, can have that direct economic transaction. It also facilitates the social relationship that isn't currently available. And it is opportunity for community to build out of that.

Wayne: Yeah, absolutely. That's, that's so interesting. I really hope this gets some progress and keeps going. Before we kind of end up you know, I want to ask listener - say what listeners can do to help support but I do have one last topic on kind of growing craft cannabis, strain names, how it's merchandised. And I'm so interested in this state by state, as the Sativa/Indica myth we'll call it, is really carried over from the legacy of the black market, Sativa thought to be uplifting, Indica relaxing, and we know now that it's really the cannabinoids and the terpene profiles that're responsible for effects. We're seeing that really get traction in Oregon. Most of the budtenders know, a lot of the consumers - some are coming in saying, what do you have dominant in Limonene, a certain terpene they like. Is that happening in Washington yet? Or does it feel like a lot of stores aren't merchandising based on actual effects? They're still that sativa-indica-hybrid, kind of binary setup?

Micah: I would say there's, there's opportunities for folks that are interested in moving beyond that, that sort of shorthand of sativas and indicas to describe experience. But I would say, predominantly, the stores are still using that vocabulary. We made an intentional decision pretty much from the, from the get-go of our brand to not use those shorthands, because that's ultimately what it is. Right? It's just, it's a sort of an easy way to say, relaxing or energizing. (Yeah, yeah.) And so I mean, I kind of understand why, why people do it.

Wayne: It's just simple, as a system. If it was true, it'd be great, it'd be nice to have these simple categories. Right?

Micah: Right. But we what we've done is, so we talked about cannabis as first, you know, in categories of type, so type one are high THC strains, type twos are mixed ratio, and type three is our high CBD low THC strains. And then within each of those categories, we've created what we've called the hues of experience. So our, all of our different strains are, are categorized by experience. And then there's, you know, three or four different categories under each of the typology, and we use a color to communicate effect. So, you know, our, some of our, what people would would traditionally call a sativa experience are, you know, yellow, or red, kind of depending on where in that spectrum they fall. And then we we have, you know, just descriptive words that talk about experience to describe each category. And so that's allowed us to create a more nuanced conversation tied into experience, rather than, you know, this, you know, plant grows...

Wayne: Yeah, tall, skinny, bushy.

Micah: Yeah. And so we've always tested all of our individual lots for terpenes. And we put that information on the, on the labels. And so we have a lot, you know, a lot of history and data from a lot of different years and strains about what the terpene breakdowns of each of those strains are and, and we've spent a lot of time trying to correlate experience with that data. It's, it is, you know, fully a part of our brand and I think it's really appreciated by a lot of people that consume our products. And it is a work in progress to, you know, to bring that to as many people as we can, and there's definitely lots of other people in the industry here that are that are having some of the same conversations. I think you guys are probably a little bit more, you know, you all down there a little ahead of us on on having those really important nuanced conversations about it, but it's definitely happening here.

Wayne: Yeah. I always wonder and you know, we do it on the edible side, we do strain specific, we look for dominant terpenes. And I've always kind of felt like, Are we too far ahead of the ball? I mean, we want to be accurate. And I mean, sativa and indicas, to me is kind of - that's what the consumer's looking for. So do you want to tell them that, although it's kind of - it's not a lie, but it's misinformation based on effects. But I wonder how far ahead we are, if we're too far ahead, or when the consumer - or will it only be connoisseurs that end up really being, having an interest in that? I would be curious to how it'll evolve.

Micah: Yeah, I mean, I think a lot of that is going to be dependent on who's making those choices. And what is their position in the supply chain? And what is their motivation? I think, you know, you just described as somebody who really understands that, the sativa/indica isn't an accurate way to describe experience, you know, as it's tempting to use that shorthand, because that's what's easy to communicate. But you know, for somebody that like doesn't even really understand the nuance of the sativa/indica inaccuracy; they're obviously just going to use that shorthand. So if you start to, if you start to allocate more of the decision making power about value to people that are more and more disconnected from production and disconnected from the plants and disconnected from the products that come out of them, I think we're going to see more generalizations and more kind of whitewashing of this nuance, because it's gonna, it's going to make it easier to commodify cannabis. So I think that's a, you know, that's an integral part of this conversation about craft cannabis. Because, because it again, it talks about scale. And it talks about ownership. And it talks about who has control over what gets produced, why it gets produced and how it gets talked about. And I don't think we, I don't think we have a very good chance of, of bringing all of the complicated, you know, nuance that we know exists in cannabis, to a broader audience if, you know, we go in a conglomerate direction for who owns the industry. I just don't think that we'll end up in a place where we get a satisfying end result in that arrangement. I think we're going to have mass produced. We're going to start to see strains that are, that are bred and produced for profit, rather than for the qualities that they express, so we're going to let you know, we're going to start seeing strains that are grown entirely based on structure, and how easily they can get, you know, processed by machines. You know, these are the sorts of things that factor into decision making. And it narrows the choices that we all are left with. (Yeah) And that's the, you know, that's the key of how does, how did the economics of a thing affect the way that it that it allows us to live our lives? And yeah, that's the, that's the core of it for me.

Wayne: Yeah, I think ultimately, both parts - all the parts should exist. If you're looking for the cheapest price, mass produced volume, you know, big scale up, Big Ag comes in that market. I think is going to exist without a doubt. The question is, will the other part of the market be able to exist? The craft, maybe that medium volume value producer. And if those things aren't set up, it's kind of skewed towards that mass volume approach. And we see in beer and distilleries, like each market exists, it's not that craft is going to be 100%. But we don't want to see mass volume become 100% or 95% of the market. (Right.) And if it doesn't happen soon, you're gonna see all of these craft businesses go out of business, and then five or 10 years, if they enact it, it kind of like, Well, you know, tons of people lost their life savings, there's so much chaos and turmoil because of it. But, you know, how does that market exist and thrive? Yeah, it's so fascinating right now.

Micah: Yeah, absolutely. And there's, you know, I mean, I, the thing I'll say about that is there, I believe that there are ways to produce efficiently at scale that don't force us to turn all the power and decision making over to, you know, large, disconnected ownership groups. I think there's ways to look at, how do we scale in, in worker cooperative forms of ownership? You know, there's examples, especially in the agricultural world and in the history of agriculture, that that producer co-ops and worker co-ops have allowed industries to scale to really very large entities that do things at a larger scale, but that are that are created through a more democratic and a more bottom-up organization then we see in our in our kind of top -down modes of ownership here, and so that's definitely something that we're talking about with, you know, in the - I think we're getting into a whole different podcast episode. But yeah, you know, we're starting this important thing, that we're having a conversation in Washington right now about social justice and equity for black Americans in the legal cannabis industry, who have largely been left out of our regulated marketplace. And one of the ways to start to fix that inequity, in my opinion, is to set up the ability for, for people to come together and work around cooperatives, which is not functionally possible in the regulated industry here in Washington right now, because it's a real direct way to have equity for the largest amount of people in real ownership equity. And I think having conversations again about scale and about ownership is really important and in looking at how did those relationships effect what comes out of an industry? And I do think we need as an industry to look towards cooperative forms of ownership to help us come out of this process with the best results for the most people.

Wayne: Yeah, absolutely. Micah, I really appreciate the time, and I really like - I really like this and what you're doing, this craft license legislation and bill. You know, I haven't heard any talk of something like this in Oregon. There was you know, this focus on the craft producer and how can we save that part of our industry? And it's kind of all been focused on export, trying to get export allowed as soon as possible. And to me this seems like a much more immediate solution, export just feels too far away. Also, as it seems like export big volume producers are going to do better when they can export. But yeah, I hope we see something like this in Oregon.

Micah: Yeah. I was surprised by that strategic choice in Oregon as well. And I, if - if you have folks that are, that are interested in pursuing an idea like this in Oregon, I'd be more than happy to, to be put in touch with them to be a helpful component of, of that.

Wayne: Yeah. I appreciate it.

Micah: Another thing I want to put in a plug for, which has been a terrific benefit for us, is there's an organization here in Washington called the Cannabis Observer. And so they're a group of people that that go to every single legislative meeting related to cannabis, every single regulators meeting at the Liquor Control Board, and they observe the meeting, they take notes, and then they put up a summary on their website. It's cannabis.observer, and, and that allows us in the industry to have a really regular, detailed, comprehensive look at what's going on from our regulators and from our lawmakers that are going to affect our industry, and has been a really valuable tool for me and for a lot of other people that are trying to stay on top of what's going on. And they're a, you know, the nonprofit, volunteer-funded and you know, people in the industry give them 10 bucks a month on Patreon to, to keep doing that work. And that has been something that has been really tremendously helpful for us. And I imagine would something like that would be a real benefit in Oregon too, because staying up to date on the on the changes can be a ton of work.

Wayne: It's difficult. Yeah, yeah. Yeah, we'll link to them in the show notes. That's a great resource. Great, and appreciate that work they're doing. So as we wrap up, you know, where can people find you? And what do you want to tell listeners - How can they help support? What are your kind of next steps? Anything listeners can do right now to help this bill and this craft license in Washington?

Micah: Yeah, absolutely. So we set up a website for this campaign called washingtoncraftcannabis.org. And you can sign up for our email us there, which is you know, we're putting out action information about what's happening with the bill as it happens. We send out instructions for how people can get in touch with legislators. Certainly, you know, people in Washington that are constituents of these legislators are the are the main people that they like to hear from, but it's certainly never hurts to you know, send some emails from elsewhere as well. And then you can find out more about Raven Grass at ravengrass.com. That's our website. And then as far as the bill this year, you know, the thing that could be the most help for folks would be to, you know, reach out to people that you know, that that live in Washington and that this would affect and let them know about the website and signing up for that. And, and as we move forward in our process, through this year and next year, we're definitely going to have moments where there's calls to action for folks to show up in Olympia and testify, or sign in on behalf of the bill, or, you know, send, send emails to legislators when we need action at particular moments. And I would say that, you know, the biggest thing that folks can do is to stay engaged, keep kind of abreast of what's going on, and, and be talking to your friends and neighbors about some of these ideas and some of these, you know, things that could potentially be available to all of us that would improve just the way we get to go through our lives and how we how we buy our cannabis and the quality of that experience and, and the downstream effects of, of how we choose to buy and sell things because it's a you know, it's a huge component of what we're doing here on this earth. And we don't always think about how the structure of it affects the results. And that I think is, you know, the big - the big message of our bill is start thinking about that and moving forward in a more intentional way.

Wayne: Yeah, absolutely. You know, I think even if you're outside of Washington, we're going to follow this. I really hope this you know, goes through and you guys are able to set this blueprint, which ultimately I think needs to be in it feels like every other state as well. And you know, the details, logistics need to be figured out, but the overall goal of it. I hundred percent, you know, believe in and stand by. So I really hope this gain some more traction, and we're able to see something like this happen. I think this is awesome work. I appreciate it.

Micah: Yeah. Thanks so much for the opportunity to come and chat with you about it. I really appreciate it.

Pe137 Change in Direction Announcement

You may have noticed a trend in recent episodes. Companies being challenged to adapt and solidify product market fit as the cannabis market evolves. We’re not immune to these changes, and have decided we need to adjust our strategy. This episode discusses our challenges at Periodic and a new direction for the podcast.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe136 WeedWeek Swapcast part2

Listen in as Wayne interviews Alex & Donnell from WeedWeek about their journey and a behind-the-scenes look at running a media company in the cannabis industry. WeedWeek has been a staple in cannabis education and activism.

Link to Forbes Article - 2019 Top Eight Cannabis Podcasts You Need in Your Life.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe135 WeedWeek Swapcast part1

Listen in as Alex & Donnell from WeedWeek interview Wayne about Periodic Edibles and why he started the Periodic Effects podcast. Get a behind-the-scenes look at decision making strategies for small “craft” companies in the cannabis industry.

Link to Forbes Article - 2019 Top Eight Cannabis Podcasts You Need in Your Life.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe134 The Mary Jane Soda Story

Matt Moody started Mary Jane Soda in 2008. After some initial success and media attention, the business ended up closing its doors. We discuss why that happened & the lessons he brought to his new company, Bellwethr. As many more Hemp CBD companies come online and competition increases in THC markets, it’s critical to adapt to changing market conditions as early traction doesn’t guarantee long term success.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe133 Longest Standing Edible Company in Oregon

Business focused episode. The cannabis landscape is evolving quickly. It moves even faster in “pro small business” States that didn’t create an Oligarchy with high costs and low license caps. Our guest is Elbe from Elbe’s Edibles, the longest standing edible company in Oregon. We discuss their 10 Years experience in cannabis and why “crystal ball” predictions are hollow.

Link to Join Email List Community for insights we don’t share anywhere else.

Episode Transcription:

Wayne Schwind, Host: Alright, joining us today is Elbe from Elbe's Edibles, otherwise known as Laura Brannan, co owner and Chief Creative Officer of Elbe's Edibles. Thanks for joining us today, Elbe. You guys just had your 10 year anniversary, you're one of the oldest, longest standing edible companies in Oregon. So I'm really excited to have you on today and get your insights, thoughts on the market. All those different things we'll dive into. So thank you for taking the time.

Laura “Elbe” Brannan, Guest: Oh, thank you Wayne. I am really excited to talk to you today. And yeah, our 10 year anniversary will be coming up on July 1. Well, we're about nine and a half years in, but we are super excited about that.

Wayne: Yeah, I'm sure it's been a hell of a journey. A lot we could talk about - how did the name Elbe come about for the company? And I always thought your name was Elbe until recently.

Elbe: Yeah, well is the name I prefer to go by, in general, my biological name or birth name is Laura Brannan as you introduced me. And when I was in junior high, my friends just started calling me LB. I think there was a character on Happy Days Lori Beth and she also went by LB, so kind of the same timing that might have been the start of that. And then I just kept being LB through high school and Coach ended up putting E-L-B-E on the back of a jersey. And that's how Elbe became LB. And that's who I've been since I was about 17.

Wayne: Awesome. I imagine early on and even still, now the market is so, you know, it's very relationship based. Was there kind of a thought when naming the company that putting the face behind it in the name? What were you kind of thinking with naming the company there Elbe's Edibles?

Elbe: Well, Wayne, if I really would have had this magic crystal ball, I wouldn't have put my name on it. Because I have to tell you that is problematic at times because I'm no longer a private person. I'm a public face. And so that is something to think about for anybody who's listening to this. When you're thinking about naming your company, really think about those things. It became Elbe's Edibles because my husband Hovering and I, we had a photography business. We were professional photographers, and we started making edibles because my best friend's mom got breast and lung cancer. And we just started making food for her. We went to a patient potluck. And these two kids walked up to us and said, "Hey, have you ever heard of brothers cannabis club?" And I was like, "no sure haven't." And they're like, "Well, we're one of the few clubs in Oregon that gets food to patients, would you come and talk to our boss?" And so when I went and talked to their boss, Bo from brothers cannabis, he's like, "Really, if you just put these in packaging and put a name label on it, we could really get these locations." Well, my name was Elbe, so we just started calling it Elbe's Edibles, and that was how the accidental business started.

Wayne: That's amazing. So that's how the - What was it, what was it like? I mean, back then was a really hard for patients, I'm assuming they could source flower, probably some extracts, RSO, but was the edible landscape really difficult for patients?

Elbe: It was ridiculous. It was really hard. In fact, most of our patients - I told you we were photographers; about three weeks after we met Bo from Brothers Cannabis, I just looked at Hov one day on a drive and I said, "I want to quit photography and I want to do this full time." And he was like, okay, crazy. Let's do that then. And we had - I think there was WeedBook, was like a forum online for a few days. There was reader boards at dispensaries. But truly in those first years, we only had three or four dispensaries that we delivered to. But most of the time we were meeting patients in the Fred Meyer parking lot after dark or going to their apartment. But you know, there was so many fears around it at that time, we really were still meeting people in dark alleys. And we were meeting people outside of their homes because they didn't want their kids to know that they were using cannabis or they didn't want their kids to know they were even sick sometimes. Yeah, it was very, very hidden, hidden in those first couple years.

Wayne: And what kind of patients - I mean how are you thinking about products? I'm guessing you probably were meeting a lot of different people with completely different kinds of ailments or issues they were trying to figure out by using cannabis. Was it difficult to figure out products early on, like what types to make and then different, you know, for different patient needs?

Elbe: You know, Yeah, that's kind of kind of a long answer to that. When we first started, we were basically just growing and making food for the majority of our friends and then their friends. It was like one of those networking things. Hey, my friend has breast cancer. Do you think you could help? Hey, my, my brother's having seizures, my sister's having migraines. And so by word of mouth, even in those first couple of months, we were flooded with requests. And though as soon as you start taking care of patients then other patients - you know, the, the, you know, if you even just thinking about how the internet was even 10 years ago, when we started this was a lot different. So you asked about how we came up with the items. Truly what we were doing at first was treating symptoms, treating side effects from medications and treating side effects from treatments for cancer. And so we were looking at things from that perspective. How do we make people who are sick, feel better? And we had the - as I mentioned before, my best friend's mom Kathy, she was really kind of our guiding force and is still kind of the voice at the back of my head. She made it very clear to me just in her actions and her words, how awful it was to go through cancer, not just because she was sick, but because everything phone calls you have to do all day paperwork you have to do explaining to other people in your family. It's just this whole life effect of having cancer.

Wayne: Money, finances, on top of all that, which is such a burden.

Elbe: Dealing with your spouse and how your spouse is doing - and here's the other thing, Kathy's husband was a retired sheriff's deputy. And he was a sergeant. So it wasn't like they were going to be open to smoking weed in their house. It was something that also too you know, the conversations had to start very delicately. That said, there wasn't a lot of information out there. There wasn't a lot of THC cookbooks out yet. There wasn't Canna-butter recipes on the internet really yet. So what I did was my mom was an antique dealer. My mom and dad, and I had a bunch of old antique cookbooks from them on hand because I always cook. And what I noticed about them was, in the old days, the cook or the mom had to be the doctor in the house because your doctors were 400 or 500 miles away. And so in a lot of these old pioneer cookbooks, they talked about different foods that were good for different ailments. And in one particular cookbook, I remember it being like, you know, they were - moms were treating heartburn, hemorrhoids, headaches, tooth aches, muscle aches, and it had all of these things in this book on how to use ingredients to make your family feel better. And I started thinking, well, if lemon was used 300 years ago for belly aches, what was that about? And so I started digging into it. And I found out that when you add lemon to something, it hits your belly, it upsets your pH balance. And then there's a signal from your brain that says, hey, we need to mellow out this belly. And so really what it was doing was, how can I use ingredients that we know how they already worked with the body? How can I figure out how that works well with cannabis? And we just started experimenting on about 12 of our friends, you know, every way we could think of.

Wayne: Getting feedback and - that's so funny. My significant other is Chinese and her grandma, you know, grew up in rural China. She doesn't speak English, but whenever like one of us gets a little bit sick or something like she's got something for you to eat. That just reminded me of that so much, because doesn't matter what it is, she's ready. She's making something, some kind of soup, some kind of terrible tasting elixir that you gotta drink and it's gonna help.

Elbe: Let me stick this thing on your chest. Yeah, I grew up here in Oregon. I was born here in 1968. My parents were parents in the 70s. They are - they hate to be called this but there they were hippy dippy. And for sure my mom would stick cloves in my mouth if I had a toothache, or made me drink aloe vera in my orange juice, you know, like, so those things were kind of already in me. And because I had this influence of moms trying to make things better on a budget or because they didn't have doctors. I just went with that. And so I spent a lot of time researching foods, how they work in the body, how the body reacts to breaking down fat and for me every little single bit of that just added to my recipe book.

Wayne: Yeah. How - What did you learn early on, and how are you thinking again, what different products you were making? And then I guess leading up to rec I want to, that probably is gonna be a separate conversation. We'll get there, but I mean, the markets changing, you're learning. Were products changing every six months every year doing new ones, or did you have some consistent, like your foundation products? I mean that right, because you went five-six years in the medical market before the rec came around.

Elbe: When we - when we went from medical to recreational I had 32 menu items. And so yeah, and they were so this is how I did it in the old days. First, we started with just a couple basic cookies. And I was like, oh, okay, that works. And you know, again, this was before labs, and what we did was, I don't know if you've noticed we have a star on our logo. We decided, well, if we make a recipe with this amount of butter in it, it's probably going to be this strong. From our test group. We had this group of friends that were all genders, all ages, some sick, some healthy, tall, short, fat and skinny. And we were collecting information on them all the time. And one of the things we found out right away was, it didn't matter size, shape or gender. Every single body reacted a different way to edibles. But that body reacted consistently to that, to edibles once you figured out their, their - their puzzle. And so we figured out that if we put this amount of butter in the candies, the - we should put a one or a two star on it because that was going to be a lower dose around. Now we would probably compare it to five or 10 milligrams, and then we had things all the way up to 12 stars. And that's how when we labeled things in the medical days, we would put the stars on our package. So a customer, a medical patient can walk into a dispensary and said well, you know, I tried one of Elbe's cookies, it was three stars, and that was a perfect dose for me. And then you could look across my menu line. And anything that was three stars, whether it was savory or sweet, would then work, that would be about the same amount of medicine getting into you. And so like I said before I started it by treating symptoms. And so first it was cookies. And then I started thinking about, well, mostly everyone I know is really nauseous from their radiation or their chemo. So how can I deal with nausea, so then I started digging in and making foods that had a lot of lemon bases in them and an orange bases in them. And then I started having a lot of patients request, I get migraines all the time, I've got headaches all the time. So then I started digging into what really works well for migraines, and then develop menu items from that. So everything in the, in the beginning days was patients coming to me and saying, I have this thing that's going on, can we fix it, and then if I can fix it for them privately, then I would introduce that to a dispensary and if people enjoyed it, then I kept it on the menu and if I introduce something dispensaries and nobody liked it, I was like, Well, obviously that didn't work. And so really everything for the first five or six years until recreational, everything here was reactionary. Like you we have a problem. Let's fix it, you have a thing that's going on. Let me see if I can make that better for you. So that's how we decided all of our product lines. And we got really sick of making candy. So we made cookies. We got sick of making cookies. So we started making pound cakes and lemon bars. And then everybody started telling me you know, sugar feeds cancer. Can you make savory products? So then we did a spaghetti sauce. We did empanadas. We did chicken pot pie, beef pot pie. Macaroni and cheese, macaroni and ghee-se. So we you know, every time somebody complained or asked for something, that's how we developed our menu, and that's really it. It was really just that that's silly and simple.

Wayne: Yeah, that's so beautiful too because the early days to be able to do - I mean that's the ultimate way I think you want to build a business, is test quickly, small product batches, and let the market tell you if they want it or not. The state we're in this, rec - you need regulations, it's, I don't know, it's always a back and forth of how much how little but you really can't operate that way now,. If you want to roll out a new product line, the control study, the packaging, the approval, like you're investing a lot of time and money just to get a new line out. You really, that's difficult to do now. And then if it doesn't work, to turn around and walk away from it, you're like, well, I just put so much money into that and time to get it through. That's great you were able to do that.

Elbe: It's the biggest stumbling block about working in edibles in the current market. We tell everybody, it's about $10,000 to bring an item from recipe to the shelf. And that's a huge investment without knowing something's going to work. Or in my case last year, I had two items that I brought to the shelf that were really working well and customers loved it. But then the state said, how you're testing it is not working and we had to pull that product. So we have this tested product. We put the money in into it the label into the labor into it. And then the state's like, "Yeah, no." (Laughter)

Wayne: Yeah, that's the other thing, that states set the regulations and enforces them and there's always a little bit of gray. You know, how they're going to interpret it. And ultimately, what comes down to it. It's their decision when they're not as informed normally, they're not inside the business doing it day to day and yeah, that's Yeah, it's growing pains. It's a big part of this now, it makes it a lot harder.

Elbe: It's also hard when you are talking about hiring employees who love to work in food, you know, we have always considered Elbe's "Food First". I try to really explain this to people. I know a lot of people get very excited, Oh, I want to work in cannabis. I want to come work at your edibles company. And I you know, I just never hire anybody who wants to work at an edibles company. I only hire people who want to work for food. Cannabis is one tiny ingredient in my food. It's just one of the things. And most of the time when people work in food, they get really excited because it's a creative environment. And you get to try new things. And, you know, I've worked in plenty of kitchens where recipes are developed on the spot. Right now, we're not really able to do that, because we can't be creative in our kitchen. And you're only allowed so much R&D and you're only allowed to try, you know, so many things. And, you know, we'll get there Wayne, but I'm not very - it's not as much fun as it was for sure. And I mean that sincerely across the board. It was a lot more fun to work in edibles in the medical day. Yeah, because there was so much satisfaction from the consumer. And from making it and I think right now one of the problems, and you probably feel this too, is you don't get a lot of joy in being able to make your product because it's so regulated and so regimented. And then we are cut off from our consumers because we have a retail store. And so we don't get that feedback from them that they like our - the only feedback we get is how many units were sold. And that's, that's hard. That's a that's - when you work in food in general, most people who work in food are making food in an area and then serving it to somebody right away, you know, and some of that stuff is lost on us.

Wayne: Yeah, that's such a change. And I think the perception of what people would think edibles are, or how this business works, you know, that you really got to correct that misconception, because it's really important one, how much it changes, you know, the business and the role or what someone might be doing. What would - You know, you talked about savory, people. I've heard that more and more. And over the last three or four years that we've been operating, people wanting more savory options. I still don't see very many of those on the market, is that because we went into the recreational market now? Was there more savory options in the medical days? Do you know why those just aren't as - I hear the demand for them, but I don't see them on the shelf just savory option edible options. There's a few but not very many.

Elbe: Yeah, I tell you, it always comes down to the same thing for me, I, I say this a lot. We're all learning at the same time. And just like you and I had to learn how to go from medical to recreational food processing, the dispensaries had to go through that change too and right now the dispensaries are retail stores, right. And the people who are running the retail stores and who are managing the retail stores. They probably didn't spend a lot of time working with their background in grocery stores or food services in general. And so until the dispensary's understand how to deal with fresh food, how to deal with rotating stock, there's just not going to be probably a lot of people who are going to take that risk and jump into savory food because your shelf life is shorter. And it requires attention from the store and from the manufacturer. And that's because food has to be handled safely. And right now, the dispensaries and I get it, It's really easily easy to handle things like gummies and things like that, right? You throw them in a safe, and you throw them on a shelf. My food has to be refrigerated. My food has to be rotated, my food has best by dates on it. And when you are running a dispensary and you have 500 brands to take care of, having a brand that requires extra care is not always easy for the dispensaries. And so when we talk about savory foods, we are going to be talking about the dispensaries having to level up on their responsibility for dealing with vendors who deal with food. Because one of the things you might have noticed is in the winter time, my food is in the refrigerators and it has all the space I need. But in the summertime, when the dispensaries get warm and the extracts start melting, suddenly my food leaves the shelf and they throw the extracts into the refrigerators. You can't do that with food. I still have, I still have dispensaries who have in the last year, taken my food out of refrigerators at night and put it into their safes to lock it and then put it back into refrigerator. That's something we can't do. You can't take food out of the refrigerator and put it into a warm space and then back into a refrigerator.

Wayne: Yeah, and they have their own regulations, they've got to store everything in their secured storage area.

Elbe: Yeah, and so until everybody kind of elevates our responsibilities and our eyes for detail. There's going to be a lot of things that are going to be coming down the road and I think savories are coming down the road kind of situation. The packaging alone is a nightmare for food, as you know.

Wayne: Yeah. And you can't make small batches. Which you probably need to do for savory. With the lab costs you have to do a big process lot. So you want to do you know, at least 1000 units, maybe around or even a little more. And then that whole time while it gets lab tested and you got to get the packaging printed with the right - and next you're looking at a three week hold. Where normally in any other food industry, you make that product, potentially go sell it the next day. There's nine weeks off your shelf life just by on the waiting time.

Elbe: That's - That's what I'm saying, it's like, do you want this chili that's been sitting in my fridge for three weeks, right? No, no. (Laughter) But, eventually we'll get to canning and we'll get to you know,. pressure - pressure containers, all of that stuff is available to us. But again, a company like ours at Elbe's, we are a tiny mom and pop, there are really six of us that - three full time people and three part time people and the six of us make the food, sell the food, deliver the food and keep the place clean. They're like that's, that's our full time job. And so we don't make a ton of money, we're not you know, nobody's making money in this industry right now. But if I want to get into savory food I have to invest $50,000 for a horizontal flow rapper machine. You know and then I have to invest another $50,000 for machine that I can make soup, you know, a kettle machine. So those are also the things that are down the line. A lot of the savory foods require huge amounts of money going out the door just for the equipment.

Wayne: Yeah, that's one thing I found so interesting, you know, smaller companies. I'm always curious, you know, cuz we're in a very similar position, smaller company and wondering how we can compete against bigger companies. But one thing that's interesting is everyone looked at this industry as the green rush, but the bigger companies that have went public or on the Canadian Stock Exchange, they have to release their numbers. I have not seen a single profitable company be listed or - that has to like publicly show their numbers, not a single one. And I still see some people say green rush every so often.

Elbe: I'm still related to people and I still have friends, even though I've been doing this for 10 years. Even though I've been broke as a joke for 10 years. They still think that I am going, like I have gold in my house, I have gold bars. But Wayne the truth is, is that Hovering and I have gone without heat for the last four years. We can't afford oil. When you say how do we - How do we survive against the big companies? I don't know. But I do know this, that we have sacrificed everything for 10 years. We work seven days a week, we work 16-18 hour days, our business partner Gretchen who works with us, she came on as an employee, we've given her part of the business. She works as many hours as we do. And we also don't have any money to waste. So when I look at the big companies, and I see them with banners everywhere and I see them at conferences everywhere. I just assume that they're losing money. But I don't know for sure. I don't, all know is for us, how we're going to manage this is we are just going to keep our head down and keep working and keep working and not ever quit. Never, ever quit, be super flexible and never quit. And I think that's how we'll stay open. If that doesn't work, then I don't really have any other math because it's just hard work and determination. And I think that any respectable brand will tell you that it's hard work and determination. Not Instagram followers. But that said, that's a huge important part of this industry that I wasn't prepared to deal with. As somebody in my 50s, I hear all the time, "Elbe, your social media game is weak." And I'm like, "Dude, I know, my computer game is weak. But my bacon game is strong." (Laughter)

Wayne: Yeah, right? I think if anything in this, you know, if anyone's selling a product online or the hemp CBD stuff, you know, it's so much more important there, because someone can hit "buy now" from your website, but I think the reputation, the relationships, and then the legacy that you've built, being in the stores, and just that word of mouth over time, I think you can be a little weaker on the social media game, I think you cover the more important part, quality and delivery of product, people skills.

Elbe: Yeah, but you know Wayne, the people who are telling me that are the people in their 20s and 30s. Like you really got to get on the social media thing. And I try to listen to them because, you know, it's - it's the world we live in.

Wayne: And you got to pick and choose, like you said, when you know, you're looking at every dollar you're spending, what's going to be the most effective- money and time to spend. How do you - This is such a hard question, but it's something we struggle with and think about, like, how do you see this playing out in three, you know, one year, three years, five years? Is there a balancing point, like some stability, where we can say, Okay, this is our revenue, it's probably going to stabilize because Oregon, there's a ceiling, Oregon's not a big state, you know, there's only so many stores you can sell into. But we've seen this flood of new companies new investments, like constantly coming. Does that end eventually? And then then I think, well, interstate commerce or federal legalization? And does it start all over again? Like it's so hard to know, this timeline that we're on? You know.

Elbe: I think one of the things that I have figured out working in cannabis is that all of the crystal balls are completely fucked. Right? None of them are right, nobody has any idea. And I mean that sincerely. Because I cannot tell you how many meetings I have set in with potential investors or idea people or future tellers or future trippers, and none of that has come true. I would say it's a lot harder than I thought it was going to be. The rules are a lot worse than I thought it was going to be. The banking is tougher than thought it was going to be. And you asked me When is it going to change? And I'm, I think that I'm going to constantly stick with this answer - it's going to change when enough white powerful people have lost enough money in cannabis that banking gets changed.

Wayne: Or the tax code would be a huge one for us.

Elbe: Tax code, again though, like what I was just talking to you about, I would love to be able to go to my bank and say, hey, I've been in business 10 years, I have a great following. People love my product. I really love to expand my product line, can I please get $150,000 so I can buy these pieces of equipment? And, and this new, you know, labeling that I need? And every other industry, you have that ability to go to your bank and if you have good credit and you are in good standing, your bank will say yes Elbe I approve that loan. And let's make you a bigger badder company so you can hire more people in your city and state. But that's not where we are. And so always until we get banking, investors are going to be sketchy. People are going to be nervous, and there's - it's almost impossible to expand your business. And so without expansion, no growth right? Without growth, you die. And so I think really truly until banking gets turned around, I don't know how this industry is sustainable.

Wayne: Yeah, yeah.

Elbe: I mean, everybody I started with is out of business.

Wayne: Yeah. 10 years. Yeah.

Elbe: Not a single person that started with me is in business. And I think that probably three or four years into it is when Sour Bots started. And Danodan, and I think he's, he's in CBD now. Like, you know, it took three or four years for people to really be in the dispensaries with me, and most everyone is gone. Yeah. And it's you know, it's devastating because these are friends and family members that you get attached to and we're all trying to work towards the same goal. And, you know, I gotta be honest, though, at this point 10 years in, I try really hard not to focus on those things anymore. Right? Honestly, when I said that, that the future tripping it does not help, it does not help trying to figure out how this industry is going to go because this industry, we don't even know who, who our president is going to be in a couple of months. Right?

Wayne: Yeah. You just got ready and adaptable constantly. Yeah.

Elbe: I mean, I think that's really the key. That is the biggest, I think the biggest reason that we're still open is flexibility. Every time we get new rules, okay, pivot, every time we get a new challenge, pivot, every time something doesn't work out, pivot. I mean, you know, Gretchen Homer, our CAO, she sent us a text on Friday when we were out delivering, saying, "Oh, the new rules are going to be published. I can't wait to read them this weekend." Because that's her jam. She loves reading the new rules, and figuring out how we're going to adapt. And I'm so happy to have somebody on my team like that, because I see the new rules and I'm like, Oh my god, what's happening? What? What can we do?

Wayne: Yeah, you know, we started in 2015 and I'm trying to - You saying that made me kind of think, you know, who I saw when we started versus now and have might be, you know, we're five years later, almost six it was late 2015 and half the companies maybe that I remember and recall, but I have seen a lot go over to the hemp instead because lower regulations, easier, there's not that tax code, maybe the banking's little easier. Have you looked at or considered the hemp CBD side or I guess have thoughts on that?

Elbe: You know, for sure we've definitely thought about it because we're awake. (Laughter) You know, we lived through watching weed go from $5,000 to $400 a pound, and we are seeing that with hemp, right. And we're also because - we lived through an unregulated market with medical and have really hardly any competition and now entering into an another unregulated market with more competition than you can handle? Like, you know, it's, it's one of those things, it's, it's something that we're definitely not opposed to. I mean, we're always looking at other states and we're talking to other investors. You know, we still don't have any investors, we're still just a mom and pop with just friends and family investment, we're still looking for that team or that person that wants to help us level up. Part of that leveling up would of course be to have CBD lines only and hemp lines and all of that. Again, though, my focus every day is keeping the doors open for my employees who work here and getting the products on the shelf for the customers who are already relying on it. The big picture ideas, I leave those up to Hovering and Gretchen, because it's not my specialty and it's really not my, what I'm interested in. I am a product developer, I am a food specialist, whatever title you want to give me, I want to be in the bakery, making the food, coming up with new ideas and, you know, just working that angle. The rest of it, whether it's CBD or hemp, I can make any recipe with those products in it if you want food wise, also topically, so yeah, the big the big answer is yes, we've looked at those things. The short answer is no, I'm not in a big rush. I'm not in a rush.

Wayne: Yeah, see how it plays out. And you almost - I mean, you can't make it in the same kitchen. That's the other huge issue, if you could it would be a lot easier. But now you need a second operation, a whole new commercial kitchen. I mean that - there's a lot of cost opening up a second location just...

Elbe: And that, I have got to tell you, it is one of the most ridiculous parts of our regulations in recreational cannabis. The rules concerning how I can use my bakery, my personal bakery that I have built and you know, that is really hard to handle for me. I get requested all the time to make non-medicated munchie food, I can't do that here. I am not supposed to make birthday cakes here for my friends and family members, you know that - the rules of how I can use my office space in off hours is really prohibitive when you're trying to build your business as well.

Wayne: Yeah, and those are side streams of income that you could really use to support yourself you know, when you're a small business, that's the adaptable part but yeah, being locked in, it's hard to be adaptable or come up with those unique creative ideas that could you know bring cash flow.

Elbe: I mean, wouldn't you love to teach classes in your, in your space? I would love to teach people how to do Canna-butter classes here, but we're not supposed to do that.

Wayne: Is the fear then - I, I don't know if you know this on the regulation side or why this is the case - are they just really afraid of cannabis or THC ingredient could somehow get into that other food accidentally and then go out into the market? Is that really the only reason why they don't allow like even making hemp products in the same kitchen?

Elbe: I think that is their public answer. But I do not believe that that's the reason. I believe the real reason they don't want that is they're afraid that we're going to put stuff into the black market without them being able to track it. It's all about taxation and tracking. You know, "we're so afraid, a random person is going to eat a cookie and accidentally get high." If that was really the fear base, we would have a lot more regulations than we actually have. So really, it's about taxation always. And, you know, even how our rules are set up, you know, you know, I think we're only allowed to give our employees a certain amount of edibles. You know?

Wayne: It's very low, yeah. (Laughter)

Elbe: Very low! And you're trying to train people, so I have to go to the dispensary and buy one of my own edibles, and pay tax on it, so I can train my employees. That's problematic for me. So but again, that's, that's down the road. And I have patience for that. You know, when I think about the big picture, really, truly that you and I get to wake up in the morning, and we get to put Canna-butter into some really amazing products, and that there are people waiting all over the state for our products to show up so they can eat them to feel better or to get high. I get real dizzy when I really think about it that way. It's really, it's really fucking exciting.

Wayne: Yeah, we have to remember that. Yeah.

Elbe: Yeah, we have to Wayne! Because when you concentrate on, where are we going to be three years from now? Or how many regulations or how many stupid rules? Or all the things that make it not fun, it can really zap the love out of your food. And so I just really tried to focus on - it's really amazing that we get to do this and this is something I think maybe you can think about too, especially because I think you and I are the only ones who use canna-butter in Oregon. Right?

Wayne: Yeah. It's all I can think of.

Elbe: And I love Crop Circle Chocolates, they put hash butter, but I think we are truly the only masters of Canna-butter in Oregon. Now think about that worldwide Wayne. How many people do you think in the world get to do what you and I get to do every day? Very few! Like that is such a rare air. And I just really concentrate on the fact that at this special time in history, you and I get to do this thing that we were both made to do. I was made to do this. My body is made to make recipes a certain way, my brain works a certain way that I understand how cannabis and food work together. All of those things came together at the perfect time for me to do this thing, which is impossibly hard and ridiculously over regulated and stupidly taxed. But it's fucking amazing.

Wayne: Yeah. It's so funny when I started - and I want to ask, you know why you decided to use Canna-butter and also why you think it's not common and almost nobody does it - and when I started originally, you know, I liked the idea it's simple and clean and I can make my own and not have to buy an extract or set up this you know, huge fire code facility. But when I started, you know, small scale doing r&d batches at home, and then you Google how to make Canna-butter at a larger scale. There's nothing that exists, and I'm like, wow, I guess I have to figure this whole process out. You know, cuz I can't use a little, you know, one gallon crock pot anymore. But why is it so rare?

Elbe: You don't have 55 magic butter machines? (Laughter)

Wayne: Yeah, on a daisy chain of 20 (Laughter) Yeah, outlets and yeah, no, but -

Elbe: I - very simply, I picked butter because I'm a foodie. I'm a food maker and a candy maker and a baker and all those things. I picked butter because butter is full of fat, and fat and cannabis love to hang out together. Oil is you know, monounsaturated or polyunsaturated at best, it has less fat in it therefore less THC in it. Also, as a baker, baking with oil makes cookies flat, baking with butter and makes them fluffy and yummy. So for me again, it's always that cannabis is just an ingredient. I am a baker and a candy maker. How you make food best when you bake is to put a shit ton of butter and sugar and flour in it. That's baking. The same with candy making - How do you make candy great, you put a shit ton of sugar and butter in it and you boil and you stir, you boil and you stir, you boil and you stir. So that's why I use butter. Why do I think everybody else is using oils and extracts? Because butter is hard to make and it's expensive, and it's a lot easier to throw an extract into some oil I have tried it and just whirling around and then put on your - it's easier. Also when you are making gummies and food like that, it's better to not have butter in it because butter is a natural product and butter has a short shelf life. And so there's a lot of reasons to not pick butter when you're doing things. But I just choose to use butter because I think it's a better effect on your body for sure when Canna-butter hits your body. It is a completely different high than when you get high off of an extract or oil based edible. It's just science, and it's just real. So we started in medical, we wanted the most bang for the buck. We wanted to get the most THC into the most fat, and I wanted to be able to make foods that tasted amazing, the number one thing with us and going back to Kathy, the woman I started this business because of, her big thing was because her life was so miserable all the time, that when she got her medicine, which is what she called my food, her medicine, she just wanted it to look good and taste good. And she didn't want to have to plug her nose to swallow it. She didn't want to have to taste stems or seeds. And she really hated the flavor of cannabis. And so well, that's what we did. We just figured out a way to pack as much THC into the butter and then to make that butter tastes amazing and so that - and another reason we use butter by the way, is I find it easier to get the cannabis flavor out of food using butter. That's just the way we make it. Does that kind of answer that for you?

Wayne: Yeah, there's a lot of good points and some things I've similarly thought it is. It doesn't fit into every type of food product. But on the cost side early on. It was interesting. I always looked at it as being a lower cost. I haven't priced out distillates and extracts, you know assuming you still want a full spectrum extract right in there, but early on, you know, it's much more labor intensive. So your costs are on the labor side, the actual ingredients compared to buying an extract were a lot lower cost, right? But I had to build this whole process to make it, there's no like resource or guide on how to make large scale Canna-butter. You know, we need 20-30 pounds a week or something like that.

Elbe: You and Hovering should really sit down and compare your methods because he is my Canna-butter maker. And he, I think there's 37 steps to it. It takes several days, and I just usually stay out of the way because what he gives me is this really clean, highly concentrated butter and you know, we're so - we're just so blessed with the abundance of amazing weed in Oregon, like you know, and I know you know that we source all of our material from Doghouse Farms. And we source indoor bud and close trim. And the reason we do that is because that also helps our process. If something's from outside or it's dirty, or it's, you know, that takes longer to get that clean. And so, for us the method like you said, it took probably a solid year of Hov tweaking the different ways to get it to work for them, you know, making 25 pounds of butter at a time. And the reason we had to figure that out quick is because as you know, when we started this, we were unfairly you, your company and my company, we were unfairly looped in as concentrate makers or extract makers, and my butter went from costing $3.59 a pound to $1,100.99 a pound. And I mean, talking about a heart attack when Gretchen told me the cost difference I was like, well, then we're just shutting the door. Yeah.

Wayne: Yeah I was having similar thoughts. I'm like, I gotta change something huge. And thankfully, I was able to meet up with you guys. We got it figured out. But yeah, that was terrifying.

Elbe: Well, luckily we hired smarter than us and Gretchen was like here I have an idea. Let's fight this, and we're like, we can fight this?

Wayne: Yeah.

Elbe: And so she did. She contacted the OLCC. She got the Department of Justice involved. They all came here, the DOJ came here, the OLCC came here, the OHA came here, all of the, the big brains who make the decisions, and we walked them through our process, and we showed them that we were not concentrating, we were actually diluting, and that this was like the safest method you could possibly, you know, extract cannabis. And when they saw what our method was, they're like, well, there's zero danger in this. Yeah, that's what we were trying to tell you. And so as you know, then we were able to not be considered a concentrate. And we now make a beautiful canna-butter that does not fall under the same restrictions that concentrates fall under so yeah, good job. (Laughter)

Wayne: Yeah, another part of the story, that was an interesting time.

Elbe: Are you considering putting extracts in your food?

Wayne: No, we aren't. We're looking at the hemp side. We've been messing around with that for a little while but even there now with craft hemp. I mean if we had these industrial hemp that wouldn't be possible, but now the craft hemp sources are so - there's a lot of them out there, we would probably just make butter and we do the vegan caramels so for that we use coconut oil instead of butter.

Elbe: Oh, right.

Wayne: But when we put so much time into the method, and we've got it down, it takes you know, the week to make it but a lot of its holding time and certain things so I don't - I can't see a reason I think our costs are still, would be lower than, even factoring in the labor, than just buying an extract or a distillate. And it's one of our big selling points now because it's not an option in almost any other edible so it really helps differentiate us I think as well.

Elbe: I want you to know too Wayne, when we're out selling. You are the company we talk about. We always sell our company with your company. And I mean that, like 99% of the time when I'm talking to somebody, and I'm explaining to them Canna-butter I go, you realize that there's only one other company in Oregon who does it like this - us and Periodic. Like, we are Canna- butter masters, and it's really full spectrum and it's not marketing. And I really try to go in with every one of these sales calls, how we do what we do and why that's different than an extract high, why that's different than an extract edible. And I am so pleased to announce that after how many years we've been doing recreational when I have these conversations now, managers are very open to listening to it customers are very open to hearing about it, because at first it just didn't matter. You know?

Wayne: Yeah, those products on the shelf now there's so many stores they're thinking like they're looking at these things now. At first it was just put products on the shelf. Customers just flood in, and you sell everything you got. That doesn't work anymore. So now it does matter. Yeah.

Elbe: Yeah. Well, I'm, I'm really proud of being able to say that we are the two companies that do it. And listen, I know there'll be more canna-butter companies coming down the line. And that's great, good luck to you all because it's hard. And it takes a lot of work. But the other thing is, is I think that one of the things that we can continually do is always educate our consumers, right? And so consumers are catching on that having the whole bud is more important than part of the bud or just this one little part of the plant and I will say that always though marketing is really tricky because there's a lot of people now calling themselves full spectrum and it's just not true.

Wayne: The worst one I've seen is - I saw a product and I won't name any names but it said infused with Canna butter but when you looked at the ingredients, you realize they just put distillate into butter, and then called it Canna-butter and I saw that and I was like oh my god..

Elbe: Oh I know exactly who you're talking about, it's very irritating. And that's why I'll publicly announce - You and I are going to start a Canna-butter Association and you have to bud into your butter to be part of our association. (Laughter)

Wayne: What have you seen around - I think another thing that we constantly are struggling with now is our pricing. So we've really maintained and held our pricing, we haven't decreased it. And it's been important to us for that margin for all these reasons we're listing, but now there's so many other lower cost options coming in. I don't know if those companies are sustainable, if it's to get market share. I just - what have you seen on the landscape? Have you considered consider doing a price reduction or is it a struggle competing against other products? Because there's all these other low low options or what do you think about that?

Elbe: Yeah, it is a struggle, but I'll tell you one thing for sure. We cannot drop our prices. We are - if we drop our prices, we're shutting our doors. We're, we're trying to stay open. And the other thing is, is I'm really irritated by that, that that that people would think that we need to drop our prices. When I have managers asked me to drop my prices lower than a pre-roll, which is bud and paper, and I put eggs, flour, sugar, fresh fruit, fresh juice, I have a bakery, I have employees, I have insurance, I gotta drive a van. And now you want an edible for real like for $1. What? You know, I think it is. It's a real it's a real hard one. In fact, I have a hard time with this conversation because I understand that everybody needs to stay in business and I understand that our tax implication has made it so retail stores have to markup our products 100% - the consumers do not understand that. Soo when they see a price at a dispensary. They think it's crazy, right? They think oh my god, I have to pay $20 for an edible? (Sigh) Yeah, you do, because there's taxes and these people have taxes and I have taxes. And this is a social experiment. We're all trying to do this together. But also, there is food in our food. And so I can't cut the cost. My food costs change all the time. I don't know what it's like to work in a gummy factory. I don't - I assume I've made plenty of gummies in my life, your costs don't really change. You put sugar and flavoring and some, like whatever your recipe is, right? My costs change all the time. And my costs change because gasoline prices because I'm getting eggs from farms, I'm getting butter. I'm getting flour, I'm getting sugar, and I'm getting vanilla. I mean, when I started this company, a bottle of vanilla was $9 and 99 cents for like, you know, like a little eight ounce? That same bottle is 49 damn dollars now because vanilla is almost extinct in America or in the world. And so the cost of vanilla has gone up ridiculously and so, I don't use fake things in my food. So I use real vanilla. I don't use, you know, imitation and so my costs are constantly going up for food. And so I can't lower my costs in the dispensaries and it's really frustrating. Do I think the companies that are selling gummies and hard candies for two or three bucks out the door are going to stay in business? I don't know how. And I also don't understand - this is another confusing part to me. If a dispensary is marking up 100% at least - Why do you want to sell a $2 item versus a $10 item?

Wayne: Yeah, yeah.

Elbe: Aren't you making more money on my item than a $2 item? Yeah, like so it's again, this is one of those things when I talk about the entire industry needs to grow and elevate - dispensaries are learning how to run a dispensary, farms are learning how to run a farm. We are learning how to run a processing facility. All of those things are happening at the same time. And that is very unusual in any industry. I think it's probably out of the world that this is all happening at the same time. Because in any other industries say we you and I decided to sell shoes. There would be watermarks or templates already for how to do that, right? Like, I know if I make a shoe, that I have to have this much margin and that Payless shoes is going to make this much on me and my taxes are going to be that, like we could understand that supply chain. In this world. We're all figuring it out at the same time. And we're all making a lot of mistakes and some small victories and so none of us really know how to do it for sure. And so, unfortunately, we have to learn on each other's backs. And so dispensaries are learning. We're learning and farmers are learning all at the same time. And so - I get that the consumer wants the price point to come down. I really do understand that, I really understand that budtenders and managers will have an easier time moving our products if they're nearly free. But in reality, in sales, I don't understand why anybody in Portland thinks or anybody in Oregon thinks that they should be able to buy an edible that gets them high for six or eight hours and spend less money on that that they spend on a coffee or a cheeseburger.

Wayne: Right. Yeah. Do you think - do you think it's like um, you know, flower, the flower market was really high per pound, 2018 it really crunched it got all the way down to $300-$400 and now it's really went back up to $1000 you know, $900 on the low end even higher. A lot of our growers are like we had a great 2019 our prices are back up. Are we now where - were we just a little bit after the growers and now what's happening to us and it seems like retailers too and it's going to. You know, potentially with backup, or does it feel like it might be a bottom that's not going to move? It's a crystal ball question again, which is never good, like we said earlier, but-

Elbe: It is a crystal ball question but one of the things we have that's different than a couple of years ago, is, and this is the first time I've seen this for our company, you know, we used to have Croptober, and then the market would kind of dry up. And then in January, the market would kind of dry - like, you know, we'd have these cycles, and that's because in the medical days, our customers were customers who were patients. And so they were getting their stuff at the dispensaries and then in the black market. And then when we first went to recreational, we had plenty of customers who were still had a foot in the black market and a foot in the recreational market, right? But as the black market has kind of shifted and done its own thing since the black market cannot - Doesn't really, can't really sell stuff cheaper than we can at this point. What's happened is a lot of customers have crossed over, and now they're just recreational users, or they never used it before, because it was illegal, and now they're users. And so our consumer population has gotten bigger, which I think kind of helps the prices stabilize a little bit. And we don't have those fluctuations because we're not just, you know, counting on the stoners to get us through the year, we're really truly getting a more robust and a bigger variety of consumers. That helps. That said, I don't think that the ebbs and flows are done yet. I do think the prices are going to go up and down and up and down. Because the consumers in Oregon really got used to medical prices, because we had such a robust medical dispensary and robust medical prices. And really, the consumer in Oregon really got used to getting weed for very, very, very cheap prices. And so when you're talking about Oregon, we're always going to have this struggle. If you and I picked up this conversation dropped us down in Michigan, or Ohio, or anyplace else in the United States and we were talking business owner to business owner. I can say to you, you know, Wayne it's probably you know, as we get more customers and our state gets more active, we're just going to get bigger and bigger. And that's a reality if you're someplace that hasn't been growing weed for 400 years.

Wayne: Yeah. Think of California.

Elbe: We ARE California! Washington, Oregon, California have been producing the best weed in the world for 100 years. Yeah? We're not sitting in - we're not sitting in the desert. We're sitting in the rain forest of the weed, huh?

Wayne: Yeah, that's interesting. Yeah, every state is so fascinating how it's so different and how that plays out in the market. And then yeah, as soon as we cross state lines. So many more questions.

Elbe: I was talking to a friend, friend of a friend who does edibles on East Coast and like a cookie that would sell here for, you know, 10 bucks out the door, sells there for 40 bucks. Because there's not that many cookies right?

Wayne: And a lot of those markets are so hyper restrictive. I mean, you'll look at like Florida or something - one company and there's like four or five companies that own all the dispensaries. I mean, I kind of - that sickens me when states create an oligarchy, and you're looking at people with $10 million or more minimum to get into it, and then they own everything. Where Oregon. I mean, we're probably as close as to a free market as you can get, looking at cannabis industries in different markets. Sure, which has been one of our struggles.

Elbe: Yeah, I'm gonna say that wasn't exactly - that didn't serve us. It didn't serve us when we - initially when we had the no out of state investor rule. I think that this, this would have been a little more fair market in Oregon. I think companies would have had a little better time, have been able to start slowly and build up. As soon as that changed, and we allowed outside money, this just became a beta testing zone for cannabis. And I really keep thinking of Oregon is that. I think a lot of people come here, try out things, see if it works. And then they want to take it to other states. And I think as long as that's going on, as long as there's a long line of people who want their licenses, a long line of people who are willing to wait, I think, again, we're just going to keep fluxing on prices up and down, up and down. But I don't know, for sure, because I'm not a farmer. And again, my crystal ball has been broken for 10 years.

Wayne: (Laughter) It's a little hazy!

Elbe: (Laughter) Oh, so hazy. It's cracked, it's full of pot smoke. (Laughter)

Wayne: One thing I want to, as we get near the end here, you mentioned Gretchen, and having employees that turned into equity owners, I was just curious. I think that's really fascinating. I've heard of other companies doing that. I just I wonder how you thought about that, making that decision. And I just I think any listener that's operating in the industry. Whether they're an owner or manager or considering something like that, how does that work exactly? Or how did that play out? And I guess, how did you go about that?

Elbe: Well, I think from the beginning Hovering and I have always been really inspired by companies like Ben and Jerry's, Chobani's. These are companies that we have, as you know, we're entrepreneurs. I told you a photography business before this. I think we've always been really interested in companies who embrace employees. It's just so rare. And we've worked in, Hov and I both worked in such places, such crappy places, and we've hated our jobs. And we've also had the privilege of working in places where we felt like family members. And so when we started this company, we sat down and we said we wanted a couple things out of it. Hov said how do you - how do you think you're going to know that we're a successful company? And I said to him just off the top of my head, when we have 30 employees, full time, full benefits, working for us, I will feel like we are doing something good with our company. And he's like, right on. So that was kind of like one of the first things we thought. And then I said, and then we started talking, and then very next thing that we - I don't know, I think Hov might have brought it up. And he's like, and what about employees owning in the company? And I'm like, absolutely.

So, for us, we kind of look at the world in a different way. We don't have kids. We don't, we're not thinking about this as a legacy we leave on to our children or you know, anything like that. We've always just wanted to build a company, hire smarter than us, stronger than us, and have more vision than us. And if those people get hired, then we would just let them take over their areas of responsibility until it was theirs. And that was just kind of a general idea. So the first five years of our business, we just had that in the back of our mind. And, you know, we've had plenty of part time people and that - there was people that you know, we considered early in our early medical years, hey, should we bring this person on as a partner and? But something never really felt right in our bellies. And then Gretchen Palmer walked into our lives, and she walked in here to do a project for us. We were going to hire her to just kind of do an autopsy on our company say, hey, what are your problems? What are you - What are you doing good, what are you doing bad. She was supposed to be here for like 30 or 60 days, two or three days after working with her, I said to have, oh, we we need her. Like this woman needs, we need to work with her. She makes my brain itch. She makes me think in a different way and Hov's like, "Oh, I was thinking the same thing. Like she has a completely different perspective on this. She hasn't worked in cannabis. She hasn't worked in this world. And so she looks at problems in a different way." So the project got done. We said, we're not, we're leaving. We want you to work with us. Please come and work with us. And she said yes. And then about three weeks after that, we were driving home one day and I looked at Hov and I said in all sincerity. I want to say this - there is no longer in Elbe's unless Gretchen Palmer's involved. And he said, I agree. I said, I don't want to do this anymore without somebody like Gretchen. I want it to be Gretchen. She makes us better. She makes us think that, you know better, she makes us think about things we've never thought about. And that's when we knew we had our first equity employee. When we realized that we had somebody that we wanted to spend off time with. We wanted to have somebody who challenged our brains, challenged how we viewed the world of business. When we had that person standing looking at us directly in the eyes, we knew we needed a partner and that was Gretchen. And that's how we - that was like our first solid one.

We also had a contractor who worked for us, who built this bakery for us. And we told her that if she helped us build this bakery on a good budget, we would give her equity in our company. And so she has a small piece. And then over the years we have told people if you come into this area and you make this area your own, and you're responsible for it and you make it bloom, we will consider making you equity in this company. And sometimes that works and sometimes it doesn't. And a lot of people think that they want to be an owner and a lot of people think that they want to do sweat equity. But sweat equity is exactly that. You work more hours than you put in, you work when you're not here. You think about it all the time. And so Gretchen Palmer fits that to a tee. She loves this company and loves this product no differently than Hov and I do. She can walk into any room and represent us. She can speak for us in any way. And that's how you know you have an employee who deserves part of your company - when you trust them and know that they can represent you when you're not there. Yeah. I think it's so important too because I don't - what do I need a full company for? What, why couldn't Why couldn't Hov and I create something that can create a better life for other families. So Gretchen Palmer now works here. Now her son in law works for us. Her daughter works here part time doing gig work for me. And occasionally her husband, who is a genius in the geek world. He fixes our stuff. And so because she's invested in us, and we've invested in her and her family, and now that will go on to when her son in law and her daughter have a kid, maybe we'll be open long enough that this will help support their family. And we just kind of think in those ways instead of just thinking of p&l, and you know.

Wayne: Yeah, no, it's definitely I mean, it's, it's such an interesting approach and it makes me think about it, it's really a long term long-sighted strategy. And also as an owner, you know, for me right now, as a single owner, it's a struggle because I have certain areas that I think I feel like I'm really good at and I enjoy doing, but I also have to cover so many other areas that I do not enjoy doing, and if I could just free myself to really go out and I'm working on that. I've got some people here that are amazing and really fill in my gaps, but you know, it's still a salary or might be hourly and you don't, it's not - they don't have equity. They're not fully invested. Right? If this thing goes amazing, they're always wondering in the back of their head, could you know I be left with just my paycheck and nothing else? Even if they're invested a lot extra into it. But it's it's interesting to think about and how you might go about that and set that up.

Elbe: I think one of the things you can think about is the risk that your employees take. You know, it's one of the things I think a lot of cannabis companies don't think about. The fact that Gretchen sets here every day and everybody else who sits here every day and works for me. They are - they're giving up other things in their life. You know, you want to go get a home loan, you want to buy a house? Try telling the bank you work for cannabis company. You want a credit card? Try telling a credit card company, you work for Elbe's edibles, it's not happening. And so that is one of the other things we think about. We know we can't pay anything. We everybody here is making a really low wage. So we have free lunch here every day, we give our employees lunch and I make them lunch every day because I appreciate that they are working here on a lower wage, I appreciate that I have to - that their bank account can get closed because I pay them money. I appreciate the fact that they are still doing a federally illegal activity every day when they show up here. Like Hov and I really get that and so, if you can just kind of think that way, your employees feel that and the loyalty that they give back to us and the hard work that they give back to us. That is why they get to own this company too - they take the risk. They do the hard work and when I cry, they try not to act too embarrassed. When I when I am upset by the rules they try to help me figure out how to fix them. You know, it's it really - I know a lot of companies talking about family but we mean it here we, this is our culture. Like I said Hov and I don't have kids. This company is our kid, and these employees are our family members. And when we are gone from this, you know, like I said, we're in our 50s, I don't want to do this for another 30 years, I certainly want to have some retirement in my life, I want to have some downtime. When I walk out of here, if I hand the key to Gretchen Palmer, I will know that she will have everybody in place that she wants to have work for her. And that's why we also put equity into her because you put the people in place that you know, will put more people in place, also to keep this getting bigger and better.

Wayne: Yeah, yeah, those are such good points. And I really appreciate - I'm glad we hit on that because I think for listeners, either just getting into the industry or thinking about it, those are the points that often aren't discussed at all. And it's, you know, it's easy to look at this with rose colored glasses and be so excited. But there's a lot of trade-offs, and it's still very early. So those points are so important to discuss.

Elbe: This is hard work. This is a brand new industry. And so yeah, anybody who's listening to this is thinking about getting into it, I always tell people this. If you really want to open a cannabis business, if you really want to work in cannabis, go work for a cannabis business, go meet the employers, go meet the owners, meet the investors, see the people that you're working with because a lot of people went into this industry all at the same time, from all different backgrounds. So there will be somebody in this industry that you are suited for. It might not be me, maybe you don't want to eat lunch with a crew at lunchtime and put down your phone and talk. Maybe you're more comfortable with your earbuds in and not - and being a little more antisocial. This is not the company for you. But there are companies in this industry for you. For sure. Maybe you like being on the road, then you need to be working for a company that's like has you on the road all the time - that it is a brand new industry that is loaded with opportunities. The opportunity that you need to not think about though is finance, cash. You know if you are getting into cannabis to make a lot of money, you need to wait. You know, listen, I have a - I have a young man in my life that's part of this part of our family like he's 18 years old. And you know, he's watching us go through this journey. And he's just like, he's always like, he goes, like, I can't wait until I'm 21. And I'm going to start a cannabis business, and I'm going to make so much money. And I just, I just think, yeah, that is great. It's so great that somebody young can think about that and think about this as a new industry to get into. That is so exciting to me. And the other part of that is yes, maybe by the time he gets into this industry, he can make a livable wage. Yeah, but we're not there yet.

Wayne: Yeah. Yeah, we're on the journey. Thank you so much, Elbe for the time. I really appreciate it. This was a really great conversation definitely went down some other areas that don't think we have in the past. So I think listeners will like this one. And then I always end on two questions. Just where can people find you if it's a website, social media, and is there anything you want to let listeners know about specifically?

Elbe: Ok, well the first part is you can - I think we're in about 160 stores around the state. So if you go to www.elbesedibles.com there is a location map on that. So if we're not in your neighborhood or not in your area, you can send us an email and we'll try to get to you because that's important to us. We I think we're on Instagram and Facebook. I alluded to earlier that I'm not very good with the social media you can find us there. If you are interested in working for Elbe's you can send a resume and a cover letter to jobs@elbesedibles.com. You should probably tell me why you like Canna-butter in edibles to even have a resume looked at -if your cover letter doesn't talk about canna-butter or edibles I'm probably not going to read it. (Laughter) Cuz you know, we're not a dispensary and we're not farmer. So if you are good at trimming, you're probably not looking to work at a bakery. Yeah, yeah. Another thing I wanted to talk about real quick is we have some exciting things coming up this year that I want you all to look for. We like I said, we have our 10 year anniversary, we are going to have a surprise edible coming out for that 10 year anniversary to celebrate that, it will be 50 milligrams of fun. So look for that. And as we get closer, we'll announce the flavor of that yummy item. And our topical line should be out in a couple months hopefully. We have some more candy coming out or - the next thing coming down the chute is some candy bits, which is basically our candy that we're already making just broken down into five milligram serving size that you can pour into your coffee or on your ice cream. That's the next thing coming down and then our lotion line will be out and then some surprises in the summer and fall.

Wayne: Awesome. Thank you Elbe. That's great. Go check those out. And yeah, appreciate the time and the insights and this will be helpful for a lot of listeners. So thank you so much.

Elbe: Thank you Wayne. And the last thing I'd like to say to your listeners is - canna-butter is different and it's better. Please try it, please try Wayne's products, please try mine - tell your friends and family Canna-butter's the way to go.

Wayne: Yeah and I'd say try them side by side - try a distillate edible, try canna-butter edible and compare.

Elbe: It's my favorite thing to do is to test different cannabis products. I love it.

Wayne: Definitely. Awesome Elbe, well thank you so much!

Elbe: Thanks, Wayne!

Pe132 Athletes using Cannabis & CBD 101

Science & Social Use focused episode. We discuss how athletes are using cannabis to better their game and the battle for allowing pros to use cannabis without getting suspended or kicked off the team. We also cover the 101’s of hemp CBD products and what to look for when selecting products. Our guest is Anna Symonds, Director of Education for East Fork Cultivars.

Non-profits supported by Anna discussed at end of episode: Last Prisoner Project, Athletes for CARE, Concussion Legacy Foundation.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe131 Cannabis Science 201: Terpene Deep Dive

Terpenes are secondary compounds produced by the cannabis plant. They’re not only responsible for the “smell” of cannabis but also the unique effects of different strains. How do terpenes work in the body? What’s the difference between inhaling them versus eating versus applying topically to the skin? Our guest is Emma Chasen, Founder of Eminent Consulting, we answer those questions and more in our deep dive into the world of terpenes.

Link to Join Email List Community for insights we don’t share anywhere else.

Episode Transcription:

Wayne Schwind, Host: Joining us today is Emma Chasen, educator and - cannabis educator and founder of eminent consulting. We've had you on quite a few times Emma, and we've done some cannabis 101 science episodes. And then few, maybe a month or two ago we did 301. And so on this one, we're going to go deep into terpenes, do a deep dive there, which we've gotten a lot of listeners are interested in terpenes. So excited to have you on and I know we can spend at least an hour, maybe more on just going to terpene. So thanks for taking the time again.

Emma Chasen, Guest: Of course, always, always excited to be here with you, Wayne, and yeah, to talk about terpenes today one of my favorite topics.

Wayne: Definitely. And I mentioned some of our other episodes we did previously in the intro, if listeners want to go back and check that out first because that those really lay a good foundation for what we're going to talk about today. And we briefly discussed or some in depth on terpenes and past episodes. But there's just so much interesting, you know, new studies information around terpenes, the vaping scare. How do they play into that - but starting off, just to kind of get listeners back up to speed again, just starting off with some basics, you know, what are terpenes? Why are we interested in them? And just I guess we'll start with a simple definition.

Emma: Sure. So terpenes are teeny tiny, fat soluble compounds that are extraordinarily volatile, meaning that they're easily degraded by heat. They are found in almost all plants, including some insects and they not only provide the aroma or the smell of the plant material, but they also have some associated physiological and therapeutic properties in regards to their consumption and they are abundantly found in cannabis and they have become quite a hot topic in the cannabis industry as many consumers now and industry professionals look to incorporate terpenes into their products.

Wayne: I read somewhere over the largest classic class of natural compounds or products are terpenes I think over 75,000 different terpenes across the entire plant kingdom have been found. What's you know, natural is a word we see on packaging often. What does that mean exactly a natural compound or product? And I see every terpene as kind of marketed as organic. Are all terpenes just organic naturally, I guess?

Emma: So this brings up a really good point more in line I guess with manipulative marketing. We've seen a lot of food be labeled as natural foods, meaning that the compound can just be found in nature. And in regards to your question around terpenes being organic, they are a class of organic compounds. That does not mean that they necessarily fall under the USDA Organic certification where they have been produced in line with the specificity of that organic certification but they are a class of organic compounds and they are as you mentioned, abundantly found in nature almost all plants and even some insects do have terpenes in their matrix.

Wayne: And I found this was another thing I heard a while ago is interesting for, you know, drug sniffing dogs he said the terpenes are responsible for the aromatic effects in the smell of cannabis. You know, THC isolate is a product I've seen in you know, legalized markets and it's like 99.9% pure THC, it's almost like a white powder. But drug sniffing dogs wouldn't actually be able to identify or smell THC, which is, you know, the main compound for that high or euphoric effects. So if you remove all the terpenes I mean, that's what drug sniffing dogs are looking for. Not actual cannabinoids from the cannabis. That's accurate?

Emma: Yes, and drug sniffing dogs have been particularly trained to identify the singular terpene caryophyllene oxide, and so they're specifically looking for that terpene. And so, yes, isolated compounds of THC drug sniffing dogs won't necessarily pick that up because that terpene is not present. And even if you do kind of what I call Frankenstein formulations where you put a bunch of isolates together and you do put some of these isolated terpenes in with your isolated cannabinoids, if caryophyllene oxide is not in there, then the likelihood of drug sniffing dogs identifying your product is quite low, actually.

Wayne: Wow, so even a strain that was grown without any caryophyllene, is the oxide - is the caryophyllene oxide a terpene that happens naturally in cannabis or is that kind of like after it dried or cured or something but a strain without that? I mean, could be like a normal cannabis strain and the drug sniffing dogs wouldn't be able to detect it.

Emma: Yes, yes. Caryophyllene oxide does show up in the plant material of cannabis. We often see beta caryophyllene as the terpene that comes up rather than the caryophyllene oxide. However, from just the various lab results and certificates of analysis that I've seen from varieties, if you do have beta caryophyllene you most likely have a little bit of caryophyllene oxide in there. But just as you said, if you have a variety that does not contain either of those compounds, then again, the likelihood that drug sniffing dogs will pick it up is very low.

Wayne: Now how many terpenes are found in cannabis specifically? And is there a group - like is it 10, 20, 30 that are normally the most common? Because I think a very high number has been found in cannabis but you know buying strains from stores. It doesn't seem as diverse with that many different terpenes available.

Emma: Yes. So we are in the hundreds now of the amount of identified terpenes in the cannabis matrix. I believe that we are over 200 identified at this point. However, there are a certain subset that do show up consistently in dominant concentration in various varieties. Just generally speaking, we have two types of terpenes that we've seen in cannabis - monoterpenes versus sesquiterpenes. And all - the biggest differentiating factor there between those two classes of terpenes are in their size whereas monoterpenes have typically to isoprene units; so that is an organic structure that forms a chain in the terpene chemical structure and sesquiterpenes have more than two isoprene units in their chain so they're just a little bit bigger, a little bit more complex from an organic chemistry standpoint. And in cannabis, generally there are way more monoterpenes then there are sesquiterpenes.

Wayne: Okay. Is, you know thinking of effects from different terpenes from monoterpenes to sesquiterpenes, is there a difference in how they then would interact in the body, is one more desirable over the other?

Emma: So each individual terpene, it seems, has their own subset of associated properties. For example, though Myrcene which is one of the most common terpenes found in cannabis varieties, it is a monoterpene. And while it does have a range of therapeutic properties, it does not come close to the range of therapeutic properties from the most common sesquiterpene, which is beta caryophyllene and beta caryophyllene specifically has such a large range of diverse therapeutic properties because it can engage our ECS by binding to the main binding site of our CB2 receptors, which our major cannabinoids can even do. However, we can look at another sesquiterpenes such as humulene, which is just the isomer of beta caryophyllene. So it has the same chemical formula. However, it's arranged in space differently and that compound doesn't really have any physiological, therapeutic properties from the standpoint of human consumption, it does provide the plant with a lot of protection from fungus and pests and pathogens, but it doesn't have that same diverse range of therapeutic properties. So my point is that really individual terpenes have their associated therapeutic properties and physiological mechanisms, and it doesn't quite seem to differentiate between the monoterpene versus sesquiterpene classification whether one group has just a greater aggregate of therapeutic action compared to another.

Wayne: Okay. Thinking of, you know, the effects around terpenes. And I think as you know, consumers, if you're trying to buy a product for yourself, and you know, looking for different effects, regardless of what that is, or, you know, product companies that are looking at different terpenes or different strains, I think, you know, getting into the individual terpenes can be really difficult and would need a couple hours on its own to dive into each one and the pros and the cons. But a big thing is, you know, everybody's body is different and may interact differently. Some people have positive experiences with certain terpenes while someone else might have the opposite. Does it seem like most terpenes, can we make a general classification that you know, this terpene will make 80% of people feel this way? Or kind of have this effect with them? Or 90% of people? Or is it really, do we not have a lot of information? Is it kind of experimenting right now to figure out how an individual is actually going to interact with a specific terpene or, you know, now we're talking about profiles or multiple terpenes at once. It gets really complex really quickly. How much do we know around that and what each terpene might do for somebody?

Emma: At this point, we do need way more research to elucidate the specific terpenes therapeutic mechanisms across human consumption, we have never really consumed terpenes in such high concentrations before, the way that we typically consume terpenes is through our olfactory glands, meaning that we just smell them. This can be in the distillation of essential oils, which has only seen a rise in the last couple of decades, or even in the smell of plant material. With cannabis, it's opening up a Pandora's box of consuming these compounds in such high concentrations, whether that be via oral ingestion or heat and inhalation, and that has never happened before. In the research that we do have around terpenes, it's looking at animal models. So typically, mice and rats are being used to elucidate the isolated properties or potential of, of these compounds and human models are quite different than animal models in some cases. I mean, it gives us a kind of landscape to play with, but it's like having the corners of the puzzle without necessarily the whole middle picture. So it's still quite fuzzy in regards to what it will do for one person over another or even how it will interact with the many other hundreds of compounds in the cannabis matrix, because again, we're just looking at the isolated therapeutic properties of each individual terpene. And at this point, we only have anecdotal experimentation to go off of.

Wayne: Right, so they could look at an isolated terpene and say, you know, this one potentially doesn't look like it has any therapeutic benefits. There might not be any safety concerns to it, but it might be inert on its own. But if you put that in combination with cannabinoids or three of these other terpenes, it may then have some kind of interaction or do something which is really hard to classify, I guess and measure something like that.

Emma: Yes, and my favorite example of this is the terpene terpinolene, where scientists did inundate rats with terpinolene. And it exhibited a decrease in muscle motility, which led the research scientists to publish findings that terpinolene on its own is a sedative. However, this directly contradicts the aggregate anecdotal evidence that we have from the cannabis community, where cultivars or varieties that are high in terpinolene cause stimulation and cerebral focus and an increase in muscle motility. And so that has made research scientists take a step back and say, okay, terpinolene and THC together may actually be causing stimulation, the THC may actually be inverting that response from the terpinolene due to acetylcholine esterase inhibition, which is an enzyme in our brains that regulates quite a lot of functioning. And so that's just one example of the way in which we need that that broader research looking at the interactivity between these compounds because it may actually flip the script on what the the physiological mechanism becomes.

Wayne: And I think this is the right term like THC is but is it biphasic effect where at a lower dose, it has a certain effect, but at a much higher dose, it could have the opposite effect. Is that the right term?

Emma: Yes, the biphasic dose response curve is something that we see in cannabis where each person has their own unique threshold dose. And that can differ per consumption method. And so somebody who is at that threshold dose, below that threshold dose with an increase in the dose of THC or cannabis in general, they can experience an increased therapeutic benefit as well as an increased benefit in regards to mood experience. But above that threshold dose, they may experience a decrease in therapeutic benefit as well as a decrease In just the general mood of the experience.

Wayne: And that - so then that does apply to terpenes, potentially as well?

Emma: Definitely. And again, we don't really know what these terpenes are doing to our body when we do consume them in such high concentrations, specifically in concentrates and extracts.

Wayne: Yeah, yeah, mix it - And that's where the dose is so critical. I mean, we all know of THC over-consuming can be a really bad experience for a lot of people. If the same applies to terpenes. Or you know, coffee as an analogy, too much caffeine, you get the jitters. It's like the opposite effects you want. Yeah, getting the right doses is really critical and difficult right now for people to figure out what that is, and measure it. Something you always hear is you know, if a product doesn't have terpenes on the label, or you're not really sure familiar with which ones work for you, it's "the nose knows". So it's - it's kind of this guideline of, smell it and your intuition will tell you kind of if your body will react well to it. Or if you kind of have this unpleasant feeling from it, it's probably not something you'd like to consume. Do we know what's going on there with "the nose knows"? Is there any science or how our intuition is telling us something maybe about this strain versus that strain because of their different terpene profiles?

Emma: So "the nose knows" is a colloquialism I'll say in the community, definitely not backed by hard science and where it comes from is that all terpenes to carry their own aroma. And so the, the thought behind this is okay, if there is not data on that particular variety or that particular batch in regards to the dominant terpenes that are at play, then smell it, see if your body responds positively to it, and then that will most likely lead you to have a good experience if you consume it. Unfortunately, that is not the case. For some people, sometimes it works but again, I'll take the the terpene terpinolene as an example, whereas it has quite a delicious in my opinion, Pine Sol, citrus, diesel, very sharp aroma. It's found dominantly often in variety such as Super Silver Haze, Jack Herer, Dutch Treat. But that terpene in particular, I think is the most polarizing in regards to people who love it or people who have a really bad experience with it. But I have never met somebody who really hated that smell. Most people gravitate towards that smell. They like it, they want to purchase it, but then they could have a really negative experience where it becomes too cerebrally stimulating and they just kind of get trapped inside their own head. And so, like we - we may like the smell of something, but that doesn't mean that again, consuming it via inhalation or ingestion is necessarily going to produce a positive results for us.

Wayne: Yeah, it's interesting. So that's almost so - I guess a myth, then the nose knows or basing off that.

Emma: Yeah, I mean, I, I think that it's a fun idea, right to be able to say, oh well smell, smell this variety, see which one you're attracted to see which one you're drawn to and then purchase that and see if you like it. However, I think that we need to be careful of saying that that is science that's not backed by hard science. That is something that that is more of a fun experimental tool where if people are going to use that because they don't have that terpene data - to me, that's okay. However, it needs to be like also included with some language around microdosing or making sure that maybe they consume it via vaporization. So they can really get the essence of that terpene, they take one hit or one pull and they wait 10 minutes before they consume more. I'd say that that also needs to be coupled with that, that nose knows or even if you do have the terpene data, that advice should be included anytime somebody consumes cannabis, in my opinion, especially if it's a new user.

Wayne: Yeah, new users, maybe if someone has a terpene palette, and they're very familiar and able to identify specific terpenes and they know what they like, they can go off that smell a little more, much more accurately, but for a brand new user, or even an intermediate user, for the most part, I mean, terpenes are really difficult to identify. There's so many. But yeah, that's tricky. Interesting. Are there any other terpenes that are as divergent in predicting effects like terpinolene is? It does seem like 50/50 - some people really like that one and some people are really have the opposite effect, really don't like it at all. Is that kind of stand out on its own as being that much of a split in effects for people or are there other ones that might be like that as well?

Emma: That is the one that I have heard is the most polarizing just again from the kind of aggregate anecdotal. I've also started to hear of accounts of people who are not responding well to myrcene or myrcene is making some people feel physically ill or nauseous. Whereas other people really liked myrcene for its muscle relaxant effects. So that one I've also started to see the camp divide a little bit, but I'd say that terpinolene, by far and wide is definitely the most polarizing where, like you said, Wayne, 50% of people really love it. 50% of people really do not.

Wayne: Yeah. So kind of come back to the science around terpenes and effects and how we might start to be able to predict things. You know, using cannabis for an experience, any kind of medicinal use, you go in and talk to a doctor, they might run tests, you know, they're trying to really predict what product or what medication is going to work for you. And whether it's recreational use of cannabis or medicinal I think that still applies. How or where are we now? Or maybe what needs to be done as far as trying to get a better handle on different terpenes and effects? And, you know, it's like we talked about Western medicine trying to isolate the singular molecule and test it - doesn't work as it interacts with other terpenes, other cannabinoids. Is there a different way to approach the science? You know, I've heard consumer science or surveys or big data being used. Where are we at now? And what would that landscape look like if as we get closer to I guess, trying to achieve that?

Emma: There is definitely a different way to be able to conduct this kind of research to provide some better results in regards to whole plant formulations. So the way in which terpenes interact with other compounds within the cannabis matrix, there is research being done with humans as well, which is a huge component that needs to happen in the research world and that's being done in Israel as well as in some countries in Europe. So that's exciting. Looking at people or populations with specific disorders and how cannabis responds to those disorders is going to be very helpful for the more medicinal side of things. I'd say that there's also some analytical data coming out aggregate anecdotal evidence that is being compiled and then statistically analyzed to be able to show, Okay, THC in combination with limonene and nerolidol is a great anxiolytic for example, for 75% of the population. That's not real data. That's just an example. And, and stuff like that is starting to come out. Because we have had now a few years in this industry, that that has created some self reporting tools to like apps to be able to better collect user experience. However, there's always going to be some heightened level of error in those kinds of reports or data because they are self reported. So there is bias in there, where it's not necessarily objective research. However, at least it paints a landscape of how people or the population is most likely responding to these different formulations. That definitely helps. And we are going to be seeing more of that I'm sure as we move forward and as this industry evolves, and I think that that coupled with the more rigorous scientific evidence coming out of places like Israel that is doing human clinical trials is going to also really help to supplement, to look at the the therapeutic range of properties for not only the terpenes, but also the cannabinoids and how they work together.

Wayne: For this next question I'm going to go through if listeners are interested, there's an article from cannabis business times it's titled "not all terpenes are created equal." If you Google that you can find it and it's really good information that dives into some of the stuff we're talking about. But I was also curious as we dive into kind of safety concerns, vaping crisis has been a big thing. But who's driving right now the research behind terpenes in the studies? Because one thing I saw in that article, it said 2002 sales for terpene patent-based pharmaceuticals was $12 billion. I mean, that's a huge, huge number. So terpenes, you know, we're interested in them in the cannabis industry, but I would imagine right now, all the research and stuff we're learning is being driven from outside of the cannabis industry. Is that accurate?

Emma: Yes. And that is most likely due to cost, as well as the patents that do exist on isolated compounds and the pharmaceutical potential to run a very small study, research study, it takes about a quarter of a million dollars, and so you need to have quite a bit of capital in order to run these research studies. And unfortunately, the cannabis industry, the people handling the plant, the people who are boots on the ground, do not have that kind of capital - more often than not - to put to research studies. And so we do see outside pharmaceutical groups who are conducting this kind of research.

Wayne: I've seen some cannabis companies partner with universities, is that a strategy or an approach that, you know, I don't know if the university covers the costs of the study, but is there something there where some cannabis companies are leading some of these studies with in partnership?

Emma: Yes, and that that is an approach however, oftentimes, the university does not cover the cost of the research study. And so again, the company has to be very well-capitalized. We also see a very few and far between in the United States research grants being allocated. Dr. Sue Sisley is a leading cannabis researcher as well as a medical doctor who is doing research on cannabis in Arizona specifically looking at the PTSD population. So there are some people who are doing that. There is some federally funded research that the cannabis comes through, I believe it's the University of Mississippi, but I have heard a lot of complaints in regards to the quality of that cannabis being used for research where it's been molded or it's older, it's dry, where there's not actual like, flower on the shelf, it comes ground up, and you have to kind of use it in that form. So that can be a frustrating limitation on research. And there are other people who are doing research on cannabinoids, terpenes, the isolated properties of such, but the way that you really get funding for cannabis research still, is that you have to be looking for a negative outcome. And so that can also be frustrating for people where the research that is getting funded is looking at the negative effects of THC or the negative effects of CBD or the negative effects of these terpenes. Whereas really we need more data on the therapeutic potential of these compounds, not only on the negative effects of them.

Wayne: So it's still stuck in the kind of war on drugs culture, where if you're going to say I'm going to study why cannabis is bad, you could potentially get funding but if you say I'm going to study how cannabis might be able to help with PTSD, even right now, there's still, that's not viewed as favorable or interesting study as far as getting money for that.

Emma: Yes, yes, the federal government is still stuck in, in quite the archaic prohibition times. Where still a good percentage of the country as well. I mean, we are rapidly evolving out of that, which is exciting. I just saw a statistic that recently reported that over 90% of the US population supports cannabis legalization. And so there is quite a popularity in, in regards to the legalization generally, but as it stands in the eyes of the federal government, cannabis is still a schedule one substance, it is still one of the most dangerous substances on the planet, according to the federal government. And so that puts quite a limitation on federal funding for research.

Wayne: Yeah. You mentioned patents. And I know on the you know, cannabis growers are really concerned, you know, big companies big Ag Monsanto, around patenting cannabis or certain strains. And if somebody's going to take control and ownership of parts of the cannabis industry, how big of ownership or control? Around terpenes, are there actual patents on specific terpenes? Or is it more around how they process or extract a terpene? And what are those - Do you know what those patents look like or how they're controlled or protected?

Emma: The patents that I've seen mostly focus on extraction methodology or a formulation process or a dose delivery system. So there's a lot of patents on how we can consume these terpenes or the technology behind extraction versus the technology behind consumption. It is hard, if not impossible to patent, I believe, like a singular organic compound. And I'm not a patent lawyer. So big disclaimer here. But it is possible to patent a formulation or a technology that will lead to a specific formulation or even a compounding device where it is a technology that will allow specific compounding formulations to occur in a device where like you could press a few buttons, let's say in its simplest form, and it'll make you an extract that has 50% THC and 5% limonene and 1% myrcene or something like that. So there, there's also possibility for patents in that realm. There is possibility for patents on specific genetics of varieties as well, which would produce at least a range of similar compounds dependent on environmental factors. Its - patent law is a very tricky, weird place especially because it is the US Patent Office. So it is a federal program. And cannabis is, is in such a gray area there. So, so it's kind of looking outside of cannabis. It's looking to the compounds within cannabis. It's looking to the extraction formulation technology that can be used on cannabis, but it's not necessarily looking at cannabis specifically. And again, this is just from what I've seen and explored.

Wayne: Yeah, I mean, there's so much now in the public domain, thankfully, but if someone was the first to you know, officially extract cannabis with co2, I mean, they potentially could have ran and patented that process maybe or something like that, where something that's so common now everyone uses - it's just assume shared technology or use of something, you know, could be eventually controlled. And that might be something we see in the future that is scary.

Emma: Yeah, definitely. And I mean, looking at just the history of the way that American industries have gone, it doesn't really paint optimistic precedent for how the cannabis industry could go and just the general corporatization of this industry and the conglomerates at play who do have a lot of capital owning, like 95% of the industry in five different conglomerate corporations and, and since it is a wellness and a medicinal and a therapeutic industry, then you also have the FDA and the pharmaceutical companies involved and again, there is not a great history behind the way that pharmaceutical companies approach the commoditization of their products and so it is scary for a lot of people who have been doing this on the black market and the gray market and now in the legal market forever where it does - it is a legacy for them that it could all be taken away, is a very scary thought for those people.

Wayne: Yeah, you know and they say history repeats itself, and these industries and kind of culture and how they approach different categories or you know, verticals of industry. I think one thing for me I always that gives me the most hope is the internet, which we haven't really - in only last 10 years in a brand new industry you know, some tech industries you know, Bitcoin but without the internet haven't really built up like this, like cannabis is now and the way we can all communicate and it just feels like right now the level of transparency or getting away with things behind the scenes is just becoming much more difficult to do, so maybe that could hopefully have some play and maybe having a different future instead of history repeating itself, but, but it's a huge concern.

Emma: Mm hmm. Definitely.

Wayne: Let's dive into some of the different terpene categories as far as where they're derived from. And maybe after that we can talk about the vaping crisis. You've been getting a lot of questions on that and we have, and there's still some unknowns there. So I think it'd be good to tie it to that. But when we think about what terpenes are in your product, you know if it's cannabis, they're cannabis derived, if it's just a flower, cannabis derived terpenes. It's kind of the most natural original form or way to get terpenes and cannabinoids strictly from the flower but so many products now - edibles, extracts, concentrates. The categories that I think are the three are cannabis derived terpenes, food grade, or sorry, food derived terpenes or botanical terpenes, and then synthetic terpenes. I want to kind of briefly discuss each of those categories and something I wasn't really sure of - is synthetic terpenes actually really a category or those in the market or is that not much as far as being in products and things like that?

Emma: Sure. So, as you said, and I will echo the safest way to consume terpenes to get the full range of terpenes present in the original plant material is to consume that plant material, and I always recommend a dry flower vaporization where you are grinding up that flower, you're putting it into a vaporization device and it convection heats it at a variety of different temperatures. And if you plug that device onto the lowest heat setting and inhale, you will get a terpene-centric experience. That to me is the safest way to consume terpenes. However, since terpenes, are quite desirable from a market standpoint and especially a consumer demand, we are seeing the integration of these botannical derived terpenes, synthetic terpenes, cannabis derived terpenes into various concentrates and extracts and if we go back to the original definition of terpenes, terpenes are degraded by heat. And so, in the extraction process for many different types of cannabis products - concentrates, extracts - you have to go through some type of heat processing typically. There is also cold solvent extraction which we can get to, but for the most part most of your oils and dabs, shatter, BHO, PHO, co2, rosin, even that involves some kind of heat and pressure processing. And so a lot of terpenes will be degraded, therefore, there are now companies that have isolated quote unquote isolated terpenes that are terpene formulations that you can purchase and then re-add into your product. From the categories that you mentioned, Wayne, we do have terpenes that are derived from plants and fruits. So for example, limonene is a terpene abundantly found in cannabis but it's also abundantly found in the rinds of citrus fruits. And so we can use a process, typically steam or hydro distillation where we take out that limonene and there are a variety of problems associated with with the resultant distillate and hydrosol that you get, which we can get into. There are also cannabis derived terpenes, where you can take your original plant material and again, run it through a distillation process where you actually remove the terpenes or remove some of the terpenes prior to really extracting out the full range of cannabinoids, and so that's conducted at a lower temperature to be able to retain more terpenes and then you add it into your final product at the end. And then there are synthetic terpenes that you can synthesize these terpenes in a lab - however, that is not that's not really prevalent on the market per se, from what I've seen available on the market, there are cannabis derived terpenes, and then there are terpenes that are derived from plants and/or fruits.

Wayne: Yeah, I think what that article I referenced earlier said was around synthetic terpenes. It doesn't seem to be much really a thing in cannabis. But where it is used on some of these really fragile, certain scents or smells, you can't actually get it from the food product because it gets degraded or destroyed. So they synthetically have to produce it in the lab, it's the only way to actually create the extract or something that they could stabilize and use and like I guess, perfumes or something like that.

Emma: Yes. And it's important to note that you do not consume perfume, right? You just spray it on yourself and you smell it. And so that is - that's important to know that these synthetic terpenes are not necessarily meant for consumption and in the article that you're referencing in Cannabis Business Times, the author Kenneth Moreau, goes on to say that, well really like botanically derived or even cannabis derived terpenes are not necessarily fit for consumption either.

Wayne: With - before we go over to kind of the vaping and inhaling different terpenes and the different types, just around cannabis derived, I think, you know, right now again, back to kind of marketing and how we're labeling products. You know, it's - if it's an extract or something new you're inhaling, the general feel as well cannabis derived terpenes are much better than botanical terpenes derived from other products, even if you know - because they're made as isolates, but if you mix 20 of them into one solution, you potentially have 20 terpenes in that extract or whatever it might be. But again, the article said, you know, not all cannabis derived terpenes are created the same and in that processing, you're often not getting what you think you are, you know if you were to say this is Sour Diesel, cannabis derived terpenes, depending on how it's extracted, that may be not what you're getting. How much variability and I guess loss is there in different extraction methods? And we're just talking about cannabis derived terpenes. And you mentioned a couple methods that might be closest to the truest form at the end, you want to hit on some of those maybe?

Emma: Sure. So, in the article specifically for cannabis derived terpenes, the author defines three different extraction methodologies to get those terpenes and we we can do co2 extraction, which is fractionalized terpenes. We can do steam distillation, hydro distillation or a combination of steam-hydro distillation or we can do thin film distillation and in each of those formulation or extraction methodologies that I just mentioned, heat is required. And so when ever you put heat to terpenes, you will get degradation. There is no way around it. Terpenes are incredibly volatile. They will either burn off completely or they can also change in composition. There are also other compounds that are riding along with these terpenes. It's not just terpenes. So you also have aldehydes and esters, which are incredibly reactive compounds that can produce other potentially harmful byproducts when exposed to heat. You also may get phenols, which phenols are not intended to be heated and inhaled. And so it's important to note that it's not just terpenes that are in these resultant 100% quote unquote terpene extractions or distillations. Most of them on the market as the author points out are also hydrosol, which are a byproduct of distillation and again are not meant for heat - not meant to be heated and inhaled, particularly because they contain water. There are some water content in there because in the distillation process, this steam is cooled and condenses into the hydrosol. And so you are not only carrying phenols and byproducts of the aldehydes and esters and potentially damage terpenes, but you also may be carrying water into that distillate. And that is not something that is fit for inhalation and for, to be heated and inhaled. And I will say on the kind of botanically derived terpenes, then most of them are labeled as organic food grade terpenes. And so right there in the title, it's food grade, our digestive systems are built to be able to waste out products that are foreign to us. That's why the liver exists and it's very good at doing its job. But the lungs don't have that. And that is the problem that we ran into with the vape crisis, is that all of these foreign substances were going into the lungs at very high concentrations, and the lungs have no way of getting rid of them and so they end up coagulating in the tissues and then can prevent that the exchange of gases that occurs and, and prevent people from breathing. And that's a big problem.

Wayne: Yeah, I mean, huge problem around the vaping crisis and there's been deaths resulting from it and many, many more ill and from everything I've seen, you know, I haven't seen much in the last month or so but for a while there, there was new report stuff coming out. And it felt like they kind of narrowed it down to some of these cutting agents, vitamin E acetate, and then I also heard potentially, metals leaching in if they're not, you know, lead or something, depending on how the actual hardware is made. Have they done anything around looking at the terpenes on the science side, or know what might be good for us or what's bad for us? And a lot of states banned the flavored stuff, if it was botanical terpenes, and then they lifted to ban. But I haven't heard anything from like the CDC or people reporting on it around the terpene side of things, whether it's botanical or cannabis derived, I guess, and extracts and concentrates. Yeah.

Emma: I also haven't seen it from the CDC. The latest report that I read, which was in November, which I'm not sure if another one has come out, did claim vitamin E acetate is the most likely culprit in causing these lung failures that people are experiencing from vaping. But we did see in the regulatory legal landscape bans on flavorings and artificial flavors and terpenes being integrated. But then in Oregon, that ban was lifted. And so it's just a lot of confusion for a lot of people because there is not - the research doesn't exist in regards to consuming these terpenes in general, there's not any kind of scientific evidence that we can point to that says, consuming these terpenes in this high, this high concentration is okay for us, period. And specifically when we look at hydrosols and the byproducts of steam distillation and the way that these terpenes are being processed, distillation or a distillate with - it produces essential oil and then it produces a hydrosol. And essential oils are used as we know in diffusers, some people put them on their skin, highly concentrated oils, but then it also produces a hydrosol, which is often the way that these terpenes are sold as hydrosols, and hydrosols used to be thought of as just a byproduct of distillation that you throw away. And now they are being used as co-products. And so in my opinion, it is a lot of, trying to meet the consumer demand of an uneducated consumer market that thinks that the higher the terpene concentration, the better the experience or the more bang for your buck. And it is also trying to make a profit where it's, okay something that used to be thrown away, now we can actually sell for really high prices. I mean, in the article, the author cites a hydrosol, a terpene hydrosol product, that was being sold at like $10 a drop, because it's claiming these high concentrations of terpenes, and maybe it does have high concentrations of terpenes, but the oil cells that are in that hydrosol are severely damaged, they do not mimic the oil cells in the original plant material and so, you are consuming something that is degraded and that has changed chemically from that original plant source and it is not contributing to the therapeutic efficacy or, or the general medicinal value of that product at all. Yes, it may give it a taste, but the taste is not in line with the taste of the original plant material. The odor is not in line with the odor of the, the original plant material and the physiological therapeutic properties are definitely not in line with the way that the compounds are expressed in the original plant material.

Wayne: Yeah, that's really surprising to me. I you know, you see Cannabis derived and I understood, whether depending on how it's extracted, if it's distilled, I assume that the essential oil that kind of captures it, I think the main, the terpene that you're trying to get, but now there's this byproduct hydrosol, that sounds like it has potentially a lot of other compounds in it. And if you're looking at a product, and now these are both being sold into the market, you don't know which one of those is in the extract or if it's a vape pen, and if it's hydrosol, that one, I mean, both could be harmful, potentially, but the other one hydrosols - many other compounds potentially that are in there that you don't want to inhale.

Emma: Exactly. And it is also important to note that you don't necessarily want to consume essential oils either, but you don't want to heat and inhale an essential oil because that can again coagulate in the alveoli in the lungs and prevent the exchange of gases. You don't really want to eat essential oils either. I know that in the natural health movement, there was a wave of people consuming very homeopathic or very small, small doses of essential oils. But we don't really have the research to say that that is okay, at least in the digestive system, you have mechanisms in place to be able to waste out those foreign products, but in the lungs, you don't and so it's not something that we should be consuming in high concentrations, I mean, terpenes are found in very small concentrations in plants. The way that we have consumed them historically has been through our olfactory, or our smell, we have not been conducting this kind of thermal chemical degradation of terpenes and then creating such high concentrations and putting them into concentrates and extracts which are then meant to be heated and inhaled. The only piece of research that I have seen has come from Portland State University actually in 2017 that looked at synthetic terpenes, because they couldn't use cannabis derived terpenes for legal reasons, and they saw that when you did dab those terpenes, that they changed chemical formulation and became benzene, which is a highly carcinogenic compound. And so these are all of the risks at play when, when you do see reintegrated terpenes, or you see added terpenes, you see products that are distillate so they have a small range of cannabinoids, and then they add in botanical terpenes, or even cannabis derived terpenes. It doesn't make it healthier. And that is the main point, especially when we look at this kind of manipulative marketing or we just look at marketing in general. You really have to dissect that language and, and be aware of what the product is saying. Higher terpene tests do not equal healthier, more therapeutic products.

Wayne: Yeah, yeah, and I mean on the business side, I mean, from our perspective, or anyone making a vape or an extract, it's - you know, I don't think there's a lot of ill-intended people, there might be some, but you know, going off the best information they have. And that might be a lot of assumption. Well, it's cannabis derived, that's better. And just so much we don't know yet. And for some reason, the CDC doesn't seem to be talking about terpenes at all with the vaping crisis. So there's no education being overlaid that way. And it's just such a new frontier and that these products are rolling out and, you know, if someone says, "We're not gonna have any terpenes in our product", if you're making a vape pen, "at all" - well, you'll probably go out of business or if it's just an isolate or something like that. So there's this weird gray middle ground that we're trying to figure out of, how do we make a good product that consumers want, while also being safe, but being able to market it? And he's so many hard things to figure out at the same time.

Emma: Definitely. I mean, cannabis companies are just trying to survive, and trying to meet consumer demand which is ever evolving and consumers want terpenes. As the consumer market becomes more educated terpenes are a large part of this conversation. I love terpenes. I personally prefer to consume them in home plant medicine, in the flower, in a dry vaporization device because that's how I know that they are going to be the safest or the quote unquote best for my body. But there is a way to extract terpenes that do not create such harmful byproducts. And that is the cold solvent extraction method that I mentioned where you're not using any heat. And so that's something like an alcohol for example, using alcohol as a solvent, organic sugar cane alcohol, putting your plant material in there, you will extract a good amount of terpenes and cannabinoids as long as you keep it in a cool, dark, dry place. You'll also extract other beneficial plant compounds, and like phenols will be included in there, polyphenols especially. But that again is meant for ingestion. It's not meant to be heated and inhaled. And so I think that a large part of the, the safety conversation does specifically, like go along with the extract and concentrate area of the market of heating and inhaling these compounds at such high concentrations, and what is that going to do to our lungs? And you're absolutely right, that there isn't the research there to tell us specifically terpenes, whether they be cannabis derived or botanically derived or not healthy or not safe that just doesn't exist yet.

Wayne: Yeah. You know, if I was a listener, and this is the first time I'm hearing this, I would think, you know, and we're focusing on a lot of the safety here, there's a lot of benefits and pros conversation we could have, but I'd be hearing it sounds like well, inhaling terpenes just sounds risky, potentially. But how do you compare - so that listener would say, well, smoking is inhaling and vaporizing is inhaling, wouldn't smoking also be potentially dangerous? Or there could be some safety because concerns - how do you compare and contrast those two on the smoking side? And are there still some safety concerns to consider on the flower, dry vaporizing, even the flower side?

Emma: Definitely. So anytime that heat comes into play, there is a concern of safety or there should at least be a kind of discussion or thought process behind the safety. What I will say is that terpenes, we have consumed them historically by inhaling them, through our olfactory glands, there just hasn't been any heat involved in that. So that's the way that our body is used to consuming terpenes is by inhaling them. But now we're getting into the heat processing of that, with smoking, you are going to conduct not only a combustion reaction, but something called pyrolysis which will actually result in the loss of quite a bit of the compounds the instant that you light up that joint or flower. And so we also don't know what that loss looks like from a terpene standpoint - are all of those terpenes just being lost to pyrolysis? Because they're really volatile and they're being exposed to such high heat, that they all just immediately denature, we don't really know. That's why dry flower vaporization at least can allow us to conjecture that those terpenes are being trapped in that convection heating, that we can heat them at a low enough temperature to be able to allow them to volatilize but not denature or change their chemical structure. And that's where terpenes that are being derived from cannabis that are being extracted from these botanical plants or fruits, they are going through a high heat extraction process that is also carrying some other compounds with them that could potentially denature those terpenes or degrade them or make them change chemical structure entirely. And then we're heating them again at very high heat in dabs or even in oil vaporization to cause them to change structure or denature or degrade all over again, so it's kind of hitting it with heat both times. And so that's where it could cause a problem. And again, we are looking at such high concentrations, whereas when you smoke flower or vaporize flower, they are in the concentration that they are in, in the plant material, which is low, I mean, I'm talking like 0.1-0.2% per terpene if you're lucky, you may see a singular terpene go above a full 1%. But that's about it. Where as with concentrated terpenes, I mean, we're looking at like 30% terpenes, which that is really high. So, so we don't have enough research to say that consuming terpenes in such concentrated form is safe at all. Whereas consuming terpenes by smoking or by dry flower vaporization or even just by smelling them, by inhaling them in the air, there you're not consuming them in such a concentrated form, and you're not heating them once and then heating them all over again and inhaling. And so that's where I think it takes a closer look at the the safety of these concentrates and extracts because of that dual thermal degradation process and the increased concentration.

Wayne: Right. Yeah, I think you know, sometimes, I don't know if it's just culture, how he grew up, but you think if something's good for you, more is better. And it's obviously not true - alcohol, one drink might help you kind of relax and be social, but enough, you know, alcohol kills people from overconsuming. And that's where that dose is so critical and a lot we don't know. I mean, going from point 1% to 30% is like one shot versus 300 shots, you know, if we're talking about alcohol like that. Yeah, it's very scary and just a lot we don't know it's really hard to quantify or qualify.

Emma: Yeah, exactly, it does really interest me to kind of get into the philosophy of the, the reasons behind consumer choice and how the the consumptive culture that we especially have in America definitely informs that, the more is better more and more and more and more and - and how that plays out specifically when we look at health and wellness. And that's where different schools of thought have have popped up, such as homeopathy where it's like, "No, you actually consume a very, very little amount". And I'm not saying that homeopathy is the end all be all, but I am saying that it definitely we need to reframe our mindset in the way that we look at health and wellness where it's not you take a concentrated, isolated dose of a compound every single day to achieve a certain result. I mean, even in the, the opioid crisis that we're experiencing, most doctors do not suggest a tolerance break for these opioids, and they will just prescribe more and more and more, at least historically they've done so and it caused us an epidemic. Whereas I think that something really exciting to me about the potential of cannabis is that it helps people to reframe their mindset of just the ways that we've been stuck in for so long, of "Oh, if this compound is helping me, I should consume more of it and I should consume it every day. And should - I should have that consistency there." Where actually no, stepping away from it for a few days may be helpful not only to reset your tolerance, but to help your body reregulate and, and looking at the therapeutic doses is actually very, very low. You don't need that much to cause the physiological actions that will help and, and that's where the biphasic dose response comes in, as well. Where actually, more could be worse for you and, and I think that that's an important kind of like sociological, philosophical shift that needs to occur in our culture in a variety of different areas and cannabis helps to catalyze that, in my opinion.

Wayne: Yeah and from you know, initial legalization I think we see this changing now but it's still very strong looking at potency levels, you know, most stores or a lot of stores, if its top shelf or top quality that it has to have 28% THC or higher, like that baseline for qualities being set on how much percentage does it have, you know, and we see that changing in a lot of stores, but it still has a lot of momentum as far as just determining quality of a cannabis strain.

Emma: Absolutely. And that is so frustrating. I mean even just this morning I saw a certificate of analysis from a variety in Oklahoma that is reporting 36% THC and like people on Instagram are popping off and the grower's boasting about it and - and it's just like, oh god, I see that and first of all, I - I doubt the reliability of those results

Wayne: Yeah, the labs is a whole other conversation, a lot of them are getting shut down right now.

Emma: Mmm-hmm. Exactly, where it's like, the first thing I think is, oh, how much money did that result cost? But then also, just from like a standpoint of like, okay, even sure if it's - if it's real, if it's true, whatever that means. I do not want to consume a variety that is 36% THC, holy shit, excuse my language but like, not for me, that's not what's going to cause a therapeutic dose for me. And guess what, that's not what's going to cause a therapeutic dose for the majority of people and I'm not talking to people who have the need to inundate their body with cannabinoids for serious medical issues. I understand that that is real and I do not invalidate that portion of the consumer market. However, for quite a large portion of the consumer market or even potential consumers, they do not need that much THC and we don't know what the - what potency could cause from a negative health standpoint I mean, we know that CHS exists, the cannabis hyperemesis syndrome exists. We know that dysregulation of the CB1 receptors can cause cognitive distortion, that it can also increase the likelihood for psychotic episodes for people who are already genetically predisposed to psychosis and we know that it can cause a - just a variety of different health issues and an anxiety, even for myself personally. I've been on a one month tolerance break as I'm calling it and I, I stopped because I was traveling and then I got sick, but I'm really enjoying it because I'm finding that my anxiety is much more regulated now that I'm not smoking and I still use low dose tincture and I'll eat a low dose edible every now and then, and that's been great for like sleep and other body issues but as far as like re-regulating my CB1 receptors, I feel it. I feel it working and I feel it helping and and that's important to talk about.

Wayne: Yeah, yeah, I mean, personally, you know, for myself and just kind of experience you know, I think - I don't know who, it might even have been Bob Marley, he said "cannabis reveals you to yourself". And for me, if I'm in a really good headspace cannabis makes me extra creative, it's more fun. But if I'm in a state of pressure, stress, anxiety, very micro dose can help, but much more, it kind of amplifies those feelings I'm already having. And it can be more anxiety from consuming. So it's it's just not always this one thing and it affects you this way. It's constantly changing, which is just I think - consumer education again, we're so brand new in this legalized market where we can actually even talk about this, you know, this wasn't even close to a conversation when we're talking about black market. But yeah, it's fascinating the different ways cannabis is used and all the different things that can do, but how it has to be used so you know, responsibly in an educated way to get what you actually want to get out of it. Yeah. Terpenes and effects. So it'd be, I think, interesting to talk about, you know, we were saying individual terpenes, myrcene might be sedating or muscle relaxing for people. How much is that changing, maybe myrcene as an individual compound or terpenes in general, when you inhale it and let's assume you're getting the right dose you should be, when you inhale it versus when you might eat it in an edible or topically on the skin. Do the effects change really significantly? Verse from different consumption methods.

Emma: So, again, we need a lot more research to be able to have some kind of conclusive information around this, but there is a big question as to the bioavailability of terpenes - are terpenes actually causing any kind of physiological reaction, especially when you eat them, or they just being denatured and wasted out by the digestive system? There are certain terpenes that will have different effects on the actual consumption method. So for example, when you do eat a cannabis product that has been infused with terpenes, or maybe it is a whole plant extracts, so there are more terpenes that are retained throughout that cold solvent extraction. So something like an alcohol extraction, for example, linalool is a terpene that will actually influence the liver enzymes, thereby influencing the way that cannabis is processed through the liver, thereby influencing your experience. And so linalool is a particular terpene that we should look to when ingesting cannabis, because we know, we have the evidence that linalool interacts with liver enzymes. Apart from that, there are cannabinoid receptors in our gut, there are enzymes in our gut, and different factors that modulate the ECS. There are serotonin receptors in our gut, there is quite a big gut-brain connection that happens, and so terpenes could be acting on these receptors, these enzymatic factors, these neurotransmitters in our gut when we ingest cannabis, thereby influencing the experience. The reason why a lot of people think that terpenes are not bioavailable, or that they don't have any effects when we eat cannabis, is because they do not show up in blood plasma readings, and that's how we measure bioavailability, where there are certain timestamps after ingestion, where we take a blood plasma reading and we see the compounds that made it to the bloodstream. Terpenes don't really make it to the bloodstream. But that doesn't mean that they're not causing a plethora of effects in the gut itself during digestion and absorption. And so, my - my thought is that terpenes do have effects in, when we eat cannabis and that they may be similar to the effects that happened when we inhale cannabis. However, the terpenes are most likely not making it to the brain. So they're just acting on receptors in a different place in the body. And so it could it could be influenced that way. With topical absorption, the - the compound or the terpene that I specifically look out for is limonene because limonene has been shown to increase the porosity or permeability of skin as well as mucous membranes and so it can help other compounds to better absorb into the skin across mucous membranes, it can help other compounds better absorb into the bloodstream, and so limonene may actually be influencing the way that cannabis is taken up when it is applied topically or when you consume it via the mucous membrane. With terpenes that are applied topically, they also don't typically make it to the bloodstream but there are cannabinoid receptors, there are enzymatic factors that exists in the skin specifically to modulate inflammation and pain, and so terpenes absolutely may be having effects on those, those factors themselves in this skin. And so we, we can say at this point, again, with the very limited research that we have, that if you eat terpenes or if you apply them topically, they most likely don't make it to your brain. However, they are also most likely interacting with cannabinoid receptors as well as enzymatic factors in either your gut or your skin to cause an effect.

Wayne: Do you know how the linalool interacts with the enzymes when you ingest it?

Emma: Not specifically, from the research that I've read linalool can interact, I believe it's with the class of enzymes, the cytochrome, whereas CBD also interacts with these enzymes, and it can help to block certain processes or it can help to speed up or catalyze certain processes. Enzymes exist in our liver to help run reactions quicker. And so if you are blocking an enzyme from doing its job, then the reaction either won't run or it'll take a very long time for it to run. So you won't really feel the effects from it. If you are further supporting an enzyme than you are speeding up the reaction and so you could feel it a lot quicker. Cannabis typically is processed by the liver via first pass metabolism as soon as it hits our gut. There are a few ways in which products have been formulated to bypass that first pass metabolism specifically through nano-encapsulation, or nano-emulsification, which I believe we've talked about before, which is basically making those compounds more water soluble, so they don't have to go through the liver. And they are more easily taken up by the digestive system, but it is in a fat soluble package. So if you've done a butter or an oil extract extraction, basically, if you haven't encapsulated or emulsified your product, then it will go through this first pass metabolism and so the resultant compounds will change morphology because of the way that they've been processed through the liver. When linalool interacts with those enzymes, it could either prohibit some of those reactions from running or it could catalyze some of those reactions even further, and so it thereby will influence the experience that you have from it.

Wayne: Yeah, with sublingual consumption, where you know if the tincture's under the tongue or some edibles you can dissolve under your tongue. Do we know if terpenes show up in the blood plasma when they're consumed sublingually because they're not going through that first pass or metabolizing is that different, potentially?

Emma: I haven't seen particular research on that topic, but I would conjecture that the terpenes would absorb into the bloodstream and even be able to make it to the brain, especially if you have that limonene in there. Where the limonene will increase the porosity or the permeability of that mucous membrane and allow compounds to diffuse quicker through that membrane. Especially if - especially because there's no heat required there. Terpenes are very small compounds, they're fat soluble, they easily pass through membranes. And so they most likely are making it to, to the bloodstream and then making it to the brain to cause a reaction that would be similar then to inhaling the terpenes. Of course, you're not getting the thermal degradation from the inhalation module, but but you are, like, up taking them into the bloodstream in a similar way.

Wayne: Yeah, I wonder if eventually we'll have, we almost need, like a chart for those four consumption methods, you know, smoking, eating sublingual, or topical, and then which terpenes under each of those categories are the most ideal because maybe the metabolism makes this terpene irrelevant, either this could be there or not there. Maybe smoking from the fire makes this turn - you know, it's like which terpenes are best for which consumption method? But, you know, it sounds like we're starting to understand or they're doing some of that research, and you mentioned a few right there, but it's just so interesting.

Emma: Yeah, definitely need a lot more research to better elucidate the role of, of terpenes, and their therapeutic properties is related to human physiology and cannabis consumption specifically for sure.

Wayne: As we get close to the end, I wanted to, I think there's - there might be three or four questions in this one statement. So I'm going to try to work through it and word it the best way possible. But something I've been curious about, as we see so many strain names on the market. And now there is genetic testing. So we, you know, hopefully farms are actually growing the strain that they put on the label. But when we look at strains, and how similar they might actually be to each other, even though they have completely different names, or you might even call one a sativa and one an indica, when you look at terpenes most strains are, most strains are THC dominant. So if we're just talking about those strains, and you look at terpenes, how many are most commonly found in the cannabis strains? It seems like there's five to 10 that I frequently see. And if you've got a shelf with 100 different strain names, is there actually only like five different varieties that you're actually choosing from regardless of the name or whether it's called sativa, or indica? Because of that terpene profile being actually quite common amongst all those strains and it's THC dominant?

Emma: So that's a really good question. The strain name game is a big thing in cannabis. And with strain names, you have to understand that they are for marketing purposes, and so people can kind of like rebrand a variety with a different strain name, even though its chemical profile may be very, very similar to another varieties chemical profile, but they give it a different name, because they've made me introduce some new genetics in the breeding process that causes a slight differentiation, even if it's in the color and not the chemical profile and so that definitely happens. However, we also have a high level of diversity in cannabis and the canvas matrix is quite complex, we still don't have the full picture of compounds that are present in the matrix. And so even a slight adjustment in the profile can create a large impact for a different user. We also have to remember that each person is unique in the way that they will process cannabis, each person has a unique ECS, and each person responds to a terpene differently. So you may in fact get quite a different set of experiences even if the chemical profile to, to the eye and to the ability of our analytical testing instruments is quite similar to another variety with a different strain name. I will say that there is about - I talk about the top six terpenes that show up consistently and abundantly in cannabis. Myrcene, Limonene, Terpinolene, Pinene, B-Caryophyllene, and Linalool seem to show up in highest concentration, though there are strains or varieties that we're seeing now that have a high Ocimene concentration or have a high Nerolidol concentration or have a high Guaiol concentration. And so these more minor terpenes are definitely showing face more often in different varieties because of breeding efforts, which is exciting. There is an order in which the terpenes are produced in the plant material. So pinene and limonene come first. If you've ever had the pleasure of walking through a cannabis garden in early flower, most of the flowers will smell like citrus or pine, regardless of their variety because those are two terpenes that pop up first and then terpenes are differentiated after. That's also why it is becoming rarer to see the dried and the cured flowers on the shelves in dispensaries have a very high concentration of Pinene or Limonene. Most often they'll have a high concentration or dominant concentration of Myrcene or Terpinolene or B-Caryophyllene, with a variety of other terpenes in combination.

And so that - I don't think I did a great job of answering your question. But there, there is a like huge variety of strain names out there, the strains or the varieties may be very similar to each other in chemical profile. However, they may cause different effects because different humans will have different experiences with those, not only dependent on their own physiological processing, but also the various situational impacts that will be had on the experience such as how much water they had, how much food they ate, where they consumed, who they consumed with, their mental health state, their emotional health state. And, and so I I wouldn't place so much value in strain names in regards to predicting the effect I would look to the available analytical data, the cannabinoid potencies as well as the terpene potencies. I would conduct an investigation as to how that particular variety was grown. Because I also believe that that creates an impact on the experience and know that strain names in in like, their essence are marketing tools, they are used to make you go oh my god Mojito Slurpee number five? Yes, please. That sounds freakin delicious. Instead of the scientific naming of it, which would be like H1N5-XZ. That's not fun. And cannabis is still fun. There's still a lot of whimsy behind it. But if we're looking at trying to predict the range of therapeutic properties, look to the chemical composition. Yes, it may be very similar to a variety with a different name. However slight fluctuations will cause, may cause dramatic changes in different people.

Wayne: Yeah, then oh, that really helps answer that thought. You know, I was thinking there's 100 strains. There's these top six cannabi- or terpenes in there. So you've really got six, maybe 10 varieties. But that's coming back to where that dose is so important because minor changes, or one ratio being a little higher can have a significant impact potentially on some people or most people. So that's really good to know. I've been curious about that.

Emma: Definitely. I'll also add, before we move on from that topic, that analytical labs, they can't test for all of the terpenes in, in the matrix. And so even terpenes, that may not show up on the analytical testing report, or the certificate of analysis, I should say, may be having dramatic effects on the physiological processing, even if it's in like miniscule, minute concentration. So that's also something to be aware of, as well. It may look similar from the data that we have, but know that the data that we're exposed to is a very, very small piece of the actual overall puzzle.

Wayne: It's a great point yeah. One last question as we wrap up, we got this from a listener. And I think we've hit on most of this. But just wonder there's a piece here. I want to clarify or ask one one time again. So shout out to Eric, Eric says I'm a pharmacist at a medical marijuana dispensary in Connecticut. And he asked, I'm on a search for a deeper dive into terpenes to predict strain effects. I've read that greater than 0.5% myrcene predicts a heavily sedating indica strain. So there's two parts that I wanted to ask. You know, I think we're kind of hitting on the dose of the terpene. And it's really hard right now to say greater than 0.5% would be sedating. But also to his comment about it being an indica strain, or making that correlation to sedating. I saw this pop up again, someone said, well, sativa strains might actually be a connection to a specific terpene. So I just want to ask again, for me and listeners - still zero correlation to a sativa, and indica, producing some specific kind of terpene that might make it uplifting or sedating just based on that sativa or indica?

Emma: Hmm. So I've also seen that 0.5% myrcene come from like - come from particularly one source SC labs that has denoted that. When I did reach out to them to try to find the source of that, and I never got an answer, or they sent me a paper that actually did not have that language in there. And so, this is also necessitates the importance of like, check your sources, check your information. We used that, that general rule of thumb at the dispensary that I worked at for a while, Farma, for a long time to help determine the kind of like sedating potential of a particular terpene, in that case, myrcene. However, that was not 100% expressed anecdotally in the population, I mean we would have cultivars and varieties come in that had over 1% of myrcene and actually create very stimulative effects for people. And so it's, it's important to understand that while these sources are reporting on this kind of data like, take it with a grain of salt, it is a general like rule of thumb that you could potentially use but it is not like really rigorously proven by science just yet in that example.

And as far as like the indica and sativa distinction, I I think that really where the damage comes in and using indica sativa to predict effect is by again looking on the internet and seeing like, Oh okay, this breeder, this grower, classified this variety as an indica, and you know, every single person who consumes this will experience sedation. And that's where like that is not good, if you look at the chemical profile or the chemotype of variety that maybe it was classified as an indica. And that variety does have a dominance of myrcene and it also has linalool and it also has B-caryophyllene, and it has some humulene even maybe, then I would predict that it would cause a sedative reaction in somebody. But again, know that that is a prediction, that is not an absolute, that is not consistent. Somebody may consume that one evening and find like great efficacy in regards to helping them with insomnia, but then a week later may not find that same efficacy. And so that's important to know again, important to understand that every single person is unique. That chemical profile may produce great efficacy in one patient or consumer but may keep another consumer really awake and alert at night. There are the again, that's the puzzle analogy that I use. There are these associated properties with these isolated terpenes that created the corner of the puzzle, but that middle piece is just missing because the research that we do have has been conducted on animals. And it has been in such high concentrations, that if we just looked at the research, we would then look at a chemotype of a variety that had terpinolene as the dominant concentration and say, Oh, damn, this is going to make you fall asleep, where really it would keep people up all night. And so that, that is an important thing to think about when we look at predicting effect, and maybe at some point in time, or even as we continue on, a grower or a breeder will classify as a variety as an indica because of the way in which it grows. And also the way in which it makes that person and maybe a few people in their community feel, but that cannot be generalized to the larger population of billions of people. We need to look at the chemical composition that comes from every single batch because also environmental factors will influence the concentration of the specific terpenes. It may not influence what terpenes are expressed dominantly because that's in a genetic code, but it may influence the concentration of not only the terpenes, but also the cannabinoids, which will thereby influence the experience. And so as far as industry professionals, people working in the industry, especially people on the dispensary side of things and making recommendations to consumers, I'm not saying to abolish indica/sativa. It is a vernacular that we have become accustomed to, it's a - it's a coded language that the industry has adopted to mean different things than the original definition and that's okay, language changes. However, we cannot use that definition to predict consistent experience for people we have to look at the chemotype of every single batch because environmental factors are at play and because different people will respond differently.

Wayne: Yeah, yeah. Awesome Emma, thanks again for coming on I - this was a really fun one. Yeah terpenes are so interesting to me and they're evolving we're learning more and you know products and different - all the things, I really appreciate the time. Is there anything you want to let listeners know about and then tell them where they can find you if they want to follow you or or learn more reach out or whatever it might be?

Emma: Sure. Thanks so much Wayne. My pleasure coming on, terpenes are, are always my favorite topic. I never get tired of discussing them. They're so fascinating to me. Um, you can find me on Instagram you can find me on the ole internet. My company is called eminent consulting. So you can find us at eminentconsultingfirm.com. You can also find us at @eminentconsulting on line or you can find me personally @echasen on Instagram. And hopefully soon, in the next quarter, we will be publishing some more in depth online courses where there is video of me speaking on not only terpenes, but also cannabinoids and a variety of other scientific information. So definitely stay tuned for that.

Wayne: Yeah. And any business listeners, Emma and I are going to be on a panel at the cannabis conference in Vegas. It's the end of April, April 20th, 21st, to the 23rd I think around there. So it'd be a lot of fun. We're going to talk about education and training internally inside the business and the science of cannabis and what it means for retail stores. So if you're heading out to that conference, come check us out. We'd love to meet any listeners that are there. So that'll be fun. I'm excited for that, too.

Emma: Yes, me too.

Wayne: Alright. Thanks, Emma.

Emma: Yep. Thanks, Wayne.

Pe130 Predicting Cannabis Trends with Data

Business focused episode. The beginning stages of a new State legalizing rec cannabis is exciting, but what comes next is anything but a smooth ride. Market conditions are constantly changing and staying on top of trends while predicting the future is critical for success. Our guest is Brad Bogus, VP of Marketing for Confident Cannabis, a data driven wholesale platform. We discuss how individual State markets are changing and consumer trends as cannabis goes mainstream.

Job Opportunity: Confident is hiring for Sales & Engineering positions, job postings link.

Link to Join Email List Community for insights we don’t share anywhere else.

Pe129 Building a Relevant Cannabis Brand

Business focused episode. There are multiple ways companies can create value. This value establishes your brand and reputation in the marketplace. You could compete on price, quality, customer service, convenience, etc, but an often overlooked value is relevance! Our guest is Christina Hadar, Co-Founder & Chief Brand Officer of Oregrown and we discuss how they are building one of the most relevant brands in the cannabis industry.

Link to Join Email List Community for insights we don’t share anywhere else.

Episode Transcription:

Wayne Schwind, Host: Joining us today is Chrissy Hadar, Co-founder and Chief Branding Officer of Oregrown. I'll let her tell you a little bit more about Oregrown, but excited to have you on today. You guys have built a solid brand excited to learn your lessons, process, your thinking and, you know, what's going on there with the business how you built it. So thank you for taking some time with us today.

Chrissy Hadar, Guest: Thank you for having me.

Wayne: For listeners, just starting with a little context, kind of tell them a little bit more about Oregrown, what you do exactly, and then your role as well with the company.

Chrissy: Okay, so Oregrown was founded in 2013 here in Central Oregon, so we're based out of Bend, Oregon. We are considered a farm to table cannabis company, meaning that we do cultivate our own cannabis. So we are known specifically for indoor cannabis, and then we also produce our own extracts at our 84 acre farm out in Tumalo which is just about seven miles north of Bend. And then we have our flagship dispensary here in Bend, we've won Best Dispensary five years in a row. And here we, you know, kind of pride ourselves on offering an exceptional retail experience that is achieved by, you know, offering the best curated cannabis products from throughout the state. And then it's backed by our lifestyle brand, which includes sponsored athletes and then select branded custom Oregrown clothing and accessories.

Wayne: Yeah, yeah, I would love to dive into all those items. Have you from the very beginning - So co-founder, from the start, were you always focused on the brand and marketing, and building that end up of the business?

Chrissy: Um, yes. I'm definitely not - I can't really speak as much for the cultivation side of the business. I have a pretty vast background in retail. So I've managed a few retail stores. And then, when we started Oregrown, we initially had a logo set made up and we had some t shirts made and we threw them online and we noticed that people were actually buying them. And I think that that's when something resonated with us, that we had this opportunity due to the name Oregrown, which is a great name, it can't really be applied to many other states. And it really connects with our consumers. Whether they use cannabis or not. And we saw great opportunity there to kind of use this, you know the way that people think of Oregon as this outdoor utopia, and to basically brand not only our cannabis products but brand the states as this - as whether or not you use cannabis, we are destigmatizing cannabis through showing people that, people that use cannabis are active, they're out there in the - in the community, they're mothers, they're doctors, they're lawyers. And so instead of just telling people that cannabis is something to not be afraid of, we're showing them. (Yeah) I've been able to achieve that through the lifestyle brand.

Wayne: Yeah. I mean, you guys really have built such a strong brand, very recognizable in the state and probably outside of Oregon as well, along with not just that retail experience, the products, the cultivation. At the beginning, you know, a lot of brands are looking at other states for growth. Now federal legalization is becoming a topic. Was that a thought or concern, that with Oregrown, would that be hard to move that outside of Oregon or would it still be possible? Are you guys really saying no, we're going to stay focused inside of Oregon long term?

Chrissy: I think that right now our focus is expanding throughout the state of Oregon. We do have our wholesale products are carried in over 200 retailers throughout the state. We are continuing to open retail stores and some of the better known areas of the states. But I do think that Oregon, prior to legalization was always known for crafting some of the best cannabis in the country. And so I do think that Oregrown as a brand has potential in other states to be successful.

Wayne: Yeah, yeah.

Chrissy: At the same token, we do have plans to take other brands that we have in mind to other states.

Wayne: Okay. Do you brand your line, on the flower side or products, differently? Or is that still all - are all of those under the Oregrown brand umbrella?

Chrissy: They are all under the Oregrown brand umbrella. So all of the extracts that we make, whether it be through our 510, or in our partnership with Pax, or our dabbles - they're all branded Oregrown. One thing that we've done a little differently and if you can see some of our packaging via our website, is we actually have taken kind of a lesson from the craft brewing industry and branded the strains. So the strains are the main focus on the branding of our products, through the artwork, and then Oregrown is kind of hidden in there in a sense. And we really did that because we found, as a retailer going into other retailers to attempt to sell our product, so they carry it and sell it to consumers, that they didn't necessarily want to support the Oregrown brands and help us you know, gain followers. So we decided to brand instead, the strains or the flavors of the product, and that's been really successful. Yeah, and actually a lot of fun.

Wayne: Yeah, I could imagine and being able to create those different brand lines or stories depending on what the strain is, I mean, there's so much room for creativity there and in cannabis right now. I mean, there's no past examples or best practices right now, we're really building the ship as each step we take forward. It's really interesting time.

Chrissy: 100 Percent.

Wayne: With - so starting early on, a lot of, I mean such a focus on retail, you've built this flagship store in Bend, also kind of a lifestyle brand, which ties nicely into retail and the apparel that you make and sell from the beginning, what was the decision making on the strategy to be fully vertically integrated, grow and process versus say, we're just going to stick to retail, and then we could expand that way more? So what was kind of the thinking behind that?

Chrissy: Well, I think that initially we didn't even want to touch retail. And that's because there's so much involved in running a retail dispensary. But after we started the grow and the extraction side of the company, we realized that we didn't really love any of the dispensaries that we were going to and we weren't going to be proud for these dispensaries be carrying our product. So we really want to kind of control the environment in which we felt our premium product would be showcased to the customer. And in addition to that, you know, control the story. And so we went out into the real estate market and attempted to acquire real estate here in Bend to have our flagship dispensary, and found that very difficult. This was back in you know, 2014 prior to legalization of medicinal dispensaries here in Oregon. And you know, we just kept knocking on doors and there happened to be this little spot on Wall Street a few blocks away from the Patagonia store and the main strip of downtown Bend, with Deschutes Brewery and all of that and the owner of the building was just - he was insistent. He was like, I'm not renting to a dispensary and finally convinced him to meet with us. And it turned out that he went to the same high school that I did in Portland, I grew up in Portland. And we had a really good bond. And and eventually he let us rent out the space, and the location has served us well. I mean, we do have a lot of locals as customers, but we definitely serve a lot of the tourists that come to Bend during the winter and summer times for outdoor activities. And that also kind of ties into what helped shape the brand, because the brand really, you know, kind of evolved through the people that were coming through our doors. And so we were able to through opening our dispensary kind of, you know, create this, this culture in cannabis through the people that work here, through our branding, through our messaging, through our advertising. And I think that, you know, after opening your own retail store and realizing what you're capable of doing and the changes you're able to make in the industry. It's something I definitely wouldn't take back despite how much work goes into running a successful cannabis dispensary. It is not for the faint of heart.

Wayne: Yeah, yeah. As soon as you're customer facing versus making the products or growing in the background. It's a lot more - it's a whole different business model. But at the same time, you're now talking to the end consumers directly. There's not that middle person or dispensary, where it's hard for us, you know, to really make that connection to the end consumer. What were you know, you said the brand evolved based on who was coming in the store, what you were learning. What were some of those things that you identified as you evolved the brand or different product lines that were really learned from having the store and being able to talk to those customers?

Chrissy: Well, I think especially during the change from medical only to the recreational market here in Oregon, you know, you found that people were still coming in for medicinal purposes, right? Like they didn't have a medical card, because they never went through the process and the headache of getting one. But they were still coming and stopping by our store on their way home after a day on the mountain to get something to help them relax in the evening or a topical for their aching muscles. And so that kind of, you know, feedback that you're getting from your customers. It was just like, Okay, well we now know the people that come to our store. Yes, they use cannabis for, I mean, we like to call it adult use instead of recreational, so adult use purposes, but they're still you know, using it for what could be deemed medicinal purposes. And so they're - they're active people or they're people coming in to help them sleep or they're people coming in to help, you know, for stress. And so that really paved the way for the brand. And right now we really focus on outdoors. Because up until now Oregrown has been based here in Bend, but with the opening of our Portland store, you know, we'll be focusing on artists and people in the culinary world. And I think that we really just, you know, I see the brand as this living organism, it's nothing that's just stagnant. It's not necessarily a reflection of myself. It's a reflection of everybody that works here and everybody that shops here. So I think the Oregrown that you see now, as this outdoor lifestyle brand, will be entirely different in two years as we move into other parts of the state. And it'll be more of a reflection of, you know, a broader sample of people.

Wayne: Yeah. Yeah, that's interesting. I was kind of thinking with where you're at in Bend, and how you evolved the brand based on those customers. I mean, Bend is such an outdoor city. I mean, great skiing so many things to do there. I'm curious if bringing that store over to Portland, how you might shift the strategy, you know, obviously, here we have Mount Hood, and still a lot of outdoors, but much bigger city. How do you make a decision? You mentioned culinary and artists. When you're coming to Portland, and maybe we could talk about the other cities, you're also going to Eugene and Cannon Beach. How do you think about shifting the brand or refocusing, when you're going into a different city? Like what do you look for? What do you looking at? How do you kind of figure that out? Like what's the right focus to take?

Chrissy: Well, I think that I have a leg up in that I'm from Portland. So I have a lot of connections to people in Portland. And I mean, I think my main goal with moving the brand into Portland is to bring on more diversity. Obviously Oregon isn't known for being the most diverse state in the country, could potentially be one of the least diverse states. But Portland does have more diversity than Bend oddly enough. And so as you know, up until now, it's been a lot of you know, powder shots and surfing out, you know, at the coast and I think it's time to really bring on more diversity, and so that's something that I'm going to be focusing on as we move into Portland. Eugene - college town, I did spend one semester at the University of Oregon and - and I think it goes without saying that we'll be targeting the college market. And the coast has its own kind of little niche where - and that will certainly be an interesting store to manage because of the seasonality at the Oregon coast. Here in Bend we have, you know, seasonality as well when it comes to tourists, but we have the winter season for skiing and snowboarding and, and mountain activities, then we have the summer season for rafting and climbing. So at the beach, you really only have summer, and the summer is quite short. So it's trying to find a way to capture locals in the coastal region, but then really tap into that that tourist market during the hot season. And I think that Oregrown as a brand as a stands now is primed to do that at Cannon Beach.

Wayne: Yeah, see the surfing focus. There's a lot of that carries over what you're doing and Ben but the seasonality of it. Yeah, makes the coast a really fascinating area to operate a business. I mean, large swings in people coming through in the summer versus the winter. Yeah, it's interesting. You talked about Eugene, a college town, kind of focused on that. What are some of the things that would make a brand more appeasing or interesting to that college town or those consumers? Are there specific things when you when you try to focus it in that direction?

Chrissy: Well, one thing we've done successfully here in Bend, and this was kind of from the onset of the opening of our retail stores, we've been really involved in the community. And so we sponsor a lot of the big festivals here in town, like Winterfest, Summerfest, Oktoberfest. And then we have a lot of partnerships with nonprofits. Probably our most notable one would be the Humane Society of Central Oregon, where we have a fund set up to aid in the adoption and support of elderly animals. And by doing that, and going out into the community and being involved, is probably how we've gained so much notoriety here in Bend and I think places like Eugene, where there are so many events constantly going on. It's really just about getting out there and getting on people's home turf where they feel comfortable to come to your booth and ask you questions and look at your swag. It really - it kind of takes that first step of them coming through your door, that fear, away. And so when they finally come into your dispensary, or they finally decide to explore cannabis as an alternative to Western medicine, let's say, you know, they're immediately going to think of your brand, they're immediately going to think of that, you know, one on one experience they had at Summerfest or Winterfest or whatever events we end up doing in other regions and - and that's really been a way for us to kind of take down barriers and also gain a lot of foot traffic.

Wayne: Yeah, yeah, I hear you talk about all those things that I've heard before. You know, being a recognizable brand. And then I heard someone say actually, it's not - the goal isn't necessarily to be recognizable because you can be recognized for the wrong thing. But being relevant, a relevant brand. And that's what I hear a lot when you're, you're talking about the different cities and how you're going to focus. What do these people and consumers care about here? That's a, I really like that kind of thinking just as a mental strategy or exercise. Because it really shifts, I could see you taking the Bend operation, like this is successful. Let's just repeat it. But it's really interesting to me like, well, maybe we need to adjust this strategy. So I...

Chrissy: Well I think, if you just kind of take this cookie cutter mentality, then you're never evolving, right? And before you know it, you're going to be irrelevant.

Wayne: We see quite a bit of that. Yeah.

Chrissy: So you have to be nimble and you have to listen to your customers. And I think that Oregrown's been successful in that, yes, we buy and sell products that we use ourselves and that we like. And that model has always, up until now worked. But that doesn't mean it's going to work forever. And so it's about you know, getting the stores open, adjusting and listening to our customers. Yeah, and we're probably going to make some mistakes, right? You know, some things aren't going to stick, but you mean you have to try to consistently evolve. And to be clear, I mean, look, Oregon isn't California, let's say, where, you know, the places that we're going to do have a similar vibe. Right? Whereas like Northern and Southern California, they might as well be separate countries. And so, you know, we're not reinventing the wheel each time we open a store. That's not our intent as we move forward. It's just to take nods from each region that we go to integrate that into our existing lifestyle model.

Wayne: Right. Before you, you go into a new city or you're looking at a location, is there any specific kind of market research you do? And maybe how do you do that? As you try to figure out what your strategy should be?

Chrissy: Um, I would say there's a lot that goes into it. We're very picky when it comes to real estate and locations. I know that some people would probably say that we've been slow to the punch when it comes to opening up additional retail stores. That's simply due to the fact that A. we are still family funded and operated. And B. we're extremely picky when it comes to real estate. We recognize the fact that location is super paramount. We look at walkability scores, we look at the neighborhoods that we're going into, we look at parking, we look proximity to office buildings and high density living and, and traffic as well - bus lines, how many cars go by a day? And yeah. And it's insanely - it's a logistical nightmare, especially with the way that the wholesale laws are set up. And the transferring of product and having to have to let you know, wholesale hubs and whatnot. I mean, just side conversations I hear of logistical issues that come from wholesaling a product which I'm sure you're very familiar with is is really not my speed. But at the end of the day, I think that retail, you know, you also have this opportunity to create a really fun environment and and sell products that you really love and believe in, and a lot of our flower growers - you know, I don't always just want to sell Oregrown products. I don't want to monopolize our own store, but I do think that working, you know, with your own brands, on the wholesale side, but also bringing on some really craft small batch growers to kind of round out your selection. I mean, that's really our North Star. And and, you know, we're getting there.

Wayne: Yeah, I was gonna kind of ask that too. I mean, I think the brand is hugely important in that relevance creating that and, but at the same time, how important is the actual just physical location to you and then coming in later to these markets, is it harder to find those ideal locations because a lot of you know for any of these cities, I mean, the I think Oregon has the most dispensaries per capita of any state in the country. Does that make it even more challenging?

Chrissy: Um, it's, it's definitely competitive out there to to get real estate for dispensaries because of the bubbles and the lack of licenses going out. The real estate that we currently have, we have been sitting on for a little bit to make sure the timing was right to open and move forward with them. And so I would say that that being that we're picky in real estate has been a challenge that has probably taken us longer to get to our second store, which we have upcoming, upcoming here shortly. But I think that it's going to pay off in the long run.

Wayne: Yeah. What made you pick - Portland makes sense, you grew up there, you have that connection. What made you pick Eugene and Cannon Beach versus other cities in Oregon?

Chrissy: Well, let's see here. So Eugene and Cannon Beach. Cannon Beach, I think for us was a natural pick for the coast. I grew up going to Cannon Beach so I obviously had a lot of great things to say about it. I think that our brand resonates well with the the brand of Cannon Beach because I do believe that even a town can, can be branded it is you know, probably one of the wealthier areas along the Oregon coast and we do consider ourselves a premium brand. And it also attracts you know some of the most tourists to the Oregon coast every year and our location, right on the main street of downtown Cannon Beach, really can't be beat. You know the coastal market, with its ebbs and flows of of traffic is going to be interesting, say the least. But I look forward to the challenge of running a store that's based off of so much seasonality. Eugene is you know, I think a great - one of the greatest towns in Oregon. And you know, probably a, I think the building that we got that we have there is in such an up and coming neighborhood that it was Real Estate we couldn't pass up. And, and we look forward to having that built out by the first quarter of next year.

Wayne: Yeah. Were you still looking at other cities, trying to find the ideal real estate location? Or was it decided on those cities and let's stick to our real estate search inside of those cities?

Chrissy: I think we were pretty open to almost anything right? I think it all kind of came down to really finding these these premium locations within a variety of different areas that we were looking at at the time.

Wayne: Okay. One more question on retail, then I want to move over to kind of influencers and the marketing piece of it. But a lot of stores, their second third location, they stick local to where they're at and then maybe some don't, but then expand maybe to other cities after that and some you know, have a lot of store count. What made you not - decide not to stay in Bend, where it's your headquarters, it's close you know the brand would work and a second, third store in that city versus going to - you know these cities are three hours away, over a mountain pass, I mean that's hard to - difficult to manage when they're that much further away. Why not stay inside of Bend and open multiple shops there?

Chrissy: You know, we had a lot of internal discussion when it came to whether or not we wanted to open another dispensary here in Bend. I for one can say I was against it. I did have the fear that it would cannibalize some of our sales at our existing location. But at the same time, Bend is flooded with dispensaries and it just you know, didn't seem worth the effort to open another dispensary here. That's not to say that we are completely against the idea down the line. I think that we are just more excited to enter new markets and start getting traction in other cities.

Wayne: Yeah. Okay. So influencer marketing, you know, it's a big piece of marketing outside of the cannabis industry, but I haven't, you know, maybe more for some California brands and there's celebrities that are signing their names on to things. But I haven't really seen a brand take influencer marketing the way some other companies do and you really have. What is the thought before you started that strategy and maybe just let listeners know kind of what are the detailed finer details of influencer marketing?

Chrissy: Okay, so we have currently athletes that we sponsor so we give them goods that have our logo on it, mainly clothing, and then oftentimes a stipend for products in store and then potentially a small cash monthly bonus to promote the brand and basically be good stewards of the brand. And that kind of came about pretty, you know, pretty organically. I think we had, we found that we had a lot of really talented individuals shopping in our store. But they weren't just talented. They were also out there doing really good things for the community. They were kind, they were really great representations of the Oregrown brand. And so I think that word of mouth is super powerful, especially in a town as small as Bend, and especially with the amount of influence that can be had on social media. And we found the best way to also get free content for our social media was by sponsoring these athletes, right? And I don't know if you've taken a look at our social media, but we do not post any cannabis. And that is, I think, probably unheard of, for the most part in the cannabis industry. We don't post cannabis in and of itself, and we also don't post pictures of people using cannabis. And that we can get into later down the line if you want. But that was after a long series of our page being taken down and I'm sure something that a lot of people in the cannabis industry can relate to. And so we have people out there who use their social media to help promote our brands, but they're also just, you know, good represent - good representatives of the Oregrown brands and kind of help spread the message of what we're all about.

Wayne: Yeah, I would imagine as probably at least in Oregon, one of the first brands to really take this influencer marketing strategy when you're approaching these people. You're talking about cash stipend or free apparel. There's no competition in influencer marketing, no one else is asking. It's like kind of a no brainer for them. I would guess on their end for the most part to go Yeah, that sounds cool. Let's do it.

Chrissy: Yeah, I mean, the only time that we've had, you know, there has been some hesitation as we get into, you know, discussions with bigger and more well known athletes, is conflicts with other existing sponsors.

Wayne: Ah yeah, being connected potential.

Chrissy: Yeah, because a lot of them are sponsored by Red Bull and other big names and we haven't yet had any issues. So...

Wayne: Is there anything you do to - I don't know, it's hard with branding, but on the influencer side, to track effectiveness or metrics when - because you could potentially have 100 influencers or maybe 10 that are a little bigger. I mean, is there certain things you look for when you're working with an influencer to say this is working for us on you know, the brand or marketing or sales or things like that?

Chrissy: Um, I think right now our big focus is ensuring that we have content for social media. Yeah. And so these are people that I can call upon if we need to do a photo shoot for clothing, or, you know, have them just shoot when they go out on the mountain and send us photos. So we always have content, new content coming in. So the brand always kind of feels fresh. And that's why as we go into Portland, it's going to be just as important to find people there who are doing what they love. And, and bringing them on to the team to kind of bring in a new perspective and a fresher, a fresher take on the brand.

Wayne: Yeah, that's really smart. I never thought of it that way. I you know, you're getting the exposure through their audience. But at the same time, the content they're creating does allow for those things that you mentioned. Do any of your influencers or have you also looked at, like writing blogs and a video production or any of them doing that kind of thing for you as well?

Chrissy: We do have so we do have some of our athletes usually kind of travel with photographers so they have friends that are photographers that that you know the kind of go with them places, so we haven't brought anybody on like that yet but that is a great idea something I'll look forward to doing in Portland.

Wayne: Yeah. Yeah. With Pax labs, I'm curious how that started initially and on the branding side aligning Oregrown and I think you did the manufacturing for their pad or pods making those. How did that deal kind of come about and what was the marketing/branding thought behind agreeing to that partnership and doing that?

Chrissy: Um, so I was in the dispensary one day and a guy came up to me, and he had this battery device thing that I had never seen before and he was asking if we had sold - If we sold the pods that went inside of it and I was like I've never even seen this before, what is this? And he had just gotten back from some Expo in Vegas where he had received a Pax Era device on the expo floor, and I immediately called my Pax rep, because at the time they were providing us with the Pax 2 and the Pax 3 flower vaporizers and I asked him what it was all about, and they had just rolled it out in Colorado. So it was the Pax Era platform. So basically Pax is a technology company that goes out and finds Brand Partners, being cannabis companies, that make extracts that can go into their pods and then sell them in the state under their license. So I had a brief conversation with some people at Pax and a few days later they flew one of their VPs out to meet with us. And at that time, they were rolling out the Pax platform in Washington, and they were going to almost do kind of a flyover of Oregon. But we really felt that the Pax vaping experience would really resonate with the Oregon market. Because of its sleek design, its ease of use, and the fact that you can really build these pods with some really quality oil. And we essentially were their only filler here in the state of Oregon until perhaps a few months to a year ago. I've lost track of time and since then they brought on other Brand Partners. But it's definitely one of my favorite ways of vaping. And then we recently came out with our own 510. So not only are we fillers for the Pax Era platform, but we do sell our own 510 vaping systems.

Wayne: Okay, how big was and still ongoing the vaping crisis for you there? What consumers were asking how you approached it? Like, I mean, what was that whole experience and still ongoing experience like for you?

Chrissy: Um, I think I, I can definitely say it did impact sales. And if anyone tells you that didn't, they're not being honest because I've seen it on the wholesale side. And I've also seen it on the retail level. But what was interesting about that is that it did impact the sales of vaporizers but it increased the sales of edibles and flower. So yeah, so for a very long time I feel that the Oregrown store is - you know, in a lot of ways because we do make our own vape and dababbles a vape store more or less. Like our flower numbers are pretty consistent throughout the year. But really when the vape apocalypse came, we saw our per-weekly flowers sales jump up two pounds. So while it did affect the amount of vape units that we were moving, and dababbles for that matter, it really just pushed people back to flower, which is I think, kind of, you know, it's an okay thing. You know, it's the purest form of consuming cannabis, edibles are always going to be there as well. And at the end of the day, now that the ban has been lifted, I think that business is kind of tracking as usual, people are still a little weary of vape. But you know, at the end of the day, we sell products that we would use ourselves and so we can stand behind every product that we sell.

Wayne: Yeah, long term if the you know, the vape or the extract brand really becomes the shining star or maybe it's the vape extracts and retail, could you see yourself potentially walking away from cultivation or, you know, whatever segment of the industry it might be? Or what would be the market conditions that you'd say, okay, we're going to kind of discontinue this line of our business and go more all in more narrow here. Did you see that occurring?

Chrissy: Um, you know, it's hard to say, because I really tried to disconnect myself from the cultivation side of the company, just because, I mean, one only has so much bandwidth, right? You know, I think - I think there was a moment there where the Oregon market felt very flooded with flower. But I think we're kind of taking a turn here and seeing that maybe we aren't as flooded as we thought. And I'm seeing brighter days ahead for the cultivation side. But really, I think we shine very brightly when it comes to retail and the experience that we offer. And I think it's easier to differentiate yourself on the retail side than it is on the wholesale side. There is obviously you've taken away that barrier to entry and being vertically integrated. You know, you aren't having to go knock on other people's doors to try to get them to sell your product. So, really what we're trying to do, and what we will likely do is create a situation where we are producing enough product on our own to supply our own stores, and rely less on third party dispensaries to sell our product.

Wayne: Yeah, that makes sense. And as you get a few more stores open, you just see - and this is just business in general, but definitely cannabis. It's like more and more, more bigger, bigger, bigger and, you know, get into as many stores as possible. But I also I mean, I really like a strategy of we make quality products, it's good, it's good value, the price is more premium, why don't we just make what we can sell in our own stores? And you can run a really successful business that way, without, you know, growing as big as possible, intentionally staying more focused. That's interesting as a strategy to do that versus trying to be in every store there is an Oregon.

Chrissy: No, and that's exhausting, right?

Wayne: Haha, yeah. You mentioned I don't know how much you maybe know about this on the cultivation side. But you mentioned the Oregon market being flooded. I'd like to at least get your thoughts. I mean, a year ago, the state said, we have a six year supply of flower. If we stop producing, it's gonna last six years, the prices are falling, everything's bottoming out, race to the bottom. And then all of a sudden, like six months ago is like, oh, the prices are coming significantly back up. Well, what happened there?

Chrissy: Yeah, where did all that weed go?

Wayne: I mean, I understand a small amount potentially going to blac/grey market but not the amount they were discussing, like that just doesn't disappear, especially when it's in the seed to sale tracking system. It's really hard to get that like out of your system illegally. Was it just a miss - analytics guests or calculation on what we actually have? Like? Do you have any idea what happened there?

Chrissy: Oh man, I would hate to speculate...

Wayne: Cuz that surprised everybody. All of a sudden...

Chrissy: I would say that there's probably some leakage to the black market, I would believe that a lot of people went out of business, so I wouldn't be surprised if a lot of it was wasted or went to extracts, which is what is commonly done with excess cannabis. But I, you know, what I do know is that the asking price for flower today is more than what it was six months ago. I mean, everyone thought that you know, as the price per pound was going down that it just wasn't going to stop. And I strongly believed that we had bottomed out. And, you know, even from a retailer's perspective, like I don't, you know, like seeing $700 pounds on the market. You know, I don't like seeing $3 grams being sold at dispensaries. I think that our growers deserve more than that, right? Like that's a lot of work to grow cannabis, whether it's good cannabis or bad cannabis, a lot of work went into all of that. And so I want to see the price per pound go up, I think that there is a happy medium in what the consumer will pay and what you know, and how much money the growers should be making and then the margins of what the middleman should get. And I'm happy to see that the price per pound is going up, I'm happy to see that there's less on the market than there was before. And I think that a lot of that can just be attributed to waste, a lot of going to waste, and not being up to par where dispensaries didn't want to purchase it. It going to be made into extracts and then potentially some leakage, but I wouldn't know how that would occur, like you said in the seed to sale tracking system, that would be a tough one.

Wayne: Yeah. How much do you think, I'm curious of if you're looking at this side - hemp CBD. A lot of farms potentially switching to hemp, and his Oregrown looking at hemp lines and products, anything around that?

Chrissy: Um, I don't know much about olcc licensed growers switching to hemp, I think if anything, they're adding on a separate farm or license to their existing olcc license, because you'd be kind of a fool to give up and OLCC growing license at this juncture, if you're set up appropriately and in compliance with state law, Oregrown does have plans to come out with a CBD line. We would be foolish not to. but I don't that doesn't. That wouldn't mean that we'd be growing the hemp ourselves being from Central Oregon. It truly amazed me this last summer how many alfalfa fields were switched, were switched over to hemp and how how much of it went to waste. So I think that a lot of people have jumped on the hemp bandwagon after the federal laws were lifted, and I think a lot of people learned some really expensive lessons this last summer. Specifically, you know, if you're going to grow something, you better know what you're going to do with it when it's done. We saw a lot of failed acreage around our property this year. And that's never, you know, fun to see. But I think next summer, people will be more prepared, and we'll see more success coming out of him crops out of Oregon.

Wayne: And you said a lot of it was wasted - was that because they just didn't have an outlet to sell it and they couldn't move it or an overgrowth or what happened there?

Chrissy: I think that they weren't prepared to how they were going to dry it. Obviously drying, you know, when you have that much material, is pretty important to prevent mold and mildew and other - and other issues. In addition, we had, you know, some strange hail storms the summer that really destroyed some crops. And yeah, at the end of the day, they had no one to purchase it to make it into oil to make it into products and that - and there was certainly a surplus of hemp coming out of the state of Oregon this year.

Wayne: Yeah. You mentioned you know, growers. I think we have a lot of growers that listen to this and a lot, either were or still are struggling. And you said if they had an OLCC license, they're set up, they're compliant, just to get rid of that wouldn't be wise. If they're struggling right now, what would someone do with an OLCC license if they're compliant? Like is there a strategy they could use just, that's not just kind of walking away from it all on their end that might help?

Chrissy: I would attempt to sell it.

Wayne: Okay. Are there still, like buyers on the grow side then, are people looking still to buy licenses? Because I think for a while there it was like - Oregon is full, like if don't, that's not the place to go to start a business now.

Chrissy: Yeah, yeah, um, but also depends what you're trying to grow, right? You know if you're trying to grow just as much cannabis as possible and you know, going into it without a way of differentiating yourself in the market, you probably won't be successful. But, you know, I think that the craft growers who are hanging on tight, you know, they're not making a lot of money but they're making just enough to get by, or maybe they've had to bring on somebody to cover their losses. I think if they hold on tight enough, and they continue to put in the work to, to create a premium product it's going to pay off in the end.

Wayne: Yeah, yep. Yeah, the quality and then the brand with the good product. That's where that there seems like there's room for that. Yeah, but as far as volume there's it's definitely been saturated. Interesting. Well, Chrissy, I really appreciate the time. A couple ending questions I like to ask guests as we wrap up. Number one, Are you hiring at all? Anything that might be an opportunity for a listener? And then the other piece if you want to let them know about the soft opening, or your other stores, potentially, um, anything around those that you want to let listeners know about?

Chrissy: Um, let's see here. Are we hiring? We're always looking for amazing team members, always. So if you're interested in a job at Oregrown, you can just go to our website and contact us through there. It's just www.oregrown.com. And let's see here. In the next couple weeks, we'll be opening our Portland store which is on the corner of Northwest - or excuse me, Northeast 12th and Couch in Portland, and we will be opening our Cannon Beach store in January of 2020. So just next month, and then our Eugene stores should be open in the first quarter of this next year.

Wayne: Awesome and where can people find you online or follow you to look for those store openings?

Chrissy: Okay, so we are just obviously our website www.oregrown.com is always the best place to go. But we are also pretty active on Instagram. So it's @Oregrown on Instagram, or @Oregrowninc.

Wayne: Awesome. And then just a clarification on the hiring piece - are mostly you looking for budtenders right now? Or could it be marketing, design? Potentially any type of position?

Chrissy: Any type of position.

Wayne: Awesome, someone passionate and like that?

Chrissy: Anybody that's passionate. Yeah. And being familiar with our brand. You know, I mean, that's kind of a tip for just, for coming in and trying to look for a job, is just being familiar with our brand before you come in as always, as always helpful.

Wayne: Yep. Awesome, Chrissy. Well, thanks again for the time. I think this will be a good one for listeners, branding and marketing in cannabis is a new frontier and I learned some new ones from this conversation. So thank you.

Chrissy: Oh, thank you so much. I appreciate your time too, have a great day.

Pe128 Understanding Federal Cannabis Policies

As State markets mature, there is a lot of uncertainty on how cannabis will progress at the federal level. Will the federal government step in with control and influence over regulations? Or will they allow States to have autonomy over their markets? Our guest is Don Murphy, Director of Federal Policies at the Marijuana Policy Project. We discuss the STATES Act, MORE Act, SAFE Banking Act and what hurdles we still have to overcome.

Link to Email List sign up “Join our Community” and get insights we don’t share anywhere else.

Episode Transcription:

Wayne Schwind, Host: Joining us today is Don Murphy, Director of federal policies for the Marijuana Policy Project. excited to have you on today Don and learn a little bit more about what's happening at the federal level. I know multiple acts are being floated around one passed the House Committee, and a lot of uncertainty and unknown from the you know, business side or people operating in the industry. So thank you for taking the time to come on and share some insights with us.

Don Murphy, Guest: Thank you for the invitation.

Wayne: Let's start with just context for listeners introduction. I'm assuming most have heard of the Marijuana Policy Project, but if they haven't, a quick introduction to what you do as an organization, and then your role there and how long you've been working with them and you know where you're at right now and what you're focusing on?

Don: Well, let me start with my history, because my history and MPP sort of intertwine. 20 years ago, I was a Maryland state legislator. Member of the House of Delegates, I was introduced to a gentleman who was using marijuana for medical purposes. I am a, or was a, law and order Republican. I got elected in part on the platform of law and order after my wife was held up in an armed robbery. I won an election, I got put on the Judiciary Committee and honestly, I was gonna lock up everybody. And I met this gentleman named Daryl Putman. He was a Green Beret Special Forces Vietnam veteran. He said to me, he was using marijuana with his doctor's approval. And, uh, you know, he said, Do you think I'm a criminal? And I hesitated, but I was pretty firm. I said, No, I don't. My dad he'd just passed away from from cancer, but I didn't know anything about marijuana as an alternative to cancer treatment or as a part of cancer treatment. That was - wasn't something that was ever suggested. And this was back in 2000, actually 1999. So he said, "Do you think I'm a criminal?" I said, "No". He said, "Well, the law does. And you're a lawmaker. So unless you do something to change the law. You know, you really do think I'm a criminal". And he had a point. So from that point on, I became the unlikely advocate for marijuana policy reform for medical patients. 20 years ago, I was introduced to the Marijuana Policy Project they were doing ballot initiatives and working in the States, they were just a brand new organization just a few years old at the time, but since then MPP is the leading advocacy group for ballot initiatives for both medical and adult use. In those states that have adult use, we're responsible for, I think, eight of them, maybe nine and a half depending - we've run all those ballot initiatives and most recently, we worked to pass through the legislature in Illinois, their adult use program.

Wayne: How many years with MPP did you say?

Don: MPP is been around almost 25 years and while I was in the legislature, I work with them and then I didn't run for reelection in 2002. And I received a grant from them to go in and mostly talk to republicans around the country about why marijuana policy reform was consistent with conservative values. And we did that off and on for a dozen years or so. And then, recently I came on board full time to work just on Capitol Hill.

Wayne: Got it. Right. And now you're mostly focused just on the federal policies, and less on individual states? I mean, that all ties together, obviously, but?

Don: Right, that's correct.

Wayne: Okay. So yeah, I thought for today's conversation, and we talked a little bit beforehand, from you know, who listens to this podcast, our background here - you know, we're small, medium sized craft businesses, and all these things, how they move around in the government, or, you know, they're confusing and a lot of uncertainty. So I wanted to get some clarity at the federal level where we're at now, you know, what the future might look like? And it seems from what I read and articles and what's going on, there's kind of a few acts that are competing, potentially to get pushed through or legalized and so you have the STATES Act, which you know, seems like initially that had some traction, more recently the MORE act and then another one, the SAFE Banking Act - between those three, and maybe none of them go through in the future, and there's a different act potentially that could come about - where do those stand? I mean, how do you compare those? Is there one that's better than the other? And I think we just start with a general overview. And then we could go deeper into each one and the details and you know, what the interests are, why it'll pass, why it won't pass. But could we do a summary of each of those and kind of clarify for listeners what each one just is exactly.

Don: Sure. So the SAFE Banking Act - You asked the question is, is one better than the other, the better - the best one is the one that passes and becomes a law. Everything else is just noise. But when you're an advocate in a space that is so new as this one, everything is historic. So we use that word too much, because everything we do is historic, right? We have, we have a bill hearing - oh, it's a historic bill hearing. We have a vote, that's historic. It passes, even if it doesn't pass - it's still historic. So we joke about that a little bit. But the point is that everything we do is kind of new here. So the SAFE Banking Act would fix the banking system, for the most part and allow folks to use financial institutions to bank their proceeds, for people to use credit cards, that sort of thing when buying cannabis in a retail shop. That has the most traction. It is a bill that was originally drafted about six years ago by Ed Perlmutter from Colorado. He's been working on it forever. When democrats took over the house, they - they finally had a hearing. They passed it out of committee. It took about four months to get it to the floor. Because the truth is, advocates - criminal justice advocates - were unhappy that, that this bill was moving and it was really just perceived to be a sop to industry and the banks. Great. What does this have to do with criminal justice and equity and all that stuff? So I will say, Marijuana Policy Project took the position that incrementalism is better than no -ism at all. Right? So we were, we were somewhat happy with this thing moving because I actually think that in order for federal policy to change the industry, the issue has to be viewed as legitimate. And an industry is not legitimate when it's cash only, right? That's a nefarious industry just on its face - it has to be right? It's under the table. It's cash. It's, it's everything you don't want in a legitimate industry. So we think fixing that is important. We also think that when you deal with the issue of equity, and social justice, there are a lot of folks in this, in this space - who aren't in the space because they don't have access to funds, right? We hear it's mostly a white industry, rich white industry. Well, the truth is there, it's not so much about race - it's class, right? You cannot just walk into this, get a license, and then go to the bank and borrow money to open up a dispensary or facility of any kind. So the SAFE Banking Act would assist with that, would help move that ball forward. So when you ask which one's better - they all are different, but the one that is most likely to pass in the near future could be viewed as the SAFE banking Act. Now, that wasn't always the case. Well, recently, we had the STATES act...

Wayne: Could I hit on that, so a couple of questions there? (Yeah) I really liked that point of, you know, the industry equity and social justice. And I think, you know, you've heard things thrown around, trying to support people that were impacted by the war on drugs, and I look at states and I always thought, well, how easy do they make it for businesses to launch in a state? I mean, if a license is really expensive, there's a cap that just I mean, you're talking about class, right? You have a lot of money to be able to do this. But with the SAFE Banking Act, if that passed, that means it wouldn't de-schedule cannabis, no federal legalization, but it could set up where another act could still come along and be passed after that to fix all those other things that are not addressed by the safe Banking Act. Is that accurate?

Don: That's correct. (Okay.) It's somewhat counterintuitive, because you're like, "Wait a second, you're going to allow banking of the ill-gotten gains from this federally illegal sale of the substance? Right? So I actually once had a member who had voted for the banking amendment when it was in appropriations back in 2014. Yet he voted against the the Rohrabacher Amendment - so he was opposed to the underlying nature of this, right? So I said, "Well, I appreciate your vote for the banking amendment, but where exactly are you expecting folks to bank these proceeds - in the federal 50 ATM machine in the federal prison you think they should be in?" It was just, it was illogical that you would be for one yet not the other. And that's kind of what's happening here. But, you know, said Congress was consistent? So I - I'm happy to take what I can get on Capitol Hill.

Wayne: Okay - yeah. Yeah. So you mentioned the STATES Act next?

Don: The STATES Act basically says, if your state is - if you have a legal program in your state, whether it's a medical or adult use, you are free from federal interference. It's still - it's still federally illegal. Still in schedule one, but but you know, it's a pure state rights play. Now, some of us have problems with this notion that in Colorado, it's not federally illegal, but right next door over the line in Kansas it is, that is. That's, that doesn't make sense to a lot of us. But again, we've got to play the hand we're dealt. So most Republicans seem to be pretty okay with a state's rights view of this right, they kind of have to be, because that's what they talk about, right? They are for - in theory, are for smaller, less intrusive government. So it becomes difficult for them to justify why they think marijuana should be illegal in Colorado when Colorado voters have adopted it. Right? It just - it's inconsistent with pretty much everything they talk about. So that's, that's how we get them. They they are quick to say, "Hey, we're not pro marijuana. We're just pro 10th amendment." Like, I'm okay with that. I don't care how you - I don't care how you get the Yes. Just - let's get there.

Wayne: Yeah, and the 10th amendment is really saying giving any rights that the state establishes or the federal gun is setting - it puts more control and oversight into the states power, is kind of the idea behind the 10th amendment?

Don: Correct. Correct. Yep. (Okay.) So now, I will say that the STATES act had momentum about a year ago, when, when what happened was - and God bless Jeff Sessions. Now I know you never thought you'd hear a federal policy guy say that. But the truth is, what Jeff Sessions did in repealing the Cole Memo is unleashed both Democrats and Republicans on the Hill to, to act - because up to that point, it was fairly they were all fairly comfortable with the status quo. Nobody was really getting arrested. No - you know, in their states, legitimate operators were not getting raided. The only guys getting raided where the guys who were getting fingered by legitimate operators, right? You know, if you are a legitimate operator, you wanted a federal government - you wanted the state to come in and bust the cartel folks, right? If you aren't operating legitimately, you wanted those folks out. So. So, up to that point, everything was fine until - until Jeff Sessions repealed the Cole memo. And look, he did it because, A. that's what he believes and B. It's an Obama era directive. Right? If you're Trump and you're Sessions, you're repealing all that Obama stuff, right? It wasn't even so much it was about pot. It was about Obama, I think was - was the issue for them. So, you know, I've had a number of people say, Trump is bad because he picked Jeff Sessions. He picked Jeff Sessions, because Jeff Sessions picked him. Right? Like Jeff Sessions was an early endorser, like probably the first I think, in the Senate to endorse Trump, which was a really big deal when you think about it, because Jeff session sat on the Judiciary Committee, along with other candidates who were wanting like, like Ted Cruz and Lindsey Graham, right? They were They will seatmates of his, yet he was endorsing Trump. So Trump picked him to be the Attorney General. And the rest is kind of history. So, but the STATES Act gained momentum because the President acknowledged to the press that he - he supported a states’ rights position like the STATES act. (Yeah. Yeah.) So, so think about it this way. So we've got republican president endorsed the STATES Act, a Republican Senator, in the republican controlled Senate, and then Republicans controlled the house and they had people on that side, so so why wouldn't you take the STATES Act and run with it? Is it perfect? Nope. But whoever thought we could pass any bill with Republican president? Like, you know what, you know, they just thought everything was going to go to hell, in November of 2016 when Trump won, yeah, and that just that just hasn't been the case at all.

Wayne: So the STATES act was really to - it was almost like what the Cole Memo was, but it was formalizing it into an actual act. It wouldn't have de-scheduled it, it still would have been schedule one if the STATES Act passed, but it would've gave the control and autonomy to the states to run their state programs?

Don: That's right. I mean, but the Cole Memo did outline eight ways to stay above the law, so to speak - or, you know, not get, run afoul of the law. And most of those things are incorporated into the STATES Act, okay. Or into those state bills, and the state laws. So anyway, but the STATES act is is sort of falling out of favor, because it doesn't go far enough. Right? So, enter the MORE Act, which comes along in July of this year. Sponsored by the chair of the House Judiciary Committee, Jerry Nadler. Suddenly everybody's like, "Whoa, this is way better." And people started like distancing themselves from the STATES Act. Like, honestly, Elizabeth Warren, who was the lead sponsor, didn't even show up to a press conference for the STATES Act. So, you know, it's like - well, that's that doesn't go far enough. So the MORE Act is a much more comprehensive bill. And so, the other part of that was, is there were advocates who didn't want the banking bill, the SAFE banking bill to move. They've tried to hold that up until the MORE act moved, because they wanted social equity. They wanted restorative justice, they wanted those folks who had been most harmed by the drug war, to benefit before bankers and rich guys. That was - that was the notion there. So there was some infighting between the advocacy community about all this and it really wasn't until it became apparent that the MORE Act was going to move. I think there were probably some negotiations in the back room like, okay, the banking bills going to move because we're going to move it and it's been four months. And you had your chance. And the Financial Services Committee was not going to be held hostage by the Judiciary Committee. And finally, one said, we're going to move this MORE Act too, so that freed up SAFE banking to go to the floor and get 321 votes of victory.

Wayne: In the House, the MORE Act did recently - that was a few weeks ago, was it? November?

Don: That's right. Right. The MORE Act passed just out of committee. Yeah, but it has not gone to the floor yet. And it may be a while for it to do so. It was also sent to a number of other committees, whether they claim jurisdiction or not remains to be seen. I think they're - they may want to slow walk this one a little bit. And, you know, we'll see.

Wayne: Yeah, so it sounds like to me, the - you mentioned, you know, incremental progress is better than no progress. And the way we went through those, those each sounded like a stepping stone, like the SAFE Banking Act is kind of on the finance side, the STATES Act gets protection, and then the MORE Act goes the furthest with what we all ultimately want to see. And, but then it seems a little confusing, because is there an issue with walking through those one at a time or, you know, first starting with the SAFE Banking Act, then the STATES act? When you said, the MORE Act comes along, and people are like, "well, we don't want those other ones now, those aren't good enough." But if you're not going to get nothing, I mean, is there a way to try pushing them all through together? Or does just really one have to be chosen, and then the other ones can't as well?

Don: Yeah, I think part of the problem is, is that some of the folks on the progressive wing of the Democrat Party want more than - more than will pass the Senate, right? Like see to me, it's not a victory if the bill doesn't become law. Right? It's incrementalism if you sort of creep along and okay, now we got it this far and got this far. But that doesn't mean much to the people who are going to get arrested tomorrow. Right? Like I would - I would like to do something that keeps those folks from, from suffering, whether you're a patient or your consumer, or a processor you know, anyone in the industry, who is subject to federal arrest, prosecution and incarceration, you want to fix something sooner rather than later. Don't let the perfect be the enemy of the good, right. And so the MORE Act, in some respects, is the perfect, but we can't get it over the finish line. So what can we get over the finish line that helps fix this problem sooner rather than later? (Yeah.) And that's where that - we watch all these candidates debate on the stage and we've had some of them say, look Bank - In fact, many of the incumbents senators who are running for president have actually said no bill should go forward that doesn't include these restorative justice provisions. That means the SAFE Banking Act isn't good enough for them and they wouldn't support it. I think that's unfortunate. I think that's short sighted. For what it's worth, we did hear some of that same concern on the health side, yet all, virtually all the democrats, all but one voted for the SAFE Banking Act in the House. So that may be just something that people just say out on the campaign trail, but when push comes to shove, they take what they can get.

Wayne: Yeah. Yeah. And it's, you know, it's confusing for us, you know, operators, you know, we're busy as hell already. I mean, these things hugely impact us, but it's very confusing. We don't fully understand it. So I was under the impression. Well, maybe if the SAFE Banking Act passes or the STATES Act, then the MORE Act can't pass and you're just never going to get those things.

Don: No, no, no, no, no, I will - I will say there are folks who believe you only get one bite at the apple. Meaning, okay, once we take up the SAFE Banking Act or STATES act or you know, something that is not the full complement of legislation that they want, it'll be another generation before they get to fix it. I'm not sure I believe - I'm not sure I believe that. But I understand their concern.

Wayne: Well if the SAFE Banking Act or the STATES Act, if neither one of those moves cannabis from schedule one, I mean, there's clearly a lot of more progress that still needs to be made if either of those passed that I don't think would take a generation. There's such momentum behind this now and it feels like it's still picking up, it doesn't - I don't think it's going to slow down. It just seems like a time thing.

Don: Yeah, well and with every passing election, we get more folks coming into Washington who agree with us. Not because the politics so much, but this is generational. Right? The old guys who have been there and been part of that drug war for as long as they've been in office, they don't just wake up one day because they met me in the hall. You know, I make some comments and they go, "Oh, you're right, maybe I was wrong all those years." They are invested in this, right? They would rather - they would rather retire or lose than change their mind on this. So when they do retire, they're replaced by new folks, those new folks are not, they are not - their fingerprints aren't on the drug war, right? They are not responsible. And that's what I've said about President Trump. He could pretty much on his own, decide this is - we're going to end this now. This is not my drug war. This is not my war. However, if you stay in office for four years or another four years and you do nothing to fix it, then it does become yours.

Wayne: Hm, I see. Yeah. The people that are still in power making those decisions. I mean, they're at all - it's not one person. It's all that momentum, you know, that's in his cabinet or whatever it might be. And then it becomes yours. Yeah.

Don: Right. Now speaking of elections and Trump and all that. The dirty little secret here is, there are reasons to not pass this that are not policy driven. It's all politics. Right? The number one target for Democrats right now is a combination of Cory Gardner from Colorado and Martha McSally from Arizona. She's on the banking committee. He's leading the effort on the SAFE Banking Act - even if it weren’t to pass, does that help him in the election? Does that help her in the election if she votes for it? Probably. You know how much it remains to be seen, but it doesn't hurt. It helps them right? We you're a Democrat, you want to pick up those seats. You're like, why don't we wait on this one? You know, if, if you think this is a win for Trump if he ends the drug war, or fixes - marijuana is descheduled, or whatever. So ends the war on marijuana. Is that good for him politically? I think so. So do democrats want to give him an advantage? No. Now, the same thing works in reverse, by the way, so it's not - this is just not Democrats doing this. But there is a reason not to act just yet for some folks, and that's unfortunate to hear. Yeah, but but you know, let's be honest. I don't think I'm telling you anything you haven't probably either heard or thought but I just wanted to be honest about it.

Wayne: Yeah. With the MORE Act then, so it would remove it from schedule one, would it deschedule cannabis completely? (Yep, yep.) Okay, so it's federally legal, and then would it leave the autonomy to the states to run their programs, or is there a situation where the federal government says, we're going to decide on the regulations or have some control over this?

Don: Well, they - they do a little bit. That's what the, you know what the MORE Act stands for. He talks about, its "marijuana opportunity reinvestment and expungement". Now, just to be clear two things that people don't seem to, they seem to misunderstand - you cannot, this does not expunge all criminal records in the States, where most of these are. This is just federal, right? This - this Act does not do that. Now, it does create some provisions for people to get their records sealed and expunged at the state level, helps him with that, but it doesn't mean that the way it does at the federal level. The other thing is this, this does not legalize marijuana. Right? If your state is a no, it's still a no, but it ends federal prohibition. Right? So it's no longer illegal at the federal level, but it could still be illegal at the state level.

Wayne: Got it - even now, we have like dry counties, for example, it could long term play out that way?

Don: Exactly. And just for what it's worth, I mean, I've seen plenty of people who actually know better to use The L Word instead of the - you know, it's not legalization. You know, it's descheduling. And that does not necessarily mean that the states are going to change, although many of the states remain illegal, because, you know, it becomes very problematic to to have a law books that violates federal law. Sure. Right? You know, how do you, how do you do that? And I know your listeners know that way more than I did. Really, they understand it firsthand.

Wayne: Yeah. Yeah, seems like I mean, you know, talking about these incremental movements. Even if the MORE Act was passed, there's still so much to do on the back end of that, for another law or bill or act to account for like, you know, you said it doesn't expunge at the state level. So now there's another one. And it feels like we want to take as many steps, figure out what steps we can actually take. And if it's only the Banking Act, like let's make that first one. Because even if it's the MORE Act, there's still a lot of work to do.

Don: Yes, and let me give a little shout out to Chris Lindsey on our staff at Marijuana Policy Project, who ran the effort in Illinois. They just passed for the first time - speaking of historic, this is historic because it's the first time a state ever created a legal marijuana framework through the legislative process, not through a ballot initiative. So that bill was something like 600 pages and includes all of this, like from my perspective, I look at what Chris did in Illinois, and say the federal government does not need to get into details here, does not need to get into the weeds about how this is done. Look at what Illinois did. I don't believe that states going forward will allow for people to be still in prison for drug crimes that were committed that are very similar to the legal market that the state puts in place. Right? (Yeah.) It would be hypocritical for a state to do that.

Wayne: I think so.

Don: You know, let's not - let's not spend a whole lot of time at the federal level that we don't need to. Let - leave it to the states to do it. If a state does not want to do this, that's - that's their prerogative. I mean, I can't, you know, after 20 years of arguing for states’ rights, I can't turn around and go "oh, you've got to make them do it." No, no, that's, you know - you want to be a dry county, be a dry county, you want to be a dry state or whatever you would call it in this instance, that's fine. It's like, it's like casino gambling, right? There was a time when only Nevada had it. And then they lifted that prohibition. And now everybody can have it if they want. They don't want it, fine. But anyway...

Wayne: Yeah, yeah. I'd like to talk a little bit about how one of these acts actually moves through the process. Because to me, and I think our listeners, that is kind of a black box that we don't understand. So looking at the MORE Act, it passes the House Committee, what stages are left for it to go through? And what are the roadblocks? Because I've heard a lot of people say, you know, this was historic, like we've been saying, that it passed, but it has no chance. What's the rest of the process look like and where the major hurdles?

Don: Okay, well, whether it's the MORE Act, the STATES Act or the SAFE Banking Act, they would all basically go through the same process. But let's just - we'll talk about more because that's the one that you asked about, but, but the SAFE Banking Act is in a similar position, right? They were in separate committees, they came out of their committees - they were voted on by their, their respective committees. The SAFE Banking Act passed on the floor, went to - goes to the Rules Committee, and they set the rules for how this has to be done and the amount of time each side gets to debate. And then it goes to the floor, whether it is open to amendment or not. And then it's voted on the floor. And then it goes to the Senate. The MORE Act has yet to go to the floor. Now, some of these bills have to go through other committees, because there are committees of jurisdiction, which have issues that may or may not be written into the bill. You know, a banking bill might have a criminal justice aspect to it, so then it has to go to judiciary. SAFE Banking Act didn't have to do that, the MORE Act may have to do that, because it's got, it's got a tax in there - there's a 5% tax right? So that has to go the Ways and Means Committee then right. In less the Ways and Means Committee signs off on it and waves jurisdiction. Okay, and that would speed the process up. I'm somewhat ambivalent about this, but I'll tell you why I might like it to go to other committees, because the more often we have hearings, the more the public debate gets to be held, we get to have this debate about whether this is the right thing to do. And I believe it is. Right? So it gets more press, it gets more talked up. It's you know, it gets a lot of things. And it ultimately has a better chance of passing, it certainly the MORE Act would have a better chance of passing I think, if it went through more hurdles, most people wouldn't think of it that way. But I think in the long run, we'd be better off. Now, could they just pass this thing on the floor and send it over the senate where it would probably die? Yeah, they could do that. And then would we have made incremental change? I guess in some respects, we have had some incrementalism but as long as - if a bill doesn't get sign does it, does it still have an effect? Maybe, maybe not, and that, you know, other people would look at it differently. But in any event, so the bill has to go over to the Senate, it has to have a hearing, generally, has to have a vote in committee, has to have a vote on the floor, and those bills have to be exactly the same. If they're not, then they have a conference committee to work them out. But more often than not, these things just never happen. Like there are thousands and thousands of bills - I think there were like 9000 bills filed last year, and only like 400 of them passed. And that's, that's a pretty low percentage. Right? So when democrats say oh, there are all these bills sitting over in the Senate. Well, there are bills sitting around the House too. But for the most part, they don't get hearings and they don't get votes, which is why even though it's historic when we have a new piece of legislation that's got marijuana in it, we don't get too excited because the chances of that passing are pretty slim.

Wayne: Right? So on the MORE Act, the name I've heard if it went to the Senate was Mitch McConnell, the senate majority leader, would just kill it. Like you mentioned, it wouldn't even have any chance at all. Is it because of this priority in the - you know, where are we at on the priority list? Is it simply that in the, to them, you know, in their mind, it's not as much a priority, or at least on this MORE Act, is there a different special interest or something going on? Because it seems like the public the majority, I mean, you look at the acceptance and people that want to legalize, and you talk to the people I mean, it's, it's alarmingly high and still growing. But so something else is going on behind the scenes of why this isn't enacting and it seems like it should be a pretty big priority, and we're talking about major social impact here.

Don: Well, you would think but, you know, when we all talk about polling, like the polling on this is 60, 7o, 80%, whatever, depending on how you quantify it, right? If it's medical it's close to 90%, if its recreational it's in the 60s or 70s some places - but that support tends to be a mile long and an inch deep. It's not like there are, you know, people on Capitol Hill on a regular basis, other than me, trying to be on these guys to do something, right? The halls aren't clogged with - they're clogged with social justice warriors and climate change, you know, folks and and, you know, pro choice people and pro life people and cancer, all these other folks, but there are very few on this issue. And it's it's somewhat evident when you think about the fact that we've had hours and hours of debate on on the presidential debate stage from the Democrats, and we almost never hear this issue come up. Now, when you poll Democrats, it's off the charts, right? It's probably closer to 100% but they don't bring it up. Why? I guess it's just not priority for them. And that's unfortunate. So in a place like the Capitol, like DC, where time is short priorities are like, you know, everybody's got their own thing. Very few people care that much about this issue. And that's where - that's where your listeners come in, they have to make sure that their elected officials make it a priority. Right? So if you're not talking to your member of Congress about it, who is? You know, you can't blame your member of Congress for not making this a priority, if you haven't made them make it a priority.

Wayne: Yeah, yeah, definitely. We'll hit on that at the end, how listeners can help and support. That's so interesting. So thinking about that, why, you know, Democrats, maybe 100% would be for this, but it doesn't seem to be on the priority list. Is it, you mentioned some of the other lobbying and the interests that are there and it's not a lot around cannabis right now. Is it simply that, that the exposure and for them they're not as aware it might seem like a smaller priority? Is there something from the other side with, you know, other interests? We think of pharma, alcohol, private prisons, like is there lobbying on the other side? Where I can imagine they're looking at this and going, "cannabis is going to be legalized eventually, but the more we can delay it, the more we'll be able to continue to make our money on our systems." Is that a part of this too?

Don: Well, it's not - it's not overtly visible to me. But I do believe it happens, right? Like, I can tell you that when we did a ballot initiative in Arizona, one of the big pharmaceuticals wrote a big check to stop us, and we lost by like a point. So I know they've weighed in. I know, some of the, you know, law and order folks, they don't want - the status quo works for them. Right? They're on the receiving end of all that money, if all that money doesn't have a need to be appropriated because you're not, no longer arresting, prosecuting, incarcerating people for the simple possession of cannabis, then, you know, where are they going to get those funds? What are they going to do? How they get - like it just, it just, that's just the way it is. Now, the sad part here is, is that we're getting fragged by some of our friends in theory, right? If you're a medical marijuana provider, and along comes a ballot initiative to make it legal for adult use in your state, you may not think that's a good thing for you financially. And we saw that play out when we ran a ballot initiative in Maine. Some of the big opponents to our effort were the small mom and pop dispensaries that were providing cannabis to medical patients. So that's all part of this as well. So I didn't want to take a swipe at Big Pharma without being honest about (Yeah) you know how we're getting hit from the inside as well.

Wayne: Yeah, no, it makes sense. There's not the unified front on our end. And that's what a lot of you know, honestly, we are afraid of if it was federal legalization is, you know, who might be behind legalizing? What did these acts mean? And we're all looking like well, big business is going to want a piece of this. And we look at some states like Florida, where you have to have millions of dollars to even operate and the cap on the number of licenses is low, versus Oregon, which is very pro small business and an oversaturation. We're struggling now because there's just so many companies, but yeah, that that fragments that even further and can delay it and make it difficult. But I like how you kind of talked about the MORE Act being, you know, descheduling at the federal level, but leaving the autonomy with the states. So Oregon can be a pro small business state, maybe Florida just doesn't want to be and things could remain that way, but it wouldn't be like a sweeping regulations from the Federal Government and change everything upside down, right?

Don: Right, right, and as I like to point out, the federal government screwed this up, they should just get out of the way. They don't have any jurisdiction with fixing this in my opinion, right? So just like, just let the states do what they want to do. It won't be perfect. This is going to be very painful for a long time and you're seeing that with some of the companies and the stock prices and all that that's, that's happening now. You know, people look at me and they go, man, you got to be making millions or something. I'm like, first of all, I don't do any of that. I don't even have a stock in any of this. Sometimes I think I'm the dumbest man on the planet because when this goes you know, full blown legal where across the states, it's not going to affect me, in fact I'll probably be out of a job. So that, there's that but you know, between now and the time it is sort of rolled out all out. There are going to be a lot of people who make a lot of money and be a lot of people who are gonna lose a lot of money too. And you probably, you all know that probably better than I do. So I'll defer to you on that one.

Wayne: Well that's why I appreciate Marijuana Policy Project advocating for consumers or patients. Because that's always our fear is, you know, who's behind the scenes? What are their motives or interests? Because depending on who pushes an act or why it's legalized, you know, there is a lot of fear of that. And it's hard to know exactly what's going on all the time. Back to the MORE Act so, again, going back to that name, Mitch McConnell, would he just knock it down? Because it's doesn't seem to be a priority. Do we know specifically why it has no chance of getting past the Senate there?

Don: Well, first of all, I think the MORE Act goes beyond where most republicans feel comfortable, okay. There's a tax added. There's, there's an opportunity fund. It's a lot of government intervention. Now, a lot of us think that that probably is necessary because this is not your typical new industry that's being developed. This is not Uber. This is not Airbnb, this is something that was totally illegal, and people suffered because of it. But how do you fix that? How do you unring that bell? Very difficult to work out. But there are a lot of folks who think the MORE Act goes way too far. Right, now, talk about Mitch McConnell - who knew two years ago that Mitch McConnell was going to be hemps best friend, right? And suddenly, like hemp is now legal. And we're working all that out. And, you know, he's putting it on his campaign literature. So you just never know how things are going to change. But he may look at that. The President might look at the MORE Act and say, let's get this done. Let's fix this. Let's do it. Let's do let's do something now. And rightm and get the credit and take it away from Elizabeth Warren. Take it away from Bernie Sanders. Don't let them use that as a campaign position to beat on Republicans. You know, Every time I go to a hearing Democrats are blaming Republicans for the drug war. Nixon, Nixon, Nixon, right? Reagan, Reagan, Reagan. Hey, when Nixon was President and Reagan was president, they had democratic controlled Congresses, right? So, you know, own - own this a little bit, guys. Like that's, to me that's part of the problem, like people won't, won't be honest about how this got done, how this got started, why we are where we are. And maybe if, if people did that - look, I'm the first one to tell you, Republicans are wrong on this issue more often than not, right? They just don't seem to get it. And maybe because, when we talk about polling, everybody says, Well it's 80/20 - 80 in favorite and 20 against - you know who those 20 are? Those 20 are people who vote in Republican primaries. That's the problem for Republicans, right? They get no real benefit for supporting this, because most people in Congress only have to win their primary. And then they're done. Right? They don't have to win a general election. So they don't have to appeal to the opposite party. They just have to not be primary and have someone come into their, you know, outflank them on the right. Democrats, the same thing. Right? AOC came and she outflanked what's his name, and now everybody's afraid of being a primary, which may be part of the reason why we've seen some of these bills move as relatively quickly as they have.

Wayne: Yeah. Was the Farm Bill really surprising for you and legalizing hemp at the federal level?

Don: Well, yes, I will say - (it happened fast!) Yeah, because we, we stayed away from that. Like, I'm, I'm happy that that happened. But we did not, we did not lobby for it. In fact, I even said to the chairman of the two respective House committees back a couple years ago when republicans controlled everything I said, if you bring the hemp bill up, we will not mess with it, we will not try to have it amended to include you know THC cannabis, higher limits, all that - we won't do that. We thought, what's good for hemp is good for us. Right? Move hemp - you know the other beauty of hemp being illegal, I always said was, it just shows how ridiculous the federal law is, right? (God, yeah.) Same thing with schedule one, like marijuana is on schedule one, heroin is on schedule one - Fentanyl? No, no, it's not. But but they're on the same schedule. It's ridiculous and no one can justify it. Right? It's just not justifiable. So, you know, the one thing we haven't talked about that is, that is out there is this talk, a constant talk now of research. Yeah, you know, a lot of folks a lot of opponents use that is a reason to slow walk. You need some research. We need more research. You know what, it's been around for thousands of years right? You had your chance to research it. If you want to research it, fine, but in the meantime, stop arresting these people for it, right? Because by your own admission, if you think you need more research, then aren't you will also saying, maybe it's not prison worthy? And look, and I've had this conversation with Jeff Sessions who says "marijuana's bad". I said, I never said it was good. I just said it wasn't worth going to prison over. It wasn't worth having your life ruined, right? I'm a conservative, fiscal conservative, I don't want to pay for able-body welfare recipients who otherwise should be able to have a job and pay for their own families. And, you know, we often talk about, or we hear about, we don't like to talk about the money, right? Oh, the billions of dollars in tax revenue we're gonna raise. No, I don't want to talk about that because I don't think we should do this for the money. But if you want to talk about tax revenue. How about the money you're not going to spend arresting, prosecuting, incarcerating people? How about the money that comes in? Because Jimmy Jones has a job, and we don't have to pay him welfare to feed his family? How about, you know, looking at it from that perspective? So, you know, it's fun to talk to Republicans about that side of the coin, especially those guys who are like, close to to this, right? You can see them, you know, like, on their face, the anguish of trying to figure out, you know, what to say to me, in support of their current position. You know, they, you know, they're like, I'm like, I love you, but I could love you more. How could I think you're so great on everything else, but you just suck when it comes to this? How could you be so wrong about this, and so right about everything else? It's inconsistent!

Wayne: Yeah, I mean, to us, it just feels like the institutional momentum of the prisons and the budgets and the things that wouldn't be needed, that taxpayers are covering and there's interest in keeping you know that status quo going. I mean, that's how we always look at it from our end, where we're really unfamiliar with what's going on. I mean, this is just our surface level view. And we're guessing, you know, referring to myself, at least operators, you know, just running a business, at the federal and the government level. I just, it's always confusing and seems like a black box of why things are happening. But things don't happen overnight, either. I mean, it's amazing. We're at, we're at now where we actually are. I mean, when I told my parents I was starting this business, they couldn't believe it. They thought it was a terrible idea. Now they're open to it. And I asked them 10-15 years ago, they couldn't imagine this happening. So I mean, we have been making progress, but - but yeah, how we get to the next stage. I have a question-

Don: Just a second to say where we are now is we have, even our opposition sort of like concedes that, oh, people shouldn't be arrested. We should decriminalize it. So my response to that is - okay so you're okay creating this legal market, okay, this legal demand, but not illegal supply, right? I mean, if you think there is a disproportionate number of arrests now between black and white, imagine what it's going to be what it's okay to consume, but not okay to produce and to sell, right? So many drug dealers are going to jail, only growers are going to jail. But, but guys like us, who maybe just want to consume in the privacy of our own home, which is nice, but we have to depend on an illicit market. And we create an illicit market by by having decriminalization only and not having a free market commercial, capitalistic enterprise with interstate.

Wayne: Yeah, I mean, you look at the vaping crisis. People using pesticides, there would be no lab testing. I mean, from a consumer safety standpoint, that is a huge issue. Medical patients are consuming this that have compromised immune systems possibly. I mean, yeah, there's a huge gap there to not legalize the business side - and regulate it, I mean, we love regulations when they're fair.

Don: Right, and when, when people say, you know, oh - this is, this is the pushback that I get from opponents. Hey, this isn't your grandfather's marijuana, right? This is like, hundreds of times more powerful. And I'm like, all the more reason you shouldn't buy it in a baggie. Yeah. Right. Like you're right, it should be labeled. You don't go to a liquor store and just buy something in a brown bottle. Right, it's got a label on it. I have a friend that makes - I have a friend that makes wine. He will give me all the wine I want - do I like it, do I do I take it from him? No, because it's crap. Right? And for the same reasons, I don't want to buy, you know, the product from a street vendor. I want to buy it from a legitimate provider, where you have some sense of the risk because you know, "Oh, this was grown here, this is seed to sale. This is the way it works. These are the pesticides, these are all these." It takes a lot of the fear out of it. And, and that's a good thing.

Wayne: Yeah. But it seems like such a weird argument to me. I mean, yes, consumer education will need to happen, things are more potent, but nobody's dying from this, you can easily go out and buy bottles of everclear that are super potent, but consumers will figure out what works for them. And regardless of the potency now being much higher or lower. I mean, I don't hear any consumers complaining about that. I always hear it used as an opposition argument. But when you look at the markets and the people, like that doesn't seem to be a problem anywhere from what I can tell. Right?

Don: Right. You just, just consume a lot less of it.

Wayne: Yeah, yeah. Or by low - Yeah, people get, their preferences, they find out what they like and then the market adapts because our products need to sell. We can't be making something -you know, if you only make everclear, you probably got a pretty small market segment you're selling into right? (Yeah) Back to what I wanted to ask about, back over to the SAFE Banking Act, I think this was just yesterday I heard Mike Crapo, he's the Senate Banking Committee Chairman, basically said the SAFE Banking Act will not pass or he'll prevent it. And so the question I had is, is that the case now with him in the way, is it not going to happen, at least on the SAFE Banking Act? And some of the things he mentioned and why this is one of his quotes, One was, it doesn't address the high potency of cannabis. There's a lack of research on effects. He's worried about marketing to children. And I was thinking - this is just about banking. Yes, it doesn't address those things, because it's not made to address those things?

Don: That is almost verbatim what I said to him. When, when I heard weeks ago, that he had this interest in in potency limits. And I said, Senator, I said - I'm hearing some rumor that you may be interested in having some potency limits in his bill? He goes, do you really think there should be 100% THC? I said, Well, whether there is or isn't, it shouldn't be in this bill. Because you are basically taking a banking bill, one that is of interest to banks and realtors and insurance companies more than it is us, by the way, right meaning us as an advocacy group, and you're turning it into something that is way more involved than your committee has the jurisdiction to cover, you know, that should be somewhere else. And oh, by the way, the states have limits. And you know, this is just about making sure that legal enterprises within those states can bank I said, and by the way, if you put a - if you put a limit on it, thanks aren't going to be able to - it's going to be untenable, because no banks going to say, when you bring in your cash or you go, you know, to do your electronic transfers, are going to say, "and what was the THC potency on on this, the sales?" They're not gonna know, we already see this with hemp, right? The 3% rule right, if it goes over three, then it's marijuana, its cannabis, it's not hemp anymore and then it's queue people subject to arrest - gonna have the same problem. I believe - and just understand where Chairman Crapo is from, right next door you guys in Washington State - he's in Idaho, right? It's like the state with the least number of legal marijuana laws on the books. There are like three or maybe just one depending on how you count it, but Idaho is the worst. And there he is in Idaho. So he's got to be very - like, to me, He's already doing more than I would have expected from somebody in a state that has nothing. (Yeah.) So I think I think this has the ability to move along. I know the people that are working on this from outside of the cannabis space - bankers, realtors, insurance folks, this is like their number one thing. They want to get the fixed because it's a problem for them. They don't want to get caught up in this. And so they need it to be fixed. I think it's going to be fixed. But you know whether the industry - like from the advocacy perspective, thinks it's much of a win, we'll cheer about it. We're working on it, but it's not what we're ultimately trying to get to (definitely) because it doesn't - it doesn't keep people, really, from prison.

Wayne: Yeah, yeah, without a doubt. When I hear arguments like that, and you kind of pause and go, let me logically think about this. And then you think like, well, that reason doesn't really make any sense. And I think one of two things, either one, he's really uninformed, he's not thinking about it fully. And maybe it's a quick quote and he's just feel like he's got to say something about it, or two there's actually another incentive or motive going on behind the scenes, but this is the only thing he could scrape together to say why to justify what he might do. Is it a lot of times it just uninformed or is, again, we're kind of going back to those, you know, big interests or other things going on - is there something else and is he the ultimate hurdle, like can it still go around without his, you know, approving it I guess or wanting to pass?

Don: Well, he could, he could vote against it and it could still pass, but he sort of has - he sort of has the gavel to let it go or not. Yeah, right. If somebody further up the food chain wants it, then it probably happens. You know, that's how you get to be chairman. Right for, for delivering for others over time. So I don't think he's, I don't want to say he's uninformed, right. He's certainly not as informed as you are. Or maybe I am on this issue. But he has staff, he knows what's going on. And he is looking at a broader picture of things here. Like what else is going on in the Senate and where can we maybe make this work or not work? You know, I think he wants to deliver this for Cory Gardner, right? I mean, I don't know that for a fact. But you don't get to keep the gavel if you lose the majority. Right? And when the majority is as slim as it is, losing the Senator from Colorado could be the difference between you having a gavel or not. So does he want to help Cory Gardner? Certainly he does. Is this going to be the bill to do it? It won't hurt.

Wayne: Right? Yeah. Well, as we get wrapping up here, Don, again, I want to hit on where, how listeners can take action and help, but the last question I wanted to ask after hitting on all you know, STATES Act, MORE Act, SAFE banking. Is it possible - I mean, it really doesn't feel like one of these is going to go through in 2020. Something could always happen. Could another act come along and be something more or different - like are more going to be introduced? Like what's the next year to two look like, or kind of your predictions on the short-midterm forecast?

Don: Well, we often say nothing happens in an election year. But I actually think the reverse could be true as well. Right? Like, this is, this is when in Maryland, we passed their medical marijuana bill in an election year. Why? Because people stood up and said, We want this, make it happen, and jammed it through. I mean, it was like an election year issue. And people didn't want to be on the wrong side of that. So if the president were to hijack the bill, or a bill, or the position, or the issue, something will happen. And there's no telling what the President's going to do, like we - you know, we've been through almost three years of that, right? There is no predicting this President. So, if you think it's not possible, that's probably when it happens. And it will happen just when you least expect it. Right? So I actually - now, understand, I'm pretty much an optimist when it comes to this stuff, if I wasn't, I would find it difficult to get out of bed, get on a train, go to Capitol Hill three days a week and lobby for an issue that was going nowhere, right, that sort of loses interest in a hurry. But I do think we're on the cusp of something very historical, and very beneficial for this issue. And for the people who are involved in it, not only as producers and from the industry side, but from the patients and the consumers as well. Everybody knows this drug war has been a disaster. Everyone knows. Now, I will say there are people who know it's a disaster and say we should double down. But, you know, at least they know we're not winning. Right? So it's time to do something different. I will say that what was disappointing to me is that yesterday, no sorry on Tuesday, the Senate Judiciary Committee had a hearing, another hearing, on the opioid crisis and what to do. And it went on for close to three hours, and no one brought up the issue of marijuana as an alternative to opioids. (Really? Wow.) It's just rarely rarely happens. And so, you know, I continue to be, you know, upset about the fact that we can let, you know, hundreds of people die every day of opioid overdoses. But we can't bring ourselves to say, is marijuana an alternative? There seems to be a number of studies that say, in states where it's legal, the opioid overdose rate is significantly lower than states that aren't. I've handed out that study to many members of Congress, and they just don't seem to want to embrace that as an alternative.

Wayne: That is crazy that it doesn't even come up. You know, obviously, I'm biased. I'm in the industry. I get a lot of emails from people that it's helped in their life. And you know, we've interviewed a PhD neuroscientist showing opioids can be used at a third of their dose, I think it was, with cannabis and have similar effects. I mean, to me, it seems like cannabis is maybe number one, that could potentially be the first steps to help this opioid crisis. I mean, what other ideas are out there? Is there anything else that can even compete with that? I mean, what, you know, lock down more drug laws and you know, hammer things down that way, but that normally just backfires then the other side ramps up. There's more crime, bigger cartels. You know, I don't know, it's interesting. What were some of the points that were discussed or brought up in that?

Don: They said - one of the responses was equine therapy, and yoga. I'm like, seriously, seriously?? It was all I could do stay in the room. So look, I would encourage your listeners who are leading the effort here, right? They are the folks who have an understanding of this issue, of the benefits that it provides for the patients - and the consumers, but you know, really patients. Nobody, nobody on Capitol Hill believes that patients should be arrested, yet they fail to act, right? So you need to put these people in front of them - whether they be patients, whether they be the providers. You don't have to come all the way to Capitol Hill, you all have, you know live somewhere or work somewhere that as a member of Congress, that if you do not invite them to your facility, they have no idea how legitimate it is. Right? They - all many of them know is what they see on The Wire. Right? That's what this is. And unless you change their opinion by sharing what you do with them - make them your biggest advocate. That's what you can do to change things on Capitol Hill. And, you know, if you got a guy who's bad, work to get them out of there - either change his mind or get them out of there. Yeah, if you guys don't do it, then the status quo just continues.

Wayne: So what's the call to action for people - if we're talking about business operators, is there a process? Or is you know, getting to Capitol Hill is really difficult for us, obviously we're busy. Money's always an issue. Do we just email a congressman and ask, "Hey, can you - would you like to come tour our facility?" Is there a specific tone or something to be said about, "here's what my values are". Like, what do you recommend that, basically a call to action for our listeners, on how they can actually take some steps that are practical for them?

Don: There are very few people, percentage wise within a congressional district, that interact with their member. I often say, if you want to be influential on Capitol Hill, well then go to Capitol Hill, but if you want to be influential, you have to know your member of Congress, and to really be influential, they have to know you, right? It's simpler than ever with social media to interact with your member of Congress. They all have a Facebook page, they all have a Twitter account. They all have an Instagram, that you can communicate, can just like them. Even if you don't really like them, you like them, right? And then you see that, you see their information come across their newsfeed and you just start the dialogue. And you make sure that they get a chance to talk to you at a town hall. You - it doesn't even cost any money, you do not have to go to a fundraiser. It's not like that. Right? Like, like if you're guy's really bad, do you really want to go to a fundraiser for them? Do you want to give them money? No, that would probably send the opposite message right? You can, you can be terrible - I'll still give you money. So why would you be good? But you need to you need to educate that person. That person does not know what you know. They have no clue what you know. Right? So share with them the reason that you're in this - you're not in this business to make money. You could do any other business and make money. Why are you doing? Why are you doing this one? Right. Why are you doing one that has so much risk. You are subject to federal arrest, prosecution, incarceration, yet you still do this - Why? So if I'm willing to do this kind of work, as a processor or a cultivator, or dispensary, the least you can do is not put my customers and my patients in risk of federal arrest. Don't make them criminals. All those veterans you talk about, how you sneak veteran should have access to this, thank the veterans you know, thank you for your service - really? You think I should be in jail because I'm using marijuana for my PTSD. That's inconsistent. Yeah, you know, I, I believe veterans will do more to advance this cause than anyone else. So if you've got, if you've got customers in your dispensary, or your facility that are veterans that are benefiting from this, and they're not talking to their elected officials, that's a loss. That's a missed opportunity.

Wayne: Yeah, yeah. I love those points. We're gonna actually - We talked about this in the past with others, you know, what can people do. But I think we're going to make a case study out of this and at least try to, you know, we're going to reach out, maybe get someone to come here and take a tour and we'll document this process. So for people that listen to the podcast and follow, we're going to make some attempts at this. I really like what you said. And I think we need to try to lead by example, and do those things. So getting someone out here and so we'll be sharing that coming up, whether we're successful or not. Either way, so hopefully we can, you know, at least be a - be an example for others that want to do the same thing. So those are really good points. Where can people find you or follow the Marijuana Policy Project if they want to stay up to date on what you are doing?

Don: Well, we have a web page, it's mpp.org. My email address is dmurphy@mpp.org. And we're on Facebook I would, I would suggest you check us out there. If you ever want to come to DC and Get the tour - happy to do that, you know, happy to introduce you to members of Congress. And and you - give you an opportunity to share your story, because your story is more impressive than my story. Right? Like, I'm not in, you know, I'm at a 30,000 foot level here. I'm not on the ground fighting this thing. And so, yeah, I'd love to have you come out and do the tour.

Wayne: Awesome. Well, thanks again, Don, for the time. I think someone can be really helpful for listeners and some clarity around what's going around at the federal level and really appreciate the time. Thank you.

Don: Thank you.